Novel pharmaceutical composition comprising particles comprising complex of double-stranded polyribonucleotide and polyalkyleneimine

A composition of double-stranded polyribonucleotides and polyalkyleneimine particles addresses stability and efficacy issues, enabling effective, less frequent dosing for cancer treatment with enhanced immune response.

JP2024160312AInactive Publication Date: 2024-11-13ハイライトセラピューティクスエセエレ

Patent Information

Application Number
JP2024131720
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-11-07
Filing Date
2024-08-08
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing formulations of double-stranded polyribonucleotides like poly(I:C) face challenges with low stability, poor homogeneity, unpredictable pharmacokinetics, and limited antitumor efficacy, necessitating frequent administration and strict regulatory compliance for clinical use.

Method used

A composition comprising particles formed by a complex of double-stranded polyribonucleotides, such as poly(I:C), and polyalkyleneimine, with specific size, zeta potential, and concentration ranges, optimized for reproducibility and stability, allowing for less frequent dosing and improved therapeutic efficacy.

Benefits of technology

The optimized composition provides stable, uniformly sized particles with enhanced therapeutic efficacy, inducing apoptosis and autophagy in cancer cells while preserving normal cell viability, and can be administered in various routes to enhance immune responses against tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160312000001_ABST
    Figure 2024160312000001_ABST
Patent Text Reader

Abstract

To provide compositions comprising complexes that are formed by polyinosinic-polycytidylic acid with a polyalkyleneimine, such as polyethyleneimine, that present uniform structural and functional features.SOLUTION: A composition includes polyinosinic-polycytidylic acid [poly(I:C)], including double-stranded polyribonucleotides, or a salt or solvate thereof, wherein (a) at least 40% of the double-stranded polyribonucleotides have at least 850 base pairs, (b) at least 50% of the double-stranded polyribonucleotides have between 400 and 5000 base pairs; (c) between 5% and 60% of the double-stranded polyribonucleotides have less than 400 base pairs; (d) between 10% and 70% of the double-stranded polyribonucleotides have between 850 and 5000 base pairs; and (e) between 0% and 10% of the double-stranded polyribonucleotides have more than 5000 base pairs.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of pharmaceutical formulations comprising particles formed by polyribonucleotides and polymers, their manufacture and their medical uses. [Background technology]

[0002] In recent years, the use of synthetic analogs of double-stranded RNA (dsRNA) mimicking viral double-stranded RNA has been explored to specifically activate the immune system against tumors, with the effect of inhibiting cancer cell growth and inducing apoptosis of cancer cells. In particular, double-stranded polyinosinic-polycytidylic acid (known as poly(I:C) or pIC) has been identified as a kind of dsRNA with various effects of therapeutic interest against several types of cancer (melanoma, hepatoma, colon, stomach and oral carcinoma, cervical cancer, breast cancer, ovarian cancer, urinary tract tumors, lung and prostate cancer) and their metastasis, which may depend on or be independent of immune system activation, natural killer and / or dendritic cell-mediated activity, and / or tumor gene expression and microenvironment changes (Non-Patent Document 1).

[0003] Unfortunately, these early preclinical reports have not been fully confirmed or validated by clinical studies with naked poly(I:C) molecules, which have demonstrated their low stability, poor homogeneity, unpredictable pharmacokinetics, and limited antitumor efficacy due to various mechanisms such as poor cellular uptake or degradation by cytosolic RNases (Non-Patent Document 1). Indeed, to achieve effective therapeutic or prophylactic effects, poly(I:C) molecules may need to be redissolved immediately or shortly before use, may be available in low concentrations in the formulation, and / or must be administered frequently (e.g., every 2 hours).

[0004] In the last few years, there has been a significant progress in formulating poly(I:C) molecules with immunomodulatory and / or therapeutic properties. Various methods have been disclosed for producing and formulating poly(I:C) molecules as powders and / or integrated into polymer-based microparticles with or without targeting moieties and additional chemical linkers (Patent Document 1; Patent Document 2; Patent Document 3; Patent Document 4; Patent Document 5; Patent Document 6; Patent Document 7; Patent Document 8; Non-Patent Document 2; Patent Document 9; Non-Patent Document 3; Non-Patent Document 4; Non-Patent Document 5; Non-Patent Document 6). Poly(I:C) molecules have been formulated with carrier polymers and in formats compatible with intranasal administration stabilized with polylysine and carboxymethylcellulose (Patent Document 12) encapsulated in calcium phosphate nanoparticles coated with cationic lipids, liposomes or other porous structures (Non-Patent Document 7; Patent Document 10; Patent Document 11), or with single-stranded RNA and cationic peptides such as protamine (Patent Document 13). Alternatively, poly(I:C) molecules have been immobilized on solid particles and carriers, such as iron oxide nanoparticles, with or without agents that may help target the poly(I:C) molecules to specific cells or tissues (Non-Patent Document 8, Non-Patent Document 9).

[0005] Some publications involve or are gene-specific with other components. have further disclosed various ternary or quaternary complexes in the submicrometer range formed by polymers, poly(I:C) molecules and / or double-stranded DNA without the use of α-carboxylase (Non-Patent Document 10, Patent Document 14, Patent Document 15, Non-Patent Document 11). However, these approaches are not aimed at selectively killing cancer cells, but at providing agents that essentially deliver DNA to cells while maintaining their viability.

[0006] Chitosan, polyethyleneimine (PEI), poly-L-lysine, polymethacrylate, It may be possible to overcome the pitfalls that limit the clinical development of poly(I:C) molecules as drugs and the compliance that requires their regulatory requirements by producing structurally complex anticancer complexes that contain poly(I:C) molecules together with drug delivery systems for cancer therapy that are often based on imidazole or cyclodextrin-containing polymers, cationic polymers such as poly(beta-amino esters), and related dendrimers. These polymer systems (also called polyplexes) are structurally and functionally different from lipid-based systems (also called lipoplexes) and hybrid systems (also called lipopolyplexes) that are also used for local or systemic delivery of nucleic acids (Non-Patent Document 12, Non-Patent Document 13). Among polyplexes, PEI is a cationic polymer of particular interest, polyalkyleneimine, which can be tuned at the level of linear / branched structure and size, chemical conjugation, degradability, and derivatization (Non-Patent Document 14) and is internalized by both clathrin- and caveolae-mediated endocytosis, unlike lipoplex internalization by cells (Non-Patent Document 15).

[0007] This therapeutic approach, which involves the creation and administration of poly(I:C) molecules associated with PEI, is exemplified in the literature by an agent called BO-110 (Non-Patent Document 16, Non-Patent Document 17, Patent Document 16). [pIC] PEI This complex, also identified as BO-110, is involved in the dual induction of autophagy and apoptosis in several cancer cell lines of melanoma and other tumor types (such as glioma or carcinoma), as well as having no or limited effect on the viability of normal cells such as melanocytes. BO-110 inhibits melanoma growth in animal models to demonstrate antitumor and antimetastatic activity in vivo, even in severely immunocompromised mice. Furthermore, similar [pIC] PEI These drugs stimulated apoptosis in pancreatic ductal adenocarcinoma cells without affecting normal pancreatic epithelial cells, and increased [pIC] in vivo. PEIAdministration of BO-110 inhibited tumor growth in tumor animal models (Non-Patent Document 18). Further effects of BO-110 administration were characterized in a model of endometriosis, where such an agent reduced angiogenesis and cell proliferation and increased apoptosis (Non-Patent Document 19). Thus, BO-110 and similar [pIC] containing double-stranded polyribonucleotides were PEI This drug is a novel anticancer strategy with a broad spectrum of action due to the combined activation of autonomous and selective autophagy and apoptosis in tumor cells while maintaining the viability of normal cells of various lineages. However, there is still a need to provide BO-110 in a formulation that, when associated with a carrier, is stable under various storage conditions, is uniformly manufactured and sized, and is more easily adapted for medical use (especially against cancer) in terms of the most effective combinations, regimens, dosages, and clinical follow-ups when using other drugs and therapies, just like other double-stranded polyribonucleotide-based drugs that have demonstrated efficacy in various preclinical models. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] Chinese Patent No. 103599071 [Patent Document 2] Chinese Patent No. 102988303 [Patent Document 3] International Publication No. 2004045491 [Patent Document 4] International Publication No. 2008057696 [Patent Document 5] International Publication No. 2013164380 [Patent Document 6] International Publication No. 2015067632 [Patent Document 7] International Publication No. 2014057432 [Patent Document 8] International Publication No. 2014165296 [Patent Document 9] International Publication No. 2015173824 [Patent Document 10] US Patent Application Publication No. 2009117306 [Patent Document 11] US Patent Application Publication No. 2011003883 [Patent Document 12] International Publication No. 2005102278 [Patent Document 13] International Publication No. 2013087083 [Patent Document 14] International Publication No. 2013040552 [Patent Document 15] International Publication No. 2013063019 [Patent Document 16] International Publication No. 2011003883 [Non-patent literature]

[0009] [Non-Patent Document 1] Hafner A et al., 2013 [Non-Patent Document 2] Schaffert D et al., 2011 [Non-Patent Document 3] Kabilova T et al., 2014 [Non-Patent Document 4] Kuebler K et al., 2011 [Non-Patent Document 5] Palchetti S et al., 2013 [Non-Patent Document 6] Saheki A et al., 2011 [Non-Patent Document 7] Chen L et al., 2013 [Non-Patent Document 8] McBain S et al., 2007 [Non-Patent Document 9] Cobaleda-Siles M et al., 2014 [Non-Patent Document 10] Kurosaki T et al., 2009 [Non-Patent Document 11] Tutin-Moeavin I et al., 2015 [Non-Patent Document 12] Bilensoy E, 2010 [Non-Patent Document 13] Germershaus O and Nultsch K, 2015 [Non-Patent Document 14] Islam M et al., 2014 [Non-Patent Document 15] Shabani M et al., 2010 [Non-Patent Document 16] Pozuelo-Rubio M et al., 2014 [Non-Patent Document 17] Tormo D et al., 2009 [Non-Patent Document 18] Bhoopathi P et al., 2014 [Non-Patent Document 19] Garcia-Pascual C and Gomez R, 2013 Summary of the Invention [Problem to be solved by the invention]

[0010] Indeed, the prior art does not provide adequate teachings to solve the problem of the most effective combination of structural and biophysical criteria that allows the production of poly(I:C)-containing compositions for the treatment of cancer. Also, regulatory agencies require strict compliance with standards for the reproducibility, storage, and size and concentration uniformity of poly(I:C)-containing particles contained in compositions for human use. General features of formulations of double-stranded polyribonucleotide systems (such as poly(I:C) molecules) and related drugs, compositions (collectively referred to as BO-11X products), as well as related processes that provide double-stranded polyribonucleotide molecules at higher and better controlled concentrations, are described in International Application PCT / EP2016 / 078078. However, preclinical and clinical characterization of the BO-11X product is still needed to improve the means of clinical evaluation and use tailored to patient compliance and to enable effective medical use of the BO-11X product as a drug (especially for cancer) in association with specific indications, ongoing treatments and / or regimens, while reducing the frequency of dosing of double-stranded polyribonucleotide molecules with a clear safety margin and therapeutic effect. [Means for solving the problem]

[0011] The present invention provides a composition comprising particles, (i) each of the above particles comprises a complex of at least one double-stranded polyribonucleotide or a salt thereof or a solvate thereof and at least one polyalkyleneimine or a salt thereof and / or a solvate thereof; (ii) at least 95% or at least 90% of the particles have a diameter of 600 nm or less, preferably 300 nm or less (e.g., 140 nm to 250 nm); (iii) the particles have a z-average diameter of less than or equal to 200 nm, preferably less than or equal to 150 nm, in particular as measured by ISO 22412:2017; Concerning the composition.

[0012] In a preferred embodiment, the present invention provides an aqueous composition comprising particles, comprising: (i) each of the particles comprises a complex of at least one double-stranded polyribonucleotide or a salt thereof or a solvate thereof with at least one linear polyalkyleneimine or a salt thereof and / or a solvate thereof, the double-stranded polyribonucleotide is polyinosinic-polycytidylic acid (poly(I:C)), and the linear polyalkyleneimine has an average molecular weight of 17 kDa to 23 kDa; (ii) at least 90% of the particles have a unimodal size distribution less than 300 nm; (iii) the particles have a z-average diameter, as measured by ISO 22412:2017, of less than or equal to 200 nm; (iv) the composition has a zeta potential according to ISO13099-2:2012 of 30 mV or more, preferably 35 mV to 50 mV; Concerning the composition.

[0013] The present invention also provides an aqueous composition comprising the particles disclosed herein, comprising: (i) each of the particles is formed by preparing a complex of at least one double-stranded polyribonucleotide or a salt thereof or a solvate thereof with at least one linear polyalkyleneimine or a salt thereof and / or a solvate thereof, the double-stranded polyribonucleotide being polyinosinic-polycytidylic acid (poly(I:C)), and the linear polyalkyleneimine having an average molecular weight of 17 kDa to 23 kDa; (ii) at least 90% of the particles have a unimodal size distribution less than 300 nm; (iii) the particles have a z-average diameter, as measured by ISO 22412:2017, of less than or equal to 200 nm; (iv) the composition has a zeta potential according to ISO 13099-2:2012 of 30 mV or more, preferably 35 mV to 50 mV; The particles are formed when the ratio of the number of moles of nitrogen of the polyalkyleneimine to the number of moles of phosphorus of the double-stranded polyribonucleotide in the composition is 2.5 or more. Concerning the composition.

[0014] The present invention also relates to compositions obtainable by lyophilization of the aqueous compositions disclosed herein.

[0015] These compositions can be further defined based on characteristics related to the following criteria: pH comprised between 2 and 4 and a concentration of one double-stranded polyribonucleotide of 0.5 mg or more per mL of total volume of said composition.

[0016] These compositions can be further defined based on the amount and size of the double-stranded polyribonucleotides, in particular: (i) at least 40% of the double-stranded polyribonucleotides contained in the particles have at least 850 base pairs, and at least 50% of the double-stranded polyribonucleotides contained in the particles have between 400 and 5000 base pairs, and / or (ii) 5% to 60% of the double-stranded polyribonucleotides have less than 400 base pairs, 15% to 30% of the double-stranded polyribonucleotides have 400 to 850 bases, 10% to 70% of the double-stranded polyribonucleotides have 850 to 5000 base pairs, and 0% to 10% of the double-stranded polyribonucleotides have more than 5000 base pairs.

[0017] These compositions are particularly suited to the desired use and method, and are more reproducible in their combination of components. The compositions have been successfully optimized for pharmaceutical manufacturing and clinical use by combining the above-mentioned properties and identifying physical and / or chemical criteria and associated numerical ranges (applicable to either the particles or the composition). Accordingly, a further preferred composition is an aqueous composition comprising particles, the composition comprising: (i) each of said particles is (a) polyinosinic-polycytidylic acid (poly(I:C)), or a salt or solvate thereof; at least 40% of the poly(I:C) molecules contained in the particles have at least 850 base pairs, and at least 50% of the poly(I:C) molecules contained in the particles have 400 to 5,000 base pairs; (b) a water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine, or a salt thereof and / or a solvate thereof; The linear polyalkyleneimine has an average molecular weight of 17 kDa to 23 kDa; The complex includes (ii) at least 90% of the particles have a unimodal size distribution of less than 300 nm (preferably less than 250 nm); (iii) the particles have a z-average diameter, as measured by ISO 22412:2017, of 60 nm to 130 nm (more preferably 80±20 nm) and a particle size polydispersity index of less than 1.5; (iv) the composition comprises poly(I:C) at a concentration of at least 0.5 mg / mL; (v) the composition has a pH of 2 to 4 and an osmolality of 200 mOsm / kg to 600 mOsm / kg; (vi) the composition has a zeta potential according to ISO 13099-2:2012 of 35 mV to 50 mV; It is a composition.

[0018] These ranges specified in the aqueous compositions and particles defined above may be further defined and / or limited as follows: (i) at least 10% of the poly(I:C) molecules contained in the particle have less than 400 base pairs, at least 40% of the poly(I:C) molecules have at least 850 base pairs, at least 70% of the poly(I:C) molecules have between 400 and 5000 base pairs, and between 20% and 45% of the poly(I:C) molecules have between 400 and 850 base pairs; (ii) between 5% and 60% of the poly(I:C) molecules contained in the particle have less than 400 base pairs, between 15% and 30% of the poly(I:C) molecules have between 400 and 850 bases, between 10% and 70% of the poly(I:C) molecules have between 850 and 5000 base pairs, and between 0% and 10% of the poly(I:C) molecules have more than 5000 base pairs; (iii) the particles have a median diameter (D50%) of 75 nm to 150 nm (preferably a median diameter of at least 85±20 nm); (v) the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine is a linear polyethyleneimine; (vi) the polydispersity index of the above particle size is included in the range of 0.2 to 0.3; (vii) the composition has a pH of 3.0±0.2 and an osmolality of 300 mOsm / kg to 310 mOsm / kg.

[0019] Additionally, the present invention relates to compositions disclosed herein, i.e., BO-11X formulations or compositions, for use as medicines, alone or in combination with other therapeutic agents. These compositions may further comprise at least one pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant, either included in the particles themselves or added to the aqueous composition, e.g., glucose, added at a concentration of 1%-10% (weight / volume). Additionally, the ... It may further comprise at least one compound, in particular a therapeutic compound, for example selected from non-coding RNA or RNA encoding a protein, an aptamer, a peptide or a protein.

[0020] Furthermore, the composition can be administered for medical use using a regimen combining different routes of administration (e.g., one or more intratumoral injections followed by one or more subcutaneous or intramuscular injections over a period of one week or more) and / or ex vivo exposure of human cells to the composition followed by re-administration of the cells to the patient. In this latter case, such a regimen includes induction of a specific activity in the patient's cells exposed to the composition, such as induction of interferon production by the cells in vitro. Otherwise, in vitro and / or ex vivo studies of immune responses to such compositions show that the BO-11X composition induces other biological mechanisms (e.g., interferon-independent and / or immune cell-targeted biological mechanisms) that can be exploited to promote therapeutically relevant events such as tumor cell death, enhanced local and / or systemic T cell immune responses in direct (in the injected tumor) or distant tumors, as well as other mechanisms that may be useful in the treatment of recurrent, non-responsive or refractory cancers to other therapies.

[0021] The dosage of the composition, in particular with regard to the content of double-stranded polyribonucleotide, can consequently be adapted to the respective administration type, regimen (e.g., highest for intratumoral injection, lower for subcutaneous or intramuscular injection, and even lower for treatment of cells ex vivo), and / or other drugs (if administered in combination therapy).

[0022] The present invention also relates to a composition as disclosed herein for use in the treatment or prevention of a cell proliferation disorder characterized by abnormal growth of human or animal cells, preferably cancer, most preferably solid cancer or lymphoma. Furthermore, the composition can be administered, for example, as an adjuvant, to treat or prevent cancer (solid or non-solid) or infection, and / or to rescue patients who are poorly responsive or resistant to drugs, including drugs for cancer immunotherapy, to alter cell metabolism and / or function (preferably in immune cells and / or cancer cells), to modulate DNA expression, replication and / or repair (including drugs targeting epigenetic mechanisms), or to support vaccines, cytokines, antigens, antibodies, chemical compounds and other compounds with immunomodulatory activity for standard therapies (such as chemotherapy or radiotherapy, or vaccine-based therapies using cancer or viral antigens).

[0023] Another object of the present invention relates to methods involving the compositions disclosed herein for assessing efficacy, the most suitable regimen, the most suitable therapeutic combination with another anti-cancer drug or standard treatment protocol, and / or subjects who show the best response to treatment with BO-11X therapy. These methods include measuring the up- and down-regulation of expression of a panel of genes in selected cell types (such as immune cells and cancer cells) after exposure to the BO-11X composition, and consequently applying appropriate measures to improve therapeutic efficacy (e.g., to stratify or select patients for further treatment, to administer or not administer drugs targeting specific biological targets, and / or to reduce or increase the dosage of BO-11X and / or other compositions).

[0024] The present invention further provides a process for producing the compositions disclosed herein, i.e., the BO-11X formulation or composition, comprising: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally further comprise a pharma- ceutically acceptable carrier, organic solvent, excipient, and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 500 nm or less to form a sterile solution; (iii) mixing the resulting sterile solutions in a mixing chamber by adding one of the solutions to the other in the mixing chamber at a rate of 1 mL / min or more, optionally by injection, or by simultaneously adding each of the solutions to the mixing chamber at a rate of 1 mL / min or more, optionally by injection, to form an aqueous composition; Also, optionally, (iv) filtering the resulting aqueous composition through a filter having a pore size of 600 nm or less to form a filtrate; or 2 centrifuging the aqueous composition obtained above to form a supernatant; The present invention relates to a process including the steps of:

[0025] The present invention also relates to aqueous compositions obtainable by the above process (including compositions that can be defined as light suspensions), as well as compositions obtained by lyophilizing the aqueous compositions, filtrates or supernatants optionally obtained, which can then be provided and / or used separately (or in a kit) with other medicinal compounds or devices (such as buffers, diluents, catheters, needles, filters or devices suitable for intratumoral administration).

[0026] Also preferably, the present invention relates to a composition comprising particles, (i) each of the above particles comprises a complex of at least one double-stranded polyribonucleotide or a salt thereof or a solvate thereof and at least one polyalkyleneimine or a salt thereof and / or a solvate thereof, wherein (a) the double-stranded polyribonucleotide is polyinosinic-polycytidylic acid (poly(I:C)) or polyadenylic-polyuridylic acid (poly(A:U)), at least 10% of the double-stranded polyribonucleotides have less than 400 base pairs, at least 40% of the double-stranded polyribonucleotides have at least 850 base pairs, at least 70% of the double-stranded polyribonucleotides have 400 to 5000 base pairs, and 20% to 45% of the double-stranded polyribonucleotides have 400 to 850 base pairs; (b) the polyalkyleneimine comprises at least 95% polyethyleneimine, the weight average molecular weight of the polyalkyleneimine is 17 kDa to 23 kDa, the polydispersity index is less than 1.5, and the ratio of the number of moles of nitrogen of the polyalkyleneimine to the number of moles of phosphorus of the double-stranded polyribonucleotide in the composition is 2.5 to 5.5; (ii) at least 99% of the particles have a diameter less than or equal to 600 nm; (iii) the particles have a z-average diameter of 30 nm to 150 nm; Concerning the composition.

[0027] Also, more preferably, the present invention relates to an aqueous composition comprising particles, (i) each of the above particles comprises a complex of at least one double-stranded polyribonucleotide or a salt thereof or a solvate thereof and at least one polyalkyleneimine or a salt thereof and / or a solvate thereof, wherein (a) the double-stranded polyribonucleotide is polyinosinic-polycytidylic acid (poly(I:C)), at least 10% of the double-stranded polyribonucleotides have less than 400 base pairs, at least 40% of the poly(I:C) have at least 850 base pairs, at least 70% of the poly(I:C) have 400 to 5000 base pairs, and 20% to 45% of the poly(I:C) have 400 to 850 base pairs; (b) the polyalkyleneimine is polyethyleneimine (PEI), wherein the weight average molecular weight of the PEI is 17.5 kDa to 22.6 kDa and the polydispersity index is less than 1.5, and the ratio of the number of moles of nitrogen of the polyalkyleneimine to the number of moles of phosphorus of the double-stranded polyribonucleotide in the composition is 2.5 to 4.5; (ii) at least 99% of the particles have a diameter less than or equal to 500 nm; (iii) the particles have a z-average diameter of 60 nm to 130 nm; (iv) the particles have a median diameter (D50%) of 75 nm to 150 nm; Concerning the composition.

[0028] Any of the compositions defined above, including compositions obtainable by lyophilization of the aqueous compositions defined above, can be further defined with respect to the characteristics of the manufacturing process. For example, the particles are formed with a ratio of the number of moles of nitrogen of the water-soluble, linear homopolyalkylenimine or heteropolyalkylenimine to the number of moles of phosphorus of the poly(I:C) molecules between 2.5 and 4.5. Preferably, the particles are formed by separately injecting a solution containing the poly(I:C) molecules and a solution containing the water-soluble, linear homopolyalkylenimine or heteropolyalkylenimine in a mixing chamber. The aqueous composition can be formed by adding glucose at a concentration of 1% to 10% (weight / total volume of the composition), preferably by adding glucose to a solution containing poly(I:C). Furthermore, the solution containing the poly(I:C) molecule and the solution containing the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine are injected separately at a flow rate of 1 mL / min to 50 mL / min for either solution, and / or mixed at a speed of 50 rpm to 600 rpm.

[0029] The more preferred ranges specified above in (i) to (vii) above with respect to the size of the poly(I:C) molecules contained in the particles, the unimodal size distribution of the particles, the linear polyalkyleneimine which is polyethyleneimine, the polydispersity index of the particle sizes, the osmolarity of the composition, and / or the pH of the composition (as well as the presence of a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant, or the presence of at least one compound, in particular a therapeutic compound) also apply to aqueous compositions comprising particles formed as indicated above.

[0030] Further embodiments of the preparation of such compositions in the form of BO-11X formulations, their characteristics, their analysis and their use (alone or in combination with other agents and in specific regimens) are provided in the detailed description and examples below, in particular to obtain improved or optimized therapeutic responses for specific indications and / or in combination with other drugs and therapies (such as chemotherapy, radiotherapy, agents targeting immune checkpoint molecules, inhibitors of kinases and other enzymes that modulate immune cell and / or cancer cell activity, including T cell-mediated responses, DNA repair and / or replication, or metabolic activity). The BO-11X formulation can be used in a method for treating cell proliferation disorders (particularly cancer) characterized by abnormal growth of human or animal cells in combination with a second therapeutic agent selected from anti-CTLA4, anti-PD1, anti-PDL1, CAR-T cells, cancer antigen vaccines, or agents targeting regulatory T cells, metabolic enzymes, DNA repair and / or replication, or proteins expressed by any of the genes of Table I (see Example 4). More specifically, the BO-11X formulation can be used to achieve synergistic therapeutic effects when administered with the second therapeutic agent, including the possibility of reducing the usual dosage and / or frequency of administration of the second therapeutic agent (thus reducing medical intervention, drug resistance, and / or patient discomfort). Furthermore, the BO-11X formulation when administered with the second therapeutic agent can enable the treatment of patients who are resistant, insensitive, or have little (or no) response to the second therapeutic agent, and may overcome any specific tumor resistance or escape mechanism (including mutations that alter the response to specific genes, pathways, and / or drugs, or endogenous compounds such as cytokines). Thus, the BO-11X formulation can be used in particular for the treatment of cancer, in the form of drug-rescue drug rescue or drug-sensitization combination therapy. [Brief description of the drawings]

[0031] [Figure 1]Figure 1 shows the GMP manufacturing and structural analysis of BO-11X aqueous compositions, exemplified by BO-112. (A) Flowchart summarizing the main steps of manufacturing the BO-112 compound as a GMP-compliant pharmaceutical formulation, including poly(I:C) molecules, a commercial JetPEI formulation, and glucose. This approach can also be applied by using other types of polyribonucleotides forming double-stranded molecules formed by poly(A), poly(U), poly(C) and / or poly(G) according to their respective pairing properties. Alternatively, this approach can include adding another compound (immune-related adjuvant or therapeutic compound, e.g. CD40L, IL12, viral or tumor antigens, miRNA, mRNA, or other (non-coding) RNA / nucleic acid-based drugs, or anti-cancer drugs such as inhibitors of kinases or other enzymes that affect cell replication, metabolism, or biological functions) together with (or instead of) glucose or other excipients in step 1. (B) The particle size distribution of the BO-112 complex is compared to three commercially available poly(I:C)-containing products (Poly-ICLC, LyoVec-HMW and LyoVec-LMW). The particle size is defined by considering the particle size in nanometers (d.nm) by dynamic light scattering (Zetasizer Nano ZS technology). These commercially available preparations also show a substantial change in particle size distribution after storage at -20°C, whereas the BO-112 preparation shows no change. [Diagram 2]Figure 1 shows the effect of various poly(I:C) formulations on cell viability in separate cancer cell models. (A) BO-112 is compared to untreated cells and cells treated with poly-ICLC, LyoVec-LMW or LyoVec-HMW, with each formulation tested at the indicated concentrations determined according to complex weight but with similar content of poly(I:C) molecules in either melanoma (SK-MEL-103) or pancreatic cancer (PANC02.03) cell models. Cell viability data was generated using a crystal violet assay method after 24 hours. This in vitro cytotoxicity assay was performed in other mouse (4T1 breast cancer, MC38 colon cancer and B16-F10-OVA melanoma cell lines) and human (PAN02.03 pancreatic cancer cell line) models by incubating cells with 0.25 μg / mL to 1.0 μg / mL of BO-112 for 24 or 48 hours to confirm the direct cytotoxic effect on such cell lines. (B) The effect of different poly(I:C) formulations on signaling molecules of therapeutic interest, such as interferon-beta (IFN-beta) expression, was assessed by RT-qPCR in SK-MEL-103 cells exposed to BO-112, poly-ICLC (or untreated, NT) for 8, 16, and 24 h. BO-112 and poly-ICLC formulations were used at concentrations providing similar contents of poly(I:C) molecules. [Diagram 3] Figure 1 shows the effect of linear PEI only, poly(I:C), and two different PEI / poly(I:C) formulations (BO-110 and BO-112) on the viability of normal, primary melanocytes (formulations 1 and 2) and four cancer cell lines, demonstrating the specific cytotoxicity of such PEI / poly(I:C) formulations against cancer cell lines. The content of poly(I:C) used in the formulations of poly(I:C) only, BO-110 and BO-112 treatments applied is identical (1 μg / mL per 40 h treatment). [Figure 4]Figure 1 shows the effect of BO-112, different poly(I:C) formulations on patient-derived melanoma cells (SK-Mel 103 cell line). BO-112 is compared to non-treated cells (NT) and cells treated with Poly-ICLC, LyoVec-LMW or LyoVec-HMW ex vivo, with each formulation tested at a concentration determined according to the complex weight but with a similar content of poly(I:C) molecules. (A) Cell viability data was generated using a crystal violet assay after 48 hours of treatment with each poly(I:C) formulation at 0.35 μg / ml. (B) Interferon-alpha / beta (IFNa / b, arbitrary units) expression was assessed 16 and 24 hours after treatment with each poly(I:C) formulation at 0.5 μg / ml. [Diagram 5] Figure 1 shows the effect of BO-112, lipopolysaccharide (LPS), and poly(I:C) formulations that make BO-112 on the expression of different types of cell death and related markers. B16-F10-OVA cells (105 cells / well) were cultured for 48 hours alone (control) or with LPS, BO-112, or poly(I:C) molecules only (with the same particle size distribution as those incorporated in the BO-112 formulation) at the indicated concentrations, and the percentage of cells that were still viable or displayed a combination of markers for early / late apoptosis, or necrosis (Annexin V and 7ADD staining; A) or expressed specific markers of immunogenic cell death such as MHC-I, CD95, or calreticulin (B) were measured by flow cytometry. [Figure 6]Figure 13 shows the effect of BO-112 on the activation of the enzyme poly ADP-ribose polymerase (PARP). 4T1 breast cancer or MC38 colon cancer cells (3x106) were cultured with BO-112 (0.5μg / mL). Activation of PARP, an enzyme involved in DNA repair, genomic stability and programmed cell death, was assessed by Western blot analysis at 0, 16 and 24 hours after BO-112 stimulation. Cell lysates were analyzed for the presence of intact 116kDa PARP protein and the 85kDa apoptosis-induced cleavage product. Tubulin was added as a control for equal protein loading. The results show that BO-112 formulations promote activation of the PARP enzyme in both MC38 and 4T1 cancer cells, providing a rationale for the use of BO-112 compositions in combination with PARP inhibitors in patients for whom PARP inhibitors are little or not effective and may need to be sensitized (see also Figure 14B and Figure 15B). [Figure 7]Figure 1 shows the effect of administration of BO-112 in an animal model for human melanoma. (A) Timeline showing the schedule of treatment. On day 0, all mice were injected subcutaneously with B16-F10 mouse melanoma cells. After randomization into five groups of mice presenting tumors of similar average size (80 mm3-100 mm3) on day 7, animals were treated with BO-112 formulations (double circles) by direct injection into tumor tissue (it treatment) at three different concentrations in groups 2, 3 and 4 (G2, G3, G4), or with vehicle alone in the remaining two groups (G1 and G5). In addition to intratumoral administration of BO-112 formulations at the same concentrations on day 7, all groups except G1 received intraperitoneal (ip) administration of anti-PD-L1 mouse antibody (150 μg / dose) on the later treatment days (days 10, 14, 17, 21 and 24). Survival was monitored daily and death was scored when a dead mouse was found or when tumor burden reached maximum allowable size. After the last treatment, monitoring continued until day 45, when the last mouse died and the experiment was terminated. (B) Survival curves comparing control groups G1 and G5 with three groups administered BO-112 formulations at the three concentrations indicated. Comparing the above groups, there was a statistical difference (p<0.0001, Log-rank Mantel-Cox test) between the control and test groups, with G4 showing the most robust increase in survival versus vehicle or anti-PD-L1 alone. (C) Therapeutic effect of BO-112 as a single agent in a further B16-F10 model of human melanoma. B16-F10 melanoma cells (5x105 cells) are injected subcutaneously as described in A, and BO-112 is administered intratumorally (8 or 9 mice / group; control group, vehicle only; treatment group, BO-112; BO-112 dose / mouse: 2.5mg / Kg in 100μl). (D) Tumor size was measured weekly by caliper and volume was calculated for each animal (length x width 2 / 2). Spider plots show individual tumor growth curves for control (vehicle) and BO-112 treated mice, showing that BO-112 formulations reduce tumor growth compared to vehicle. [Figure 8]Figure 1 shows the abscopal effect of BO-112 administration in an animal model for human melanoma. (A) Mice with two cancers induced by implantation of melanoma B16-F10-OVA were treated by intratumoral administration only in one mass (for BO-112) and / or systemically by intraperitoneal administration (for anti-PD-L1) using the same regimen and dose as in the experiment shown in Figure 7 (n=10 mice / group). (B) Tumor volume increase was measured in four groups of control, single agent treatment or combination treatment, both in the treated and in the untreated distant masses. Tumors were measured weekly by caliper and the volume was calculated for each animal in the group (length x width 2 / 2). [Figure 9] Figure 1 shows the effect of BO-112 administration in an animal model for human breast cancer. (A) Model and treatment scheme with 4T1 breast cancer cells (5x105 cells) injected subcutaneously (sc) into the right flank of 8-10 week old female BALB / c mice (6 or 7 mice / group; control group, vehicle only; treatment group, BO-112). Treatment was initiated when tumor volume was 80-100 mm3 (day 9). BO-112 and vehicle administration was intratumorally by a single direct injection (dose / mouse: 2.5 mg / Kg in 100 μl) into the right flank mass on the days indicated. Tumors were measured weekly by caliper and volumes were calculated (length x width 2 / 2) for each animal in a group, with data shown for each such animal separately (number of animals for each group indicated) (B) or for each group together (C). A statistically relevant reduction in tumor volume was observed in the BO-112 treatment group. [Figure 10]Figure 1 shows the effect of BO-112 administration in an animal model for human colon cancer. (A) In the first model and treatment scheme, MC38 colon cancer cells (5x105 cells) were injected sc into the right flank of 8-10 week old female C57BL / 6 mice (7 or 8 mice / group; G1 control group, vehicle only; G2 treatment group). Treatment was started when tumor volume reached 80-100 mm3 (day 16). BO-112 and vehicle were administered intratumorally by a single direct injection into the right flank mass (dose / mouse: 2.5 mg / Kg in 100 μl) on the indicated days. (B) Mouse survival in this first model was assessed using Kaplan-Meier analysis. Tumors were also measured weekly by caliper and volumes were calculated (length x width 2 / 2) for each animal in a group, with data presented for each such animal separately (C) or combined for each group (D). A statistically relevant reduction in tumor volume was observed in the BO-112 treatment groups. [Figure 11] Figure 1 shows the effect of BO-112 administration in a second model for human colon cancer using different treatment schemes. (A) MC38 colon cancer cells (1x106 cells) were injected sc into the right flank of 8-10 week old female C57BL / 6 mice (4-11 mice / group; G1 control group, vehicle only; G2 treatment group). Treatment was started when tumor volume was 80-100 mm3 (day 11). BO-112 and vehicle were administered intratumorally by a single direct injection (dose / mouse: 2.5 mg / Kg in 100 μl) into the right flank mass on the indicated days. The remaining mice that did not bear tumors after BO-112 treatment were re-challenged with MC38 cells (2.5x105 cells) injected sc into the left flank on day 60 and tumor growth and mouse survival were followed. (B) Mouse survival in this second model was also assessed using Kaplan-Meier analysis, and showed that four animals rechallenged on day 60 were still alive at day 80, suggesting that treatment with IgG4 may induce cancer cell apoptosis while simultaneously promoting immune memory against cancer cells. [Figure 12]Figure 2 shows the effect of BO-112 treatment in a model for adaptive immune response activation in human cancer. (A) An MC38-based model for human colon cancer is established as previously described, but incorporating two additional groups that also receive antibodies that deplete either CD4- or CD8-positive T cells (treatment schedule: BO112: d8, d11, d15, d18, d22, d25; anti-CD4 or anti-CD8: d7, d8, d11, d15, d22, d29). (B) Analysis of tumor growth curves of MC38 tumor-bearing mice treated with BO-112, showing that only depletion of CD8-positive T cells impairs the therapeutic properties of the BO-112 formulation (tumor volumes are shown in parallel for the different groups, N is the number of mice per group, and the dotted line indicates the end of BO-112 treatment at d25). (C) Effect of BO-112 therapy on T cell recruitment and activation to the tumor, and on priming of antigen-specific CD8+ T cells. The frequency of various cell markers for T cell subsets (CD8+ or CD4+) and T cell activation (CD137, IFN-γ, and PD-1) is measured by flow cytometry in B16-F10-OVA tumors (draining lymph nodes for tetramer analysis) from mice treated with vehicle or BO-112 formulations 24 hours after the second BO-112 dose. The graphs show that BO-112 therapy significantly increases CD8+ T cells in this model and promotes CD4+ and CD8+ T cell activation in the tumor infiltrate. (D) The frequency of various cell markers for T cell subsets (CD8+ or CD4+) and T cell priming (OVA and Trp2 tetramer) showing that BO-112 also significantly enhances the frequency of antigen-specific CD8+ T cells in the tumor (for OVA and endogenous Trp2 antigen) and in the draining lymph nodes (especially for Trp2 antigen). All data (even from different experiments) consistently demonstrate that BO-112 formulations have the potential to activate anti-tumor adaptive immune responses and induce systemic immunity. [Figure 13]Figure 1 shows the therapeutic effect of BO-112 in a model evaluating the dependency on interferon expression in human cancer: (A) IFN-independent in vitro tumor cell cytotoxicity is assessed by MTS assay at 24, 48 and 72 hours for cell viability. Briefly, cells of each cell line: B16, B16-IFNα / β (IFNγ unresponsive; from InvivoGen) and B16-IFNγ (IFNα / β unresponsive; from InvivoGen) were cultured (5×103 cells / well, 96 flat-well plates) alone or with 0.5 μg / ml BO-112 for 24, 48 and 72 hours, and alone or alternatively with BO-112 (0.5 μg / ml) or with 2′3′cGAMP STING agonist (7 μg / ml) for 24 hours (demonstrating the superior potency of BO-112 over the reference STING agonist). Two independent assays were performed with at least 8 wells per condition. The in vivo therapeutic efficacy of BO-112 against an IFN-resistant B16-based model of human melanoma was tested in B16-IFNα / β (B) and B16-IFNγ (C) cancer cells as described above, injected sc (5×105 cells) into the right flank of 8-10 week old female C57BL / 6 mice (7-10 mice / group). Treatment was initiated when tumor volume reached 80-100 mm3 (day 8). BO-112 and vehicle were administered intratumorally by a single direct injection into the right flank mass (BO-112 dose / mouse: 2.5 mg / Kg in 100 μl; 2 doses / week for 3 weeks). Tumors were measured weekly by caliper until sacrifice, and volumes were calculated. The graphs show that BO-112 reduced tumor volume (individual spider plots) and significantly improved survival (Kaplan-Meier curves) in mice treated with BO-112 compared to vehicle, indicating that the BO-112 formulation has a potent therapeutic effect on cancer cells resistant to IFN. [Figure 14]1A-1D show alternative means and regimens of BO-11X administration. (A) Administration of BO-11X formulations such as BO-112 can begin with one to four intratumoral injections (BO-11XI.T.) given weekly, every two weeks, or every three weeks (0.4 mg-2.4 mg / injection; or at greater intervals up to once every six weeks as may be performed in responding or stable patients during clinical studies). The initial administration can be followed by several subcutaneous or intramuscular injections of BO-11X (BO-11XSQ / IM; 0.2 mg-2 mg / injection). For other intratumoral treatments, the regimen may include injections into the same lesion (if still present), or into other lesions if the original lesion is no longer present or if the initial intratumoral injection has not reduced such lesion (due to systemic immune activation or other response) or other signs of tumor burden, stage, persistence, metastasis, and / or recurrence. (B) Alternatively, BO-112 administration can be accomplished by intratumoral injections spaced over 20 weeks (every week, every 2 weeks, every 4 weeks, every 6 weeks or more), alternating IT administration in the same (black diamonds) and other cancer lesions (gray diamonds), with or without concurrent treatment (triangles, e.g., applied every 2 weeks or every 3 weeks) with other regimens and / or administrations initiated before or after BO-11X treatment, such as chemotherapy, radiotherapy, small molecules, checkpoint inhibitors, antibodies, etc. In the former case, initial BO-11X monotherapy regimen A can be combined (e.g., with pembrolizumab or ipilimumab) or BO-11X monotherapy regimen B can be combined (e.g., with nivolumab) to rescue or support the treatment of a second therapeutic agent that would otherwise be less (or not at all) effective. In the latter case, either BO-11X monotherapy regimen A or initial BO-11X monotherapy regimen B (each of the two regimens combined with an antibody listed above) allows for sensitization of the tumor (or patient) to additional therapeutic agents (particularly immunotherapy).(C) As an adjuvant to be used ex vivo on cells obtained from a patient (such as a vaccine adjuvant for ex vivo maturation of dendritic cells DC), treatment can be initiated by obtaining a blood sample from the patient to isolate the relevant cell type by hemofiltration, a procedure that separates cells by positive selection, and cell sorting for such subsets of dendritic cells (DC), such as monocyte-derived dendritic cells (Mo-DCs), the BDCA3 positive subset that are the main producers of type I interferon in response to stimuli such as poly(IC) molecules and other subsets of dendritic cells, or CD34+ derived dendritic cells. These cells can then be expanded and / or matured ex vivo for a given number of days during which the cells are exposed to a BO-112 formulation for various times (e.g., 1 hour, 3 hours, 8 hours, 24 hours or more) before being used for antigen loading to complete the DC-based vaccination formulation. Such activation of DCs can also be pursued and completed (or achieved directly) by induction of immunogenic cell death in tumors by intramuscular or subcutaneous injection of BO-112, intratumoral injection of BO-112 and / or in vivo delivery of tumor antigens. [Figure 15]Figure 1 shows alternative means for evaluating and using BO-11X in patients. (A) Flowchart summarizing medically relevant readings for evaluating administration of BO-11X formulations such as BO-112. Tracking of medical status can be performed, for example, by physical examination and imaging techniques to identify and measure tumor burden and / or monitor cancer-specific biomarkers in blood to evaluate response to treatment or recurrence. A series of sub-criteria can be associated with each of the three main evaluation criteria (i.e., the lower box of the flowchart) using evaluation of specific parameters in tumor tissue and / or blood samples obtained by biopsy, including changes in the expression of and / or response to cytokines (such as interferons or interleukins, individually or in specific combinations, see Example 4) or circulating / infiltrating immune cells. (B) A flow chart summarizing the therapeutic opportunities available following (and potentially beginning at the same time or even prior to) administration of a BO-11X formulation, such as BO-112, using the readouts set forth in the previous flow chart and additional readouts (e.g., by analysis of gene expression, protein expression, mutational burden status, or T-cell clonality in specific cells or tissues before and after administration of BO-112). This analysis results in a molecular signature induced by BO-112 that may indicate continuation with the same or a different regimen of BO-11X treatment, or a different type of medical follow-up, including the possibility of using a treatment (e.g., radiation therapy, chemotherapy, anti-PD-1 or other immunomodulatory therapy, cancer vaccination, cell therapy, etc.) to which the patient's tumor was identified as poorly responsive, resistant, or insensitive prior to administration of the BO-11X formulation (i.e., the bottom box of the flow chart). [Figure 16]Figure 1 shows clinical data generated in a patient's metastatic lesion. A 46-year-old woman with metastatic leiomyosarcoma developed progressive disease after undergoing several treatments (notably chemotherapy and anti-PD-1 / anti-LAG-3 combination). The woman had a cancer lesion of the abdominal wall suitable for injection and received an intratumoral injection of BO-112 with informed consent. After three doses of 0.6 mg BO-112, the patient received no further systemic treatment, only palliative irradiation for the femoral (bone) metastasis. (A) Arrows indicate associated lesions showing increasing radiological signs of tumor necrosis established by imaging analysis in four different locations (left column) and repeated in a similar location 3 months later (right column), showing improvement in both BO-112-injected and non-injected lesions. (B) Populations of circulating immune cells (defined based on specific or combined cell surface markers such as CD4, CD8 or CD8) were assessed in this patient's peripheral blood before and after BO-112 treatment, showing that (after an initial reduction) BO-112 treatment can increase the amount of specific cell subpopulations in the circulation, particularly NK cells and CD16 positive cells. [Figure 17] Figure 1 shows clinical data generated in a 72-year-old female patient presenting with metastatic melanoma (stage IV) with progressive disease. The woman had previously undergone multiple surgeries, including phalanx amputation and inguinal lymphadenectomy, as well as radiation therapy. Previous systemic treatments included pembrolizumab and fotemustin followed by interferon. The patient was assessed to have a 9 cm lesion in the groin suitable for intratumoral injection. With informed consent, the groin lesion was injected with a single 0.6 mg dose of BO-112 under ultrasound guidance, followed by imaging analysis, which was repeated in the same location the following week. One week after this dose, the size of the target lesion was reduced to 8 cm. The patient was then treated with ipilimumab (anti-CTLA4 antibody, 3 mg / kg every 3 weeks for 4 cycles), resulting in further improvement of the cancer lesion. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] The present invention discloses a composition comprising what is defined in the composition claim of PCT / EP2016 / 078078 (defined as BO-11X in PCT / EP2016 / 078078 and exemplified in Examples 1 and 2 thereof, where X is an integer). The group of features of the BO-11X composition disclosed in PCT / EP2016 / 078078 are included in the BO-112 composition. In particular, the BO-112 composition can be further defined by combining certain features that apply to either the particles included in the BO-112 composition or the physicochemical features associated with the aqueous composition.

[0033] A preferred BO-112 composition is an aqueous composition comprising particles, (i) each of the particles comprises a complex of at least one double-stranded polyribonucleotide, or a salt or solvate thereof, and at least one linear polyalkyleneimine, or a salt and / or solvate thereof, wherein the double-stranded polyribonucleotide is polyinosinic-polycytidylic acid (poly(I:C)), and the linear polyalkyleneimine has an average molecular weight of 17 kDa to 23 kDa; (ii) at least 90% of the particles have a unimodal size distribution less than 300 nm; (iii) the particles have a z-average diameter, as measured by ISO 22412:2017, of less than or equal to 200 nm; (iv) the composition comprises polyinosinic-polycytidylic acid (poly(I:C)) at a concentration of at least 0.5 mg / mL; (v) the composition has a pH of 2 to 4; (vi) the composition has a zeta potential according to ISO 13099 of 35 mV to 50 mV; It is a composition.

[0034] In a preferred embodiment, the BO-112 composition is a composition according to above, wherein at least 90% of said particles have a monomodal size distribution between 30 nm and 150 nm.

[0035] In a more preferred embodiment, the BO-112 composition is a composition according to the above, wherein at least 40% of the double-stranded polyribonucleotides contained in said particles have at least 850 base pairs, and at least 50% of the double-stranded polyribonucleotides contained in said particles have between 400 and 5000 base pairs.

[0036] In an even more preferred embodiment, the BO-112 composition is a composition according to above, wherein said composition has a zeta potential comprised between 38 mV and 45 mV.

[0037] In an even more preferred embodiment, the BO-112 composition is a composition according to above, wherein said linear polyalkyleneimine is a water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine.

[0038] In an even more preferred embodiment, the BO-112 composition is a composition according to above, wherein said linear polyalkyleneimine is a linear polyethyleneimine.

[0039] In an even more preferred embodiment, the BO-112 composition is a composition according to above, having a particle size polydispersity index of less than 1.5.

[0040] In a further preferred embodiment of the above, the BO-112 composition is a composition according to the above, in which, in polyinosinic-polycytidylic acid (poly(I:C)), 5% to 60% of the double-stranded polyribonucleotides have less than 400 base pairs, 15% to 30% of the double-stranded polyribonucleotides have 400 to 850 bases, 10% to 70% of the double-stranded polyribonucleotides have 850 to 5000 base pairs, and 0% to 10% of the double-stranded polyribonucleotides have more than 5000 base pairs.

[0041] In an even more preferred embodiment, the BO-112 composition is a composition according to the above, further comprising at least one pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant.

[0042] In an even more preferred embodiment, the BO-112 composition is a composition according to the above, further comprising at least one compound selected from an organic compound, an inorganic compound, a nucleic acid, an aptamer, a peptide or a protein.

[0043] In an even more preferred embodiment, the BO-112 composition is a composition according to the above, further comprising glucose or mannitol in a concentration of 1% to 10% (weight / volume).

[0044] In an even more preferred embodiment, the BO-112 composition is a composition according to the above, which is an aqueous composition having an osmolality of 200 mOsm / kg to 600 mOsm / kg.

[0045] In an even more preferred embodiment, the BO-112 composition comprises: (i) each of the particles is formed by preparing a complex of at least one double-stranded polyribonucleotide, or a salt or solvate thereof, with at least one linear polyalkyleneimine, or a salt and / or solvate thereof, wherein the double-stranded polyribonucleotide is polyinosinic-polycytidylic acid (poly(I:C)), and the linear polyalkyleneimine has an average molecular weight of 17 kDa to 23 kDa; (ii) at least 90% of the particles have a unimodal size distribution less than 300 nm; (iii) the particles have a z-average diameter, as measured by ISO 22412:2017, of 200 nm or less; (iv) the composition comprises polyinosinic-polycytidylic acid (poly(I:C)) at a concentration of at least 0.5 mg / mL; (v) the composition has a pH of 2 to 4; (vi) the composition has a zeta potential of 30 mV or more according to ISO 13099; The particles are formed with a ratio of moles of nitrogen of the polyalkyleneimine to moles of phosphorus of the double-stranded polyribonucleotide in the composition of 2.5 or greater. The composition according to the above.

[0046] In an even more preferred embodiment of the present invention, the BO-112 composition comprises polyinosinic-polycytidylic acid (poly(I:C)) (i) a polyinosinic acid (poly(I)) preparation in which 80%-99% of the molecules have less than 400 bases, 0%-20% of the molecules have 400-850 bases, 0%-5% of the molecules have 850-5000 bases, and 0%-5% of the molecules have more than 5000 bases; (ii) polycytidylic acid (poly(C)) preparations in which 20%-85% of the molecules have less than 400 bases, 10%-40% of the molecules have between 400 and 850 bases, 0%-50% of the molecules have between 850 and 5000 bases, and 0%-5% of the molecules have more than 5000 bases; The composition according to claim 1, wherein the first and second electrodes are formed by annealing the first and second electrodes.

[0047] In yet a further preferred embodiment and a more preferred embodiment of that preferred embodiment, The BO-112 composition is a composition according to the above formed by further adding glucose or mannitol at a concentration of 1% to 10% (weight / total volume of the composition).

[0048] In a more preferred embodiment of the above, the polyinosinic-polycytidylic acid (poly(I:C)) is (i) a polycytidylic acid (poly(C)) preparation in which 20%-82% of the molecules have less than 400 bases, 15%-40% have between 400 and 850 bases, 3%-50% have between 850 and 5000 bases, and less than 1% of the molecules have more than 5000 bases; (ii) a polyinosinic acid (poly(I)) preparation in which 80%-99% of the molecules have less than 400 bases, 1%-20% of the molecules have between 400 and 850 bases, 0%-5% of the molecules have between 850 and 5000 bases, and less than 1% of the molecules have more than 5000 bases; It is formed by annealing.

[0049] More preferably, the polyinosinic-polycytidylic acid (poly(I:C)) is (i) a polycytidylic acid (poly(C)) preparation in which 33%-73% of the molecules have less than 400 bases, 20%-37% of the molecules have between 400 and 850 bases, 5%-48% of the molecules have between 850 and 5000 bases, and less than 1% of the molecules have more than 5000 bases; (ii) a polyinosinic acid (poly(I)) preparation in which 81%-98% of the molecules have less than 400 bases, 6%-17% of the molecules have between 400 and 850 bases, 0%-3% of the molecules have between 850 and 5000 bases, and less than 1% of the molecules have more than 5000 bases; It is formed by annealing.

[0050] In the above-mentioned even more preferred embodiment, the BO-11X composition and the BO-112 composition contain poly(I:C) molecules having a particle size distribution in which 7% to 57% of the molecules contained in the poly(I:C) have less than 400 bases, 20% to 45% of the molecules have 400 bases to 850 bases, 20% to 70% of the molecules have 850 bases to 5000 bases, and 0% to 9% of the molecules have more than 5000 bases. It is more preferred that the BO-11X composition and the BO-112 composition contain poly(I:C) molecules having a particle size distribution in which 10% to 30% of the molecules contained in the poly(I:C) have less than 400 bases, 20% to 30% of the molecules have 400 bases to 850 bases, 40% to 60% of the molecules have 850 bases to 5000 bases, and 0% to 5% of the molecules have more than 5000 bases. It is even more preferable that the BO-11X composition and the BO-112 composition contain poly(I:C) molecules having a particle size distribution in which 11% to 28% of the molecules contained in the poly(I:C) have less than 400 bases, 23% to 27% of the molecules have 400 to 850 bases, 42% to 55% of the molecules have 850 to 5000 bases, and 0% to 3% of the molecules have more than 5000 bases.

[0051] The BO-112 compositions are also compositions that may be obtained by lyophilization of an aqueous composition according to any of the above embodiments. These lyophilized BO-112 compositions can then be reconstituted with an appropriate solution to obtain formulations, in particular compositions comprising particles, exhibiting one or more of the characteristics defined above, (i) each of said particles comprises a complex of at least one double-stranded polyribonucleotide, or a salt or solvate thereof, and at least one polyalkyleneimine, or a salt and / or solvate thereof; (ii) at least 95% or at least 90% of the particles have a diameter of 900 nm or less, preferably 500 nm or less (e.g., 140 nm to 400 nm or 140 nm to 250 nm); (iii) The particles may have a z-average diameter of less than or equal to 300 nm, preferably less than or equal to 200 nm, more preferably less than or equal to 150 nm, in particular as measured by ISO 22412:2017.

[0052] Furthermore, the present invention also relates to a preparation that can be obtained by ex vivo treatment of cells or tissues derived from a subject with a BO-11x composition, preferably a BO-112 composition, as defined herein.Preferably, said preparation comprises cells or tissues derived from a subject that have been treated ex vivo with a composition disclosed herein.More preferably, said cells or tissues are cells or tissues in a sample derived from a subject, such as a blood sample, a lymph sample or a tissue biopsy.

[0053] The present invention also provides a means for generating an aqueous solution of poly(I:C) molecules (already containing or not containing excipients such as glucose or mannitol), with characteristics suitable for mixing with an aqueous solution of polyalkyleneimine (such as polyethyleneimine) to produce BO-11X formulations. The poly(I:C)-containing formulation resulting from mixing these two aqueous solutions may then be maintained as a batch preparation (preferably still as an aqueous solution or in lyophilized form) or directly prepared in aliquots, each contained in a single-use vial, syringe, or other suitable container for storage, single use of such aliquots, and / or lyophilization. The BO-11X formulation (liquid or lyophilized form) may be stored at room temperature, at temperatures comprised between 8°C and 2°C, or at temperatures below 0°C or below -20°C.

[0054] In such preferred embodiments, additional compounds (such as one or more antibodies, hormones, peptides, excipients, carriers, inhibitors of enzyme activity, chemotherapeutic agents, antibiotics, stabilizers, labeling agents, organic solvents, preservatives, carriers, or other drugs) may be added to each of the two aqueous solutions either before their mixing (provided they do not alter the correct formation of the particles or any other characteristics listed above for the BO-11X formulation) or after the BO-11X formulation is produced by mixing the two aqueous solutions (double-stranded polyribonucleotide and polyalkyleneimine). Such additional components, which are subsequently administered simultaneously with the BO-11X component, may provide the composition with improved bioavailability, efficacy, pharmacokinetic / pharmacodynamic profile, stability, metabolism, or other properties of pharmaceutical interest that are not observed when the original BO-11X formulation or each of the additional components (e.g., another compound of pharmaceutical interest) is administered alone or when the original BO-11X formulation or each of the additional components is administered separately.

[0055] In a further preferred embodiment, the BO-11X formulation is formulated (e.g., as an injectable aqueous composition, optionally including pharma- ceutically acceptable carriers, excipients and / or adjuvants) and used as a medicament, such as a pharmaceutical composition administered for the delivery of double-stranded polyribonucleotides to organs or tissues in a state of health that presents a disease associated with an exogenous pathogen (such as a bacterium or virus) or that presents alterations due to a cell proliferation disorder characterized by abnormal growth of human or animal cells, such as cancer (i.e., involving oncogenic transformation, metastasis, toxic compounds), or a gynecological disorder characterized by abnormal growth of cells of the reproductive organs of female mammals. Thus, in a preferred embodiment, the present invention relates to a method for treating a disease comprising administering a composition of the present invention to a human or animal. In a further preferred embodiment, the present invention relates to a method for treating a cell proliferation disorder characterized by abnormal growth of human or animal cells, as defined herein, comprising administering a composition of the present invention to a human or animal.

[0056] The BO-11X formulation is preferably used in methods for reducing, ameliorating or preventing cancer growth, survival, metastasis, epithelial-mesenchymal transition, immunological evasion or recurrence in the therapeutic field, inducing (directly or indirectly) the death of tumor cells or inhibiting tumor cell growth. More preferably, the BO-11X formulation is used in methods for treating solid tumors, such as carcinomas, gliomas, melanomas or sarcomas. In particular, the BO-11X formulation is administered either directly into the tumor or close to the tumor, such as systemically, or to the margins of tumor masses, surrounding epithelial cells, lymphatic or blood vessels (e.g., intratumoral or peritumoral injection), or to abnormally growing cells of the reproductive organs of female mammals. A further preferred embodiment of the present invention relates to a BO-112 composition as defined above, for use as a medicament. A further preferred embodiment of the present invention relates to a BO-112 composition as defined above, for use as a medicament. The present invention relates to a BO-112 composition for use in the treatment of chronic bronchitis, wherein said medicament is an injectable aqueous composition optionally comprising pharma- ceutically acceptable carriers, excipients and / or adjuvants.

[0057] Another embodiment of the present invention relates to a BO-112 composition as defined above for use in the treatment of a cell proliferation disorder characterized by abnormal growth of cells in a human or animal. A preferred embodiment relates to a BO-112 composition for use according to above, wherein said cell proliferation disorder is cancer or a gynecological disorder characterized by abnormal growth of cells of the reproductive organs of a female mammal. A more preferred embodiment of the above-mentioned embodiment relates to a BO-112 composition for use according to above, wherein the composition is for use in intratumoral or peritumoral injection. Alternatively, a more preferred embodiment of the above-mentioned embodiment and its preferred embodiments relates to a BO-112 composition for use according to above, wherein the composition is for use in injection at the level of the skin or visceral or internal tissues.

[0058] Another embodiment of the present invention relates to a BO-11X composition, preferably a BO-112 composition, as defined above, for use as a vaccine. Similarly, the present invention also relates to a method for treating a disease in a subject (patient) using said vaccine. Preferably, said BO-11X or BO-112 composition is for use as a vaccine in the treatment of a cell proliferation disorder characterized by abnormal growth of human or animal cells, more preferably in the treatment of cancer. Alternatively, said BO-11X or BO-112 composition is for use as an infectious disease-related vaccine.

[0059] In some embodiments, the BO-11X formulation is produced according to the manufacturing method, and then structurally and functionally defined as described in the examples as BO-112 formulation. The BO-11X formulation may further exhibit the biological activity characterized for BO-110 described in Patent Document 16, i.e., the activation of family helicase MDA-5 or NOXA expression level, regardless of the degree of improvement, in conjunction with the induction of autophagy in cancer cells or preferably in cell lines derived from cancer cells of human origin. Independent of the process of characterizing the properties and mechanism of action of BO-110 described in Patent Document 16, examples of cell lines for validating the BO-11X formulation are human SK-Mel-19 cells, SK-Mel-28 cells, SK-Mel-103 cells, and SK-Mel-147 cells, and mouse B16 cells, which melanoma cell lines present increased expression of molecules such as interferon beta when exposed to the BO-11X formulation. Furthermore, the BO-11X formulation does not exhibit toxicity at doses that promote tumor cell death in cancer cell lines against normal cells used as controls, such as melanocytes or other skin cells, which usually present secondary sites of toxicity in cancer treatments, as well as against cells of the immune system. The BO-11X formulation also induces the release of cancer cell antigens, following autophagy and apoptosis of cancer cells (or any other effect of therapeutic interest that the formulation may induce in such cells), which may act as inducers of tumor-specific immunological responses, particularly when the BO-11X formulation is administered locally to cancer cells or tumors (e.g., by peritumoral or intratumoral injection to the margins of tumor masses, surrounding epithelial cells, lymphatic or blood vessels, or directly into the tumor mass), with or without the simultaneous or sequential administration of another drug or other treatment for the same indication.

[0060] BO-11X formulations can also produce effects of therapeutic interest on targeting cells other than cancer cells (including immune or other cells in the blood circulation or located near the cancer) following administration at a location distant or independent of the tumor mass (e.g., by intramuscular or subcutaneous injection, or by ex vivo administration to cells obtained from the patient and then reinfused). Such effects can be due to induction of release of tumor-specific effectors or migration of cells into cancer cells or tumors, even when peri- or intratumoral injection is not possible (such as in non-solid tumors such as leukemia or other blood cancers).

[0061] The present invention also provides a process for making the compositions disclosed herein, comprising: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally further comprise a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 500 nm or less to produce a sterile solution; (iii) mixing the resulting sterile solutions in a mixing chamber by adding one of the solutions to the other in the mixing chamber at a rate of 1 mL / min or more, optionally by injection, or by simultaneously adding each of the solutions to the mixing chamber at a rate of 1 mL / min or more, optionally by injection, to form an aqueous composition; and, optionally, (iv) filtering the resulting aqueous composition through a filter having a pore size of 600 nm or less to form a filtrate, or filtering the resulting aqueous composition at a wavelength of 22,480 m / s 2 and, optionally, centrifuging the above to form a supernatant. (v) lyophilizing the resulting aqueous composition, filtrate, or supernatant; The present invention relates to a process including the steps of:

[0062] Thus, in one preferred embodiment, the present invention provides a process for making the compositions disclosed herein, comprising: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally further comprise a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 500 nm or less to produce a sterile solution; (iii) mixing the resulting sterile solutions in a mixing chamber by adding one of the solutions to the other in the mixing chamber at a rate of 1 mL / min or more, optionally by injection, or by simultaneously adding each of the solutions to the mixing chamber at a rate of 1 mL / min or more, optionally by injection, to form an aqueous composition; (iv) optionally lyophilizing the resulting aqueous composition; The method may relate to a process including:

[0063] In another preferred embodiment, the present invention also provides a process for producing the composition disclosed herein, comprising: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally further comprise a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 500 nm or less to produce a sterile solution; (iii) mixing the resulting sterile solutions in a mixing chamber by adding one of the solutions to the other in the mixing chamber at a rate of 1 mL / min or more, optionally by injection, or by simultaneously adding each of the solutions to the mixing chamber at a rate of 1 mL / min or more, optionally by injection, to form an aqueous composition; (iv) filtering the resulting aqueous composition through a filter having a pore size of 600 nm or less to form a filtrate, or filtering the resulting aqueous composition at a wavelength of 22,480 m / s 2 Centrifuge the mixture over the above temperature. forming a clear solution; (v) lyophilizing the optionally obtained filtrate or supernatant; The method may relate to a process including:

[0064] More preferably, the process of the present invention does not include a final step of lyophilization. In the process (or method) of the present invention, the double-stranded polyribonucleotide, the polyalkyleneimine, and the pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant are as disclosed herein. Sterilization of each solution is performed by filtering the solutions separately through a filter having a pore size of 500 nm or less, preferably filtering the solutions separately through a filter having a pore size of 300 nm or less, more preferably filtering the solutions through a filter having a pore size of 200 nm or less to form a sterile solution. The resulting filtrates are mixed by large-scale vortex convective transport followed by elimination of concentration differences by pure diffusion transport. The mixing chamber may be any chamber or vessel, such as a flask, reactor or mixer, that initiates mixing of the solutions, and has any suitable shape (such as cylindrical, spherical or other shapes that allow precise mixing within the chamber) in which mixing is controlled within a limited space. More preferably, said mixing chamber has a fixed volume of 0.1 mL to 20 mL (or even larger volumes such as 25 mL, 50 mL, 100 mL or more, allowing continuous higher yields of product, especially under GMP conditions), more preferably 0.2 mL to 10 mL, even more preferably 0.5 mL to 8 mL. More preferably, mixing is performed by addition, optionally by injection at a rate of 1 mL / min to 2000 mL / min, even more preferably 10 mL / min to 1000 mL / min, even more preferably 20 mL / min to 500 mL / min. Optimal filtration of the resulting aqueous solution to form or collect a filtrate may then be performed through a filter having a pore size of 600 nm or less, preferably not exceeding 500 nm, more preferably not exceeding 400 nm, even more preferably not exceeding 300 nm. Alternatively, any subsequent centrifugation of the resulting aqueous composition to form or collect a supernatant may be performed at a speed of 22480 m / s. 2 (5000 rpm with a rotor having a radius of 0.082 m), preferably 27202 m / s 2 (5500 rpm with a rotor having a radius of 0.082 m), more preferably 32372 m / s 2greater than (6000 rpm with a rotor having a radius of 0.082 m), and even more preferably 44062 m / s 2 (7000 rpm with a rotor having a radius of 0.082 m). In a particularly preferred embodiment, step (iv) is mandatory when the composition of the invention is not achieved by steps (i) to (iii) of the process of the invention, i.e. when the addition is carried out at a rate such that less than 95% of the particles contained in said aqueous composition have a diameter of 600 nm or less and / or when said particles have a z-average diameter of more than 200 nm, more preferably when said particles do not have a monomodal size distribution. This may be the case when the addition is carried out at a rate of 1 mL / min to 20 mL / min, in particular in a mixing (reaction) chamber of 0.5 mL to 20 mL. Finally, the aqueous composition, the filtrate or the supernatant obtained may be subjected to lyophilization to obtain the composition of the invention as a particulate solid.

[0065] Thus, in an even more particularly preferred embodiment of the process of the invention, said process comprises the steps of: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally further comprise a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 200 nm or less to produce a sterile solution; (iii) adding one of the solutions to the other in a mixing chamber at a rate of 20 mL / min to 100 mL / min, optionally by injection, or at a rate of 20 mL / min to mixing the resulting sterile solutions in the mixing chamber by simultaneously adding, optionally by injection, each of the above solutions to the mixing chamber at a rate of 100 mL / min to form an aqueous composition; wherein the mixing chamber has a volume of 0.2 mL to 10 mL; (iv) filtering the resulting aqueous composition through a filter having a pore size of 500 nm or less to form a filtrate, or filtering the resulting aqueous composition at 32372 m / s 2 or more (6000 rpm on a rotor having a radius of 0.082 m) to form a supernatant; (v) lyophilizing the optionally obtained filtrate or supernatant; Includes.

[0066] In another even more particularly preferred embodiment of the process of the invention, said process comprises the steps of: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof; wherein either or both solutions optionally contain a pharma- ceutically acceptable carrier, organic solvent, excipient and / or adjuvant; (ii) filtering each solution separately through a filter having a pore size of 200 nm or less to produce a sterile solution; (iii) mixing the resulting sterile solutions in a mixing chamber by adding one of the solutions to the other in the mixing chamber at a rate of 30 mL / min to 100 mL / min, optionally by injection, or by simultaneously adding each of the solutions to the mixing chamber at a rate of 30 mL / min to 100 mL / min, optionally by injection, to form an aqueous composition; wherein the mixing chamber has a volume of 0.5 mL to 8 mL; (iv) optionally lyophilizing the resulting aqueous composition; Includes.

[0067] In a further embodiment, the BO-11X formulation is obtained according to a manufacturing process comprising mixing two aqueous solutions, a first comprising a double-stranded polyribonucleotide (or a salt thereof or a solvate thereof) and a second comprising a polyalkyleneimine (or a salt thereof or a solvate thereof), such that the particles obtained exhibit the characteristics defined above, in particular with regard to diameter and monomodal size distribution, together with the appearance as an essentially transparent colloidal solution.

[0068] In a further optional step, an additional compound (which is an immune-related adjuvant or therapeutic compound, such as CD40L, IL12, a viral or tumor antigen, or an anti-cancer drug) can be added during step (i) or after any of steps (i)-(v) or (i)-(iv) in the process of manufacturing the composition as defined above. The resulting composition, which when presenting the combination of characteristics as described above can be named BO-11Xm, more specifically BO-112m, can be used according to any of the embodiments disclosed herein for the use of BO-11X compositions, specifically BO-112 compositions.

[0069] As described in more detail in the Examples, the BO-11X formulation can be provided as a bulk or single-use liquid composition free of visible aggregates by filtering and / or centrifuging a pharmaceutical composition comprising particles formed by double-stranded polyribonucleotides and water-soluble polycationic homo- or heteropolymers. Such a process for producing the composition includes: (i) Aqueous solutions of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and at least one polyalkyleneimine, or a salt thereof, or a solvate thereof, are combined with a pharma- ceutical acceptable carrier, an organic solvent, an excipient, and a soluble amine, optionally present in either solution. and / or an adjuvant; (ii) mixing the solutions; (iii) filtering the mixture through a filter having a pore size of 600 nm or less, or filtering the mixture through a filter having a pore size of 22480 m / s2 Centrifuging at ultra low temperature; Includes.

[0070] This process may be further adapted to the actual components of the composition (double-stranded polyribonucleotide, polyalkyleneimine, and any further components), as well as the desired method of use, storage, transport, packaging, and / or administration of the composition, especially when the composition requires to be prepared immediately prior to use or, as is more common in pharmaceutical compositions, prepared in the form of multiple containers (e.g., sterile vials or syringes) for long-term storage and / or each for single use, containing particles of the most uniform size, poly(I:C) content, stability, solubility, and finally, biological activity when administered.

[0071] The above mixing step (ii) and filtering step (iii) may be adapted at the level of filtering and / or mixing order, mixing method, mixing speed, and / or amount of solutions mixed. In a further preferred embodiment, the method for preparing the BO-11X formulation comprises: (i) preparing an aqueous solution of at least one double-stranded polyribonucleotide, or a salt thereof, or a solvate thereof, and an aqueous solution of at least one polyalkyleneimine, or a salt thereof, or a solvate thereof, with pharma- ceutically acceptable carriers, organic solvents, excipients and / or adjuvants, optionally present in either solution; (ii) sterilizing each solution by filtering separately; (iii) mixing the solutions in a container by first adding one solution and then the other solution at a flow rate of 1 mL / min to 50 mL / min and a flow rate of greater than 50 rpm for storage, lyophilization, and / or use of the composition; (iv) sealing the container; and Includes.

[0072] In a further optional step, another compound (be it an immune-related adjuvant or therapeutic compound, such as CD40L, IL12, a viral antigen or a tumor antigen, or be an adjuvant or therapeutic compound, such as an anti-cancer drug) can be added during step (i) or after any of steps (i)-(v) or (i)-(iv) in the process of making the composition as defined above. The resulting composition (which may be named BO-11Xm, more specifically BO-112m when it presents the combination of features (i)-(vi) above) can be used according to any of the embodiments disclosed herein for the use of the BO-11X composition, specifically the BO-112 composition.

[0073] Depending on how the aqueous composition of the present invention is to be administered (e.g., by subcutaneous or intratumoral injection), the BO-11X composition or BO-112 defined above may be provided in a container and / or amount most suitable for single use or multiple administration.

[0074] combination The compositions according to the invention can be used in combination with other compounds or treatments known to be compatible if they do not provide an additive or even synergistic effect.Furthermore, compositions named BO-11Xm (specifically BO-112m) can be prepared as described above to obtain new products in which the combination of a BO-11X composition, such as a BO-112 composition, with another compound results in an improved therapeutic effect or other pharma- ceutical relevant effect (including stability or efficacy at lower doses, generally or for a particular indication or administration route) compared to a combination in which the BO-11X composition and the other compound are simply mixed prior to use.

[0075] For example, poly(I:C) molecules have been used in combination with various anticancer drugs, antibodies, radiotherapy or chemotherapy (Le U et al., 2008; Le U et al., 2009; Taura M et al., 2010; Matijevic T et al., 2011; Levitzki A, 2012; Yoshino H and Kashiwakura I, 2013; Non-Patent Document 1) or in combination with poly(I:C) molecules of various lengths (Zhou Y et al., 2013). In addition, vaccination with cancer antigens or cell lysates (Ammi R et al., 2015), drugs that block the PD-1 / PD-L1 pathway (Nagato T and Celis E, 2014) , other TLR agonists such as TLR9 agonist CpG ODN (Zhang Y et al., 2014), dichloroacetic acid (Ohashi T et al., 2013), IL27 (Chiba Y et al., 2013), and so Kinase inhibitors such as rafenib (Ho V et al., 2015), proapoptotic proteins such as NS1 (Gupta S et al. 2016), zoledronic acid (Non-Patent Document 7), or all-trans Poly(I:C) molecules have been used as adjuvants or synergistic agents when combined with other agents such as retinoic acid (Szabo A et al., 2012). Other uses of BO-11X formulations include inhibiting differentiation of preadipocytes and adipocytes (Yu L et al., 2016) and enhancing the immunosuppressive effect on mesenchymal stem cells (Cho K. et al., 2017). al., 2016;Vega-Letter A et al., 2016), or NK cell activation (Perrot I et al., Recently, specific cell-specific markers have been demonstrated, at least using in vitro assays such as those used by researchers such as Dr. This may become clear when considering the activity of poly(I:C) molecules against cell types.

[0076] In some embodiments, the present invention relates to a pharmaceutical composition comprising an effective amount of a BO-11X formulation and an effective amount of one or more immunomodulatory agents, particularly agents that target immune checkpoint molecules (such as PD-1, PD-L1, PD-L2, CTLA-4, CD134, CD134L, CD137, CD137L, CD80, CD86, B7-H3, B7-H4, B7RP1, LAG3, ICOS, TIM3, GAL9, CD28, AP2M1, SHP-2, PPP2R5A, or OX-40), which are commonly named checkpoint inhibitors (CPIs). Alternatively, immunomodulatory agents, such as inhibitors of drug targets such as IDO, TGF-β, STAT3, or CSFR1, block the immunosuppressive effects of regulatory T cells.

[0077] Thus, the present invention provides compositions and methods useful for combination therapy and dosing regimens involving the administration of a BO-11X formulation (or a BO-11Xm formulation) and another therapeutic agent or treatment (including radiation therapy, chemotherapy, cryotherapy, tumor ablation, or photodynamic therapy). In particular, the present invention relates to a method of treating, ameliorating, or preventing cancer growth, metastasis, ulceration, immune evasion, or recurrence in a subject, comprising administering a BO-11X formulation and one or more anti-cancer drugs, preferably immunomodulatory agents, wherein said administration is simultaneous (as separate formulations or in the context of a combined drug) or sequential (in any order or in successive administration cycles). In some embodiments, the present invention relates to a method of treating cancer, comprising administering an effective amount of a BO-11X formulation and an effective amount of one or more immunomodulatory agents to a subject in need thereof, particularly where the subject is undergoing cancer therapy with one or more immunomodulatory agents.

[0078] In some embodiments, the immunomodulatory agent is preferably an antibody, including monoclonal antibodies and other antibody formats, or any other pharma- tically available agent that binds to cell surface proteins that regulate immune responses and acts as a CPI, which can block, reduce, and / or inhibit PD-1, PD-L1, or PD-L2, and / or the binding of PD-1 to PD-L1 or PD-L2. Alternatively, the CPI can block, reduce, and / or inhibit the reduction and / or inhibit the activity of other immune checkpoint molecules, such as CTLA-4, AP2M1, CD80, CD86, SHP-2, and / or PPP2R5A. As a further option, the CPI increases and / or stimulates the binding of CD137 (4-1BB) to one or more 4-1BB ligands and TRAF2.

[0079] In some embodiments, methods including combination therapies and dosing regimens for the treatment of cancer that include administration of a BO-11X formulation (or a BO-11Xm formulation) may be further defined with respect to a specific administration method in which the BO-11X formulation is administered by a route different from one of the other therapeutic compounds, such as an immunomodulatory agent, preferably a CPI. The method may include administering the BO-11X formulation by intratumoral or peritumoral injection (in the tumor, at the edge of the tumor mass, in surrounding epithelial cells, lymphatic or blood vessels), or by administering the BO-11X formulation directly into or adjacent to (e.g., not indirectly, e.g., via the bloodstream) the cancer cells or organs containing the cancer cells, and by other means that allow for systemic administration of the CPI or other immunostimulant. Intratumoral or peritumoral injection of the BO-11X formulation may be performed at the level of the skin, i.e., into the skin (e.g., for the treatment of melanoma or in conjunction with a vaccine), or at the level of the organ or tissue, i.e., into said organ or tissue (e.g., by injection into the liver to treat liver cancer, or administration into vesicles for bladder cancer). Such local administration of the BO-11X formulation is preferably performed after administration of an immunostimulant, or (preferably) followed by administration of an immunostimulant.

[0080] The BO-11X formulation (or BO-11Xm formulation) can also be administered in combination with cell therapy, where BO-11X is directly co-administered to the patient with cell therapy or used to treat cells obtained from the patient (from blood or from biopsy material containing cells in the tumor mass, at the edge of the tumor mass, peripheral epithelial cells, lymphatic or blood vessels). These cells can be exposed to the BO-11X formulation in appropriate laboratory conditions, with or without positive or negative selection for specific cell types, to generate cells that present markers, secrete proteins, and / or expose antigens after this treatment, which are useful for further cancer treatment. Such autologous cells can be administered to the patient, again with or without further negative or positive selection. At a later stage of treatment, the BO-11X formulation can be further administered to the patient by any suitable means (by intratumoral injection, or preferably by intramuscular or subcutaneous injection). Ex vivo treatment of cells derived from a patient may be carried out for periods of more than 1 hour, preferably more than 3 hours, more preferably more than 8 hours, even more preferably more than 24 hours or more, and at concentrations lower than a single intramuscular or subcutaneous injection (preferably 50%, more preferably 25%, even more preferably 10%, even more preferably 5%, or even more preferably 1%).

[0081] Additive Effects and Use In further embodiments, the present invention provides pharmaceutical uses and methods comprising administration of BO-11X formulations (or BO-11Xm formulations) to increase immune responses against pathogens or undesirable biological agents, in particular to enhance anti-tumor immune responses that may themselves act as immunomodulators. Such effects can be monitored by measuring tumor-associated immune responses to the tumor site and tumor microenvironment (or in the bloodstream, other body fluids, and tissues) at the level of relevant cell types and subpopulations (e.g., dendritic cells, regulatory T cells, T cells, and / or NK cells), and / or immunological biomarkers (e.g., chemokines, growth factors, cytokines, and their receptors).

[0082] In particular, when BO-11X formulation (or BO-11Xm formulation) is clinically administered by intratumoral injection, apoptosis and / or necrosis are observed in the tumor, which may promote the presentation of tumor antigens to resident dendritic cells. Also, signaling cascades may result in the recruitment of immune cells, especially CD4+ and CD8+ T cells, to the tumor mass, promoting the immune effect against the tumor and contributing to the cytotoxic effect of BO-11X.

[0083] Another embodiment is a method of inducing interferon production in a cell or tissue in vitro, comprising contacting the cell or tissue with a composition, wherein the cell or tissue exhibits a cell proliferation disorder characterized by abnormal growth of human or animal cells, and the composition induces BO- 11X, more preferably BO-112. Thus, the present invention relates to a method for inducing interferon production in cells derived from a subject in vitro, comprising: (i) obtaining cells from a subject; (ii) contacting the cells with a composition of BO-11X, preferably BO-112; The present invention relates to a method comprising the steps of:

[0084] Pharmaceutical Compositions Also provided are methods of making pharmaceutical compositions of BO-112 (and / or other BO-11X formulations, such as BO-11Xm or BO-112m formulations) by mixing the BO-11X formulation with one or more pharma- ceutically acceptable adjuvants, diluents, carriers, or excipients thereof. Such components can be tailored for a particular medical indication (e.g., solid or hematological cancers) and / or for administration means, for example, by injection (peritumoral, intratumoral, intrahepatic, intrapancreatic, intramuscular, or subcutaneous injection), by inhalation, topically, or orally.

[0085] Combination treatments based on the BO-11X formulation may include the same or different routes of administration for the BO-11X formulation and the other compound. In particular, the BO-11X formulation may be administered in combination with other immunostimulatory RNA agents, therapeutic antibodies acting as CPIs, such as PD-1 / PD-L1 pathway inhibitors (Bald T et al., 2014), or systemically administered to activate T cells (Amos SM et al., 2011). It can be administered by intratumoral or peritumoral injection, which can activate the immune system prior to administration. Alternatively, the BO-11X formulation can be administered in combination with CpG molecules or resiquimod (Sajadian A et al., 2014) or dendritic cells (Fujimura T et al., 2015) to enhance the efficacy of anticancer vaccination. The compounds may be administered together with other therapeutic compounds that are TLR agonists or ligands, such as TLR agonists (TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, ​​TLR-7, TLR-8, TLR-9, TLR-11, TLR-12, TLR-13, TLR-14, TLR-15, TLR-16, TLR-17, TLR-18, TLR-19

[0086] Immunomodulators BO-11X formulations (including BO-11Xm formulations) may be combined with one or more immunomodulatory agents. In some embodiments, the immunomodulatory agent is a co-stimulatory or co-inhibitory molecule (e.g., one or more immune cells, such as, but not limited to, T cells and NK cells). In some embodiments, the immunomodulatory agent is an agent that modulates CD4 and / or CD8 T cells, for example, by acting as an agonist or antagonist with respect to CD3, CD4, CD8, PD-1, PD-L1, PD-L2, CTLA-4, CD137, CD96, CD73, CD90, CD47, CD69, CD26, TIM3, and LAG3. In other embodiments, the immunomodulatory agent is an agent that modulates NK cells, for example, by acting as an agonist or antagonist with respect to CD3, NKp46, CD16, NKG2D, NKp44, and NKp30. In other embodiments, the immunomodulatory agent is an agent that modulates tumor stromal and tumor endothelial biomarkers, for example, by acting as an agonist or antagonist with respect to CD45, PD-L1, PD-L2, PTEN, and CD31, or combinations thereof. Combinations of immunomodulatory agents can be used to target different immune populations, such that the combined agents target cells expressing different immune cell populations.

[0087] Immunomodulators are provided as further compounds in the form of organic or inorganic compounds, nucleic acids, aptamers, peptides, proteins, more particularly antibodies that bind to relevant targets in body fluids or on the cell surface. Antibodies may be polyclonal or monoclonal; intact or truncated (e.g. F(ab')2, Fab, Fv); bispecific or multispecific; heterologous, allogeneic, syngeneic or modified forms thereof (e.g. chimeric or humanized antibodies). When the immunomodulator is a monoclonal antibody, it may be a monoclonal antibody derived from a non-human mammal, a recombinant chimeric monoclonal antibody, a recombinant humanized monoclonal antibody, or a combination thereof. , or a human monoclonal antibody.

[0088] Antibodies that act as immunomodulators may further comprise structural elements normally required to exert the required biological activity, such as four polypeptide chains, two heavy (H) and two light (L) chains interconnected by disulfide bonds, capable of binding one or more antigens (e.g., bispecific or multispecific antibodies) and presenting the Fc region of an immunoglobulin (e.g., IgA, IgG, IgE, IgD, or IgM) that interact with Fc receptors to activate an immune response, resulting in depletion and / or cell death of immune or other cells. Each heavy chain comprises a heavy chain variable region (V H The heavy chain constant region is composed of three domains, CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (V L ) and the light chain constant region. The light chain constant region is composed of one domain, CL. H Area and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with regions that are more conserved, called framework regions (FRs). H Or V L ) comprises three CDRs, designated CDR1, CDR2 and CDR3. Each variable region also comprises four framework subregions, designated FR1, FR2, FR3 and FR4. The term antibody includes all types of antibodies, including, for example, IgA, IgG, IgD, IgE and IgM, and their respective subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. In some embodiments, antibody also refers to antibody fragments and antigen-binding fragments.

[0089] Antibodies suitable for carrying out the methods described herein may be of various antibody formats, e.g., monoclonal, polyclonal, bispecific, multispecific, including, but not limited to, human, humanized or chimeric antibodies, including single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library and / or binding fragments of any of the above. Antibodies also refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain at least two antigen or target binding sites for at least two targets as described herein. The immunoglobulin molecules described herein may be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. Furthermore, antibodies (e.g., monospecific, bispecific, and / or multispecific) suitable for carrying out the invention described herein may be provided in any of the alternative formats disclosed in the literature, e.g., Diabodies; Flexibodies; Camel antibodies; Immunobodies; Triomabs, Pepbodies, Vaccibodies, minibodies, Fcabs, Unibodies, or Duobodies (Storz U, 2011). good.

[0090] PD-1 (also known as CD279 or programmed cell death protein 1) is a member of the receptor B7 family. In some embodiments, PD-1 is expressed as the human PD-1 sequence (see, e.g., NCBI Reference Sequence: NP_005009) and any naturally occurring alleles, splice variants, and their processed forms (Keir M et al., 2008;UniProt:Q15116). PD-1 is a member of the B7 family It binds PD-L1 (also known as CD274 or B7-H1) and PD-L2 (also known as CD273 or B7-DC), which are also involved in the development of PD-L1. In embodiments, PD-L1 refers to human PD-L1 (see, e.g., GenBank: AF233516) and PD-L2 refers to human PD-L2 (see, e.g., NCBI Reference Sequence: NM_025239), along with any naturally occurring alleles, splice variants, and their processed forms.

[0091] In some embodiments, the immunomodulatory agent targets one or more of PD-1, PD-L1, and PD-L2. In particular, the immunomodulatory agent is a PD-1 inhibitor. In some embodiments, the immunomodulatory agent is an antibody specific for one or more of PD-1, PD-L1, and PD-L2. Such immunomodulatory agents are antibodies such as, but not limited to, nivolumab, (ONO-4538 / BMS-936558, MDX1106, OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011), MK-3475, BMS 936559, MPDL3280A, and others recently reviewed (Tan S et al. 2016).

[0092] In some embodiments, the BO-11X formulation (or BO-11Xm formulation) is combined with one or more of BMS-936559 and MEDI4736, for example, for the treatment of advanced solid tumors. In some embodiments, the BO-11X formulation is combined with one or more of MPDL3280A (optionally with vemurafenib) and MEDI4736 (optionally with one or more of dabrafenib and trametinib) for the treatment of melanoma. In some embodiments, the BO-11X formulation is combined with one or more of MPDL3280A (optionally with erlotinib) and MEDI4736 (optionally with tremelimumab) for the treatment of NSCLC. In some embodiments, the BO-11X formulation is combined with MPDL3280A (optionally with one or more of bevacizumab and sunitinib) for the treatment of RCC. In some embodiments, the BO-11X formulation is combined with MPDL3280A for the treatment of solid or hematological malignancies. In some embodiments, the BO-11X formulation is combined with MPDL3280A (optionally with one or more of bevacizumab, chemotherapy, and cobimetinib); MEDI4736 (optionally with tremelimumab) and one or more of MSB0010718C for the treatment of solid tumors. In some embodiments, the BO-11X formulation is combined with AMP-224 for the treatment of advanced cancer. In some embodiments, the BO-11X formulation is combined with nivolumab (optionally with iliolumbar (anti-KIR)) for the treatment of advanced solid tumors. In some embodiments, the BO-11X formulation is combined with nivolumab for the treatment of castration-resistant prostate cancer, melanoma, NSCLC, and RCC. In some embodiments, the BO-11X formulation is combined with pembrolizumab for the treatment of colon cancer. In some embodiments, the BO-11X formulation is combined with pembrolizumab for the treatment of gastric cancer, head and neck cancer, TNBC, and urothelial cancer. In some embodiments, the BO-11X formulation is combined with nivolumab (optionally with ipilimumab) for the treatment of gastric cancer, pancreatic cancer, small cell lung cancer, and TNBC. In some embodiments, the BO-11X formulation is combined with nivolumab (optionally with ipilimumab) for the treatment of glioblastoma.In some embodiments, the BO-11X formulation is administered intravenously or in combination with nivolumab for the treatment of hepatocellular cancer. In some embodiments, the BO-11X formulation is combined with pembrolizumab for the treatment of Hodgkin's lymphoma, myeloma, myelodysplastic syndrome, and non-Hodgkin's lymphoma. In some embodiments, the BO-11X formulation is combined with pidilizumab for the treatment of malignant glioma. In some embodiments, the BO-11X formulation is combined with nivolumab (optionally ipilimumab, and one or more of multiple class 1 peptides and montanide ISA 51 VG; and optionally ipilimumab) for the treatment of melanoma. In some embodiments, the BO-11X formulation is combined with one or more of nivolumab (optionally with one or more of gemcitabine / cisplatin, pemetrexed / cisplatin, carboplatin / paclitaxel, bevacizumab, erlotinib, and ipilimumab) and pembrolizumab for the treatment of NSCLC. In some embodiments, the BO-11X formulation is combined with one or more of pidilizumab (optionally with gemcitabine) for the treatment of pancreatic cancer. In some embodiments, the BO-11X formulation is combined with pidilizumab (optionally with one or more of sipleucel-T and cyclophosphamide) for the treatment of prostate cancer. In some embodiments, the BO-11X formulation is administered in combination with nivolumab (optionally with one or more of sunitinib, pazopanib, and ipilimumab), pembrolizumab (optionally with one or more of sunitinib, pazopanib, and ipilimumab), or combination therapy with nivolumab (optionally with one or more of sunitinib, pazopanib, and ipilimumab), for the treatment of RCC. In some embodiments, the BO-11X formulation is combined with one or more of anti-LAG3 (BMS-986016, optionally with nivolumab), nivolumab (optionally with interleukin-21), and AMP-554 for the treatment of solid tumors. In some embodiments, the BO-11X formulation is combined with pembrolizumab for the treatment of solid tumors.

[0093] In some embodiments, the immunomodulatory agent targets one or more of CD137 or CD137L. In some embodiments, the immunomodulatory agent is an antibody specific for one or more of CD137 or CD137L. For example, in some embodiments, the immunomodulatory agent is an antibody, such as, but not limited to, urelumab (also known as BMS-663513 and anti-4-1BB antibody). In some embodiments, the BO-11X formulation is administered in combination with urelumab (optionally with nivolumab, lirilumab and urelumab) for the treatment of solid tumors, and / or B-cell non-Hodgkin's lymphoma, and / or head and neck cancer, and / or multiple myeloma. In some embodiments, the immunomodulatory agent is an antibody, such as, but not limited to, ipilimumab (MDX-010, MDX-101, Yervoy, BMS) and / or tremelimumab (Pfizer). In some embodiments, the BO-11X formulation is combined with ipilimumab (optionally with bavituximab) for the treatment of one or more of melanoma, prostate cancer, and lung cancer.

[0094] In some embodiments, the immunomodulatory agent targets CD20. In some embodiments, the immunomodulatory agent is a CD20-specific antibody. For example, in some embodiments, the immunomodulatory agent is an antibody, such as, by way of non-limiting example, ofatumumab, obinutuzumab (GAZYVA), AME-133v, ocrelizumab, TRU-015, and veltuzumab.

[0095] Validation of BO-11X formulation Preclinical validation of the therapeutic efficacy of BO-11X formulations (including the BO-11Xm formulation according to the present invention and exemplified by BO-112 in the examples) can be performed in cell-based assays and, most interestingly, in animal models, where various experimental criteria can be tested and compared to establish the most suitable conditions for effectively achieving a therapeutic effect using the BO-11X formulation alone or in combination with a candidate or approved anti-cancer drug. These criteria include the dose, route of administration, sequence and / or frequency of administration of any compound to the extent that they identify which are the more favorable conditions for the therapeutic use of the BO-11X formulation (alone as the BO-11Xm formulation or synergistically with a candidate or approved anti-cancer drug) in terms of efficacy, safety and / or clinical use. When using animal and / or ex vivo models, BO-11X formulations can be validated using one or more of the following criteria: cancer cell cytotoxicity, PARP activation, immunogenic cell death, therapeutic efficacy (particularly via apoptosis and / or necrosis of cancer cells directly or indirectly via an abscopal effect), increased expression of markers on immune cell populations, increase in immune cell populations, and other assays shown in the examples.

[0096] The effect of various dosages of BO-11X formulations (or BO-11Xm formulations), number and / or sites of administration (particularly by injection at one or more sites), each compound, route of administration, frequency, and / or time points of administration can be related to relevant endpoints and physiological parameters measured in biological samples obtained from cells or (preferably) animals exposed to the test compounds alone or in combination with other drugs. A non-limiting list of such parameters includes regression of tumor size, inhibition of tumor growth and / or proliferation of tumor cells, reduction of apoptosis, tumor angiogenesis or metastasis, overcoming resistance to common anti-cancer drugs (or improving the response to such drugs in a treated population), reduction of tumor-related adverse events on normal tissues and functions, modulation of immune responses and / or immune cells with specific activities and characteristics, and the like. These endpoints include the identification of biomarkers in biological materials or specific cell populations (e.g., present in cancer cell preparations, tumor biopsies, or bodily fluids) whose increase (or decrease) is known in the literature to be generally associated with cancer treatment efficacy, particularly in animal models, and in some cases, with survival in cancer patients. Whenever possible, such endpoints are measured at intermediate and final time points following administration of each test compound, or combination of compounds tested at a given dose and / or dosing regimen, using a particular route of administration and / or pharmaceutical formulation.

[0097] The therapeutic anti-cancer efficacy of the BO-11X formulation (or BO-11Xm formulation) can be tested alone or in combination with conventional treatments that are standard of care (radiotherapy, chemotherapy, cellular kinase inhibitors, drugs with epigenetic effects, etc.) or treatments that include novel mechanisms and / or novel candidate anti-cancer drugs. Indeed, a category of novel anti-cancer compounds that can be tested in combination with the BO-11X formulation is one that improves anti-tumor immune responses within the tumor microenvironment by providing systemic anti-tumor immunity that targets the disseminated tumor cells that are eliminated. This approach has been proven successful in animal models and patients and can improve the outcome of conventional treatments such as radiotherapy or chemotherapy (see, for example, Galluzzi L et al., 2014; Vacchelli E et al., 2013; Van der Jeught K et al., 2015).

[0098] This growing panel of new anticancer drugs targets the mechanisms by which cancer cells escape immune detection and destruction by the human body. Compared with other cancer therapies (e.g., tumor cell specific), cancer-specific immunotherapy may offer a series of advantages. Indeed, the identification of a series of molecular targets for cancer immunotherapy has brought about great progress in uncovering the mechanisms and compounds that can provide the appropriate co-stimulatory (or co-suppressive) effect on the immune response against tumors in relation to tumor plasticity, heterogeneity, resistance or microenvironment.

[0099] A non-limiting list of passive or active immunotherapies for cancer, each acting on a different molecular target and / or mechanism, includes tumor-targeted or other immunomodulatory monoclonal antibodies, oncolytic viruses, immunostimulatory cytokines, adoptive cell transfer and other cellular therapies, DNA or peptide-based vaccines, inhibitors of immunosuppressive metabolism, or agonists of pattern recognition receptors. Among these mechanisms, molecular targets for which antibodies or other compounds have either agonistic or antagonistic activity (depending on their role in the immune response or in evading the cancer from the immune response) include a series of cell membrane proteins, such as PD-1, PD-L1, PD-L2, CTLA-4, CD137, CD38, OX-40, CD26, TIM3 and LAG3, which are checkpoints against tumor development, for which various agonistic or antagonistic antibodies are commercially available or available in scientific repositories to characterize their specificity and / or level of anti-cancer effect against human antigens or (when dealing with animal models) against the corresponding rodent antigens.

[0100] Despite impressive patient responses to drugs targeting these costimulatory or co-inhibitory molecules (e.g., anti-PD-1 or anti-PD-L1 antibody-based therapies), clinical responses to immune checkpoint inhibitors are still incomplete or inefficient to achieve the desired therapeutic effect in too many cancer patients. BO-11X formulations in appropriate combination with compounds such as anti-PD-1 antibodies, anti-CTLA4, or anti-CD137 antibodies may enhance (or increase the number of subjects exhibiting) the reduction in tumor growth and metastasis, possibly beyond the additive effect that may be expected, when compared with the effect of administration of one of the two anti-cancer drugs alone.

[0101] The BO-11X formulation (or combination thereof) is preferably administered in one of several cell line models based on isolated or mixed cell cultures, including primary cancer cells or established cancer cell lines of human origin. can evaluate the therapeutic effect of BO-11Xm formulation. Examples of cancer cell lines for validating BO-11X formulation can be defined according to cancer type, such as melanoma (human SK-Mel-19, SK-Mel-103 and UACC62 cells; mouse B16 cells), carcinoma (mouse Hepa1-6 cells; rat FAO cells), breast cancer (human BT483, HCC1143, HCC1937, MDA-MB-231, MDA-MB-415, MDA-MB-468 and BT549 cells), pancreatic cancer (human MiaPaCa2, IMIM-PC2, Panc1, Panc0203, Panc3.27 or BxPc3 cells), or other relevant cell lines available through ATCC, other public or academic repositories, or commercial providers. The anti-cancer efficacy of the BO-11X formulation may be assessed by multiple metrics, including the duration, frequency, and / or dose required to have inhibition of proliferation, death, levels of biomarker expression, and / or release of signaling molecules (such as chemokines or interferon beta) indicative of potentially relevant effects of the BO-11X formulation observed under various physiological conditions.

[0102] Thus, the efficacy of the BO-11X formulation (or BO-11Xm formulation) can be evaluated in tumor animal models in which anti-tumor responses due to administration of an exemplary formulation such as BO-112 are assessed for both monotherapy and combination treatment (e.g., with a CPI such as an anti-PD-1 antibody) for shorter or longer periods of time following administration, with different protocols. The studies can be performed at a given time of tumor development due to proliferation of the injected cells, i.e., after a certain number of days following injection of the cancer cells, or (preferably) at a desired tumor size (e.g., 80 mm). 3 ~100mm 3Studies may be pursued by administering BO-112 and / or anti-PD-1 antibodies in animals presenting tumors (average size of 100-200 mmHg) or after disappearance of tumors (for evaluation of any effect of each drug or drug combination on tumor recurrence). The studies may also include control compounds that are either negative controls (e.g., vehicle alone), such as chemotherapeutic drugs or other anti-cancer drugs, or positive controls, designated in the literature as a benchmark for drug efficacy against a particular tumor and / or in a given animal model. Confirmation of these activities in animal models and animal cells may also lead to the development of BO-11X formulations for veterinary use.

[0103] The animal model is typically a mouse model in which cancer occurs as a result of either human cancer cell transplantation and engraftment (derived from immortalized cell lines or cancer biopsies obtained by patients) or induction (or transfer) of mouse tumor cells in animals. The cells may originate from different types of tumors (e.g., lung cancer, melanoma, or lymphoma) and may be subcutaneously injected into the flank of each mouse for tumor detection and analysis of tumor size and / or composition during the study. The mice are then treated by randomization into groups of different sizes (e.g., 3, 5, 10, 12, 15, 20 or more animals for each control or treatment group) that allow statistical analysis of the results.

[0104] The potential improvements afforded by BO-11X formulations, such as BO-112, and checkpoint inhibitors, such as anti-PD-1 antibodies, may induce improvements in animal models of cancer (especially when appropriately combined with respect to amount, sequence, or other dosing criteria), increasing post-treatment animal survival and / or tumor disappearance, reducing tumor recurrence, limiting or delaying the effects of toxicity and / or resistance, and improving response to re-challenge with tumor inoculation after termination of treatment with BO-112 and / or anti-PD-1 antibodies.

[0105] The BO-112 formulation and the exemplary BO-11X formulation, structurally and functionally identified above as an anti-PD-1 antibody, can be administered (alone or in combination, in single or multiple doses) to different locations and / or in different amounts relative to the tumor cells. Typically, BO-112 and a monoclonal antibody specific for mouse PD-1 (e.g., BioLegend) are administered. (clone RMP1-14 from Sigma-Aldrich, Inc., or similar clones available from other sources) was injected subcutaneously or intravenously. Inject intratumorally, intraperitoneally, peritumorally, or intratumorally (depending on the model and tumor molecular and pathological characteristics) at a concentration determined with respect to the animal weight (e.g., 0.01 mg / kg to 2.5 mg / kg), concentration in the injection volume (e.g., 0.01 mL to 0.5 mL), and / or content in each dose (e.g., 0.01 μg to 250 μg per dose). In particular, the dose response of various concentrations of BO-112 in combination with a fixed anti-PD-1 antibody dose (or vice versa) may allow for the determination of any beneficial effects (e.g., unaffected or even improved efficacy and / or safety profile; abscopal effects in tumors at different, untreated locations) following a significant reduction in the amount of either compound administered, due to the combination with the other compound.

[0106] The BO-112 composition (or BO-112m composition) may be injected in one cycle, or in multiple cycles (e.g., 2, 3, or 4 or more) separated by a fixed desired number of days (1, 2, 3, 5, 7 or more days). Alternatively, when BO-112 is co-administered with an anti-PD-1 antibody, the BO-112 may be administered immediately before (or after) the antibody (or in a single injectable formulation), again in one or more cycles (separated by a given number of days). Still alternatively, the two agents may be formulated or administered in any consecutive order, but separated by a variable period of time (e.g., 1 hour, 3 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, 2 days or more). In particular, if BO-112 is administered after the anti-PD-1 antibody, the later administration (alone or in further combination with the anti-PD-1 antibody) may provide an anti-tumor rescue effect in animals in which the anti-PD-1 antibody is not effective against the tumor cells, overcoming any specific tumor resistance or escape mechanisms. At the end of the treatment period, all surviving animals may be left untreated for one, two, three or more consecutive weeks to monitor if and how the tumor reappears, with or without rechallenge of all animals that have had complete regression of the tumor with further subcutaneous injections of cancer cells.

[0107] The effect of the BO-112 composition (or the BO-112m composition), alone or in combination with the anti-PD-1 antibodies described above, to identify molecular characteristics of tumor and / or normal cells (including total numbers and / or specific subpopulations of NK cells, tumor infiltrating lymphocytes, splenocytes, incorporation of radiolabeled precursors, and other cells that may be involved in anti-tumor local or systemic immune responses, such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs); tumor-associated neutrophils (TANs), M2 macrophages, and tumor-associated macrophages (TAMs)) can be determined as intermediate results reported during the study without sacrificing the animals (e.g., by measuring tumor size, percentage of mice still alive, body weight, or behavioral criteria), or after sacrificing the animals (or in mice that have already died). In parallel, the presence / absence of relevant biomarkers can be identified by PCR amplification of relevant RNA, or at the level of proteins on the cell surface circulating in tissues or in the blood, such as cytokines or chemokines, using standard immunological assays and kits.

[0108] This global phenotypic analysis can be performed using cells isolated from the tumor, blood, spleen, lymph nodes or other relevant tissues and locations to detect any statistically and / or therapeutically relevant changes in the number of cells expressing cell surface markers such as CD3, CD4, CD25, FoxP3, CD8, PD-1, PD-L1, PD-L2, PTEN, CTLA-4, CD137, CD96, CD73, CD90, CD47, CD69, CD26, TIM3, LAG3, Gr1, CD11b, Ly6C, Ly6G, NKp46, CD16, NKG2D, NKp44, NKp30, CD45, and CD31, as detected by flow cytometry and described in the literature. Such cells can also be assessed for tumor antigen-specific immune responses, levels of expression of associated transcription factors, cytokines or chemokines (e.g., IFN-gamma, IFN-beta, TNF alpha, HIF1a, HIF2a, p53), or using other cell-based assays.

[0109] Furthermore, gross and microscopic pathological analysis of organs and skin in either immunodeficient or fully immunocompetent animal models can further indicate the efficacy of the studied compounds (alone or in combination) or their toxicity, such as organ inflammation and necrosis. Quantitative data generated in similar studies can be compared between different experimental groups, with and without correction for multiple tests, by use of appropriate statistical tests, in the area of ​​evaluating which therapeutic (especially antitumor) effects are provided by administration of BO-11X formulations alone or in combination with another anticancer drug.

[0110] Treatment and patient selection In some embodiments, the present invention relates to a method of treating, reducing, ameliorating, or preventing cancer growth, survival, metastasis, epithelial-mesenchymal transition, immune evasion, or recurrence, comprising administering a BO-11X formulation (or a BO-11Xm formulation) and one or more immunomodulatory agents. The cancer may be an oncological disease. The cancer may be an occult tumor that may result from cancer metastasis. An occult tumor may also be left behind from surgical removal of a tumor. The cancer recurrence may be, for example, tumor regrowth, lung metastasis, or liver metastasis.

[0111] In some embodiments, the cancer is selected from the group consisting of basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, peritoneal cancer, choriocarcinoma, connective tissue cancer, gastrointestinal cancer (including esophageal, stomach, colon, rectum, or other gastrointestinal cancer), eye cancer, head and neck cancer, glioblastoma, liver cancer, hepatoma, intraepithelial neoplasia, kidney cancer, adrenal gland cancer, or renal cancer, leukemia, liver cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), melanoma, myeloma, neuroblastoma, oral cancer (lips, larynx, tongue, mouth, and pharynx), pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, respiratory system cancer, salivary gland cancer, skin cancer, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine, endometrial, cervical, vulvar, ovarian, or other uterine cancer. gynecologic cancers; cancers of the urinary tract; lymphomas, including B-cell lymphoma, Hodgkin's and non-Hodgkin's lymphoma (NHL; including specific types such as low-grade / follicular, small lymphocytic, intermediate-grade / follicular, intermediate-grade diffuse, high-grade immunoblastic, high-grade lymphoblastic, high-grade small noncleaved cell, or bulky mass disease NHL), mantle cell lymphoma, and AIDS-related lymphoma; chronic lymphocytic leukemia; acute lymphoblastic leukemia; hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; post-transplant lymphoproliferative disorder (PTLD), as well as vascular proliferation disorders associated with phacomatosis or edema (such as those associated with brain tumors). In some embodiments, the cancer is biliary tract cancer. In some embodiments, the biliary tract cancer is selected from pancreatic cancer, gallbladder cancer, bile duct cancer, and cancer of the ampulla of Vater. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is colon cancer. In some embodiments, the biliary tract cancer is cholangiocarcinoma and / or adenocarcinoma. Alternatively, cancer is defined according to incidence criteria defined in Europe or the United States, and is listed on the websites of organizations such as the International Rare Cancers Initiative (http: / / www.irci.info) or RaraCare (http: / / www.rarecare.eu). The rare disease may be on the list of rare diseases as set out in the regularly updated list available on the Internet at:

[0112] In some embodiments, the BO-11X formulation (or BO-11Xm formulation) and / or immunomodulatory agent is used to treat cancer at various stages (e.g., stage I, stage II, stage III, or stage IV). As a non-limiting example, using a global staging classification, stage I cancer is localized to one part of the body, stage II cancer is locally advanced, as is stage III cancer. Whether a cancer is designated as stage II or stage III may depend on the specific type of cancer. In one non-limiting example, stage II of Hodgkin's disease shows affected lymph nodes on only one side of the diaphragm, whereas stage III shows affected lymph nodes above and below the diaphragm. Thus, the specific criteria for stage II and stage III vary depending on the diagnosis. Stage IV cancer often has metastasized or spread to other organs or throughout the body.

[0113] In some embodiments, the BO-11X formulation (or BO-11Xm formulation) and / or the immunomodulatory agent reduces side effects of treatment that may be experienced by the patient. For example, combination therapy of a BO-11X formulation with one or more immunomodulatory agents may allow for lower doses of the BO-11X formulation and / or one or more immunosuppressants (e.g., compared to monotherapy), thereby increasing the therapeutic window of either agent. In some embodiments, the reduction in dose reduces one or more side effects without (or with minimal) loss of efficacy. In some embodiments, the BO-11X formulation and / or the immunomodulatory agent is used to treat a subject with a treatment-refractory cancer. In some embodiments, the BO-11X formulation is It is used to treat subjects who are refractory to one or more immunomodulatory agents, particularly those in active combination with the BO-11X formulation.

[0114] In some embodiments (see also Example 3), the subject is refractory to PD-1 and / or PD-L1 and / or PD-L2 agents, including, for example, nivolumab (ONO-4538 / BMS-936558, MDX1106, or OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011), MK-3475, BMS-936559, ibrutinib, and / or is an MPDL3280A refractory patient. For example, in some embodiments, the subject is refractory to an anti-CTLA-4 agent, for example, an ipilimumab (Yervoy) refractory patient (e.g., a melanoma patient). In some embodiments, the subject is refractory to a BO-11X formulation. Thus, in some embodiments, the present invention provides methods of cancer treatment that rescue patients who are non-responsive to various therapies, including BO-11X formulations or monotherapy with one or more immunomodulatory agents.

[0115] In particular, certain types of cancers can be selected for treatment with the BO-11X formulation (or the BO-11Xm formulation) depending on their sensitivity to immunotherapy with anti-PD1 antibodies, anti-PD-L1 antibodies, or anti-CTLA4 antibodies, etc. These cancers include melanoma, non-small cell lung cancer, head and neck cancer, renal cell carcinoma, bladder cancer, hepatocellular carcinoma, and Hodgkin's lymphoma. Alternatively, the BO-11X formulation (or the BO-11Xm formulation) can be used to treat cancer types that have not previously demonstrated any sensitivity to immunotherapy, such as prostate cancer, breast cancer, colon cancer, or subtypes of these cancers that have, for example, a high mutation load (or microsatellite instability), such as those that have not previously demonstrated any sensitivity to immunotherapy, ... It may be administered for the treatment of those presenting with JAK, POLE or other mutations detected by gene sequence and / or expression profiling that affect response to interferon gamma.

[0116] In general, the BO-11X formulation can be combined with miRNA (or other non-coding RNA molecules that act as inhibitors or regulators of the expression of specific genes, such as RNAi shRNA or siRNA; Ling H, 2016, Larsson M et al., 2017), mRNA (i.e., RNA that codes for a protein when intracellularly), or any other RNA-based drug, in which case the BO-11X formulation, such as the BO-112 formulation, can improve the delivery, activity and / or stability of the RNA (e.g., miRNA for silencing IDO, TGF beta, or NKG2D ligand) by this combined or co-administration method. Synergistic combinations of the BO-112 formulation with complementary mechanisms of action include drugs designed to reduce immune suppression and T cell exhaustion, enhance T cell activation, or increase the number of tumor-specific T cells. These drugs can target tumor cells, T cells, or other cells in the tumor microenvironment and are classified as immunomodulatory mAbs (CTLA4, PD1 or PDL1, LAG3, TIM3, CD137, OX40, GITR, CD40, CD25), activating cytokines (IL2, IL12), other neutralizing mAbs (TGF beta, IDO1, IL10, NKG2d ligand), CAR-T cells, or cancer antigen vaccines. Current data also support the combination of agents targeting Tregs and drugs involved in (and targeting) DNA repair and / or replication.

[0117] In some embodiments, the terms "patient" and "subject" are used interchangeably. In some embodiments, the subject and / or animal is a mammal, such as a human, a mouse, a rat, a guinea pig, a dog, a cat, a horse, a cow, a pig, a rabbit, a sheep, or a non-human primate, such as a monkey (e.g., a baboon), or a chimpanzee.

[0118] In some embodiments, the methods of the invention are useful for treating a human subject. In some embodiments, the human is a child. In other embodiments, the human is an adult. In other embodiments, the human is an elderly person. In other embodiments, the human may be referred to as a patient or subject. In some embodiments, the human is a female. In some embodiments, the human is a male.

[0119] Treatment regimens and combination therapies In one embodiment, the present invention provides a method for producing a method for the treatment of a disease comprising the steps of: (i) administering to said subject (patient) at least one treatment with said composition or said formulation, followed by (ii) tracking (analysis) of the medical condition of said subject (patient) and / or tracking of gene expression in said tumor, cancer and / or immune cells, together with or subsequent to said tracking (analysis) of the medical condition of said subject (patient), (iii) assessment of (a) cellular infiltrates (e.g., CD8 and / or CD4 positive T cells) within a tumor biopsy, (b) necrosis and / or apoptosis of cancer cells in a tumor biopsy, or (c) an increase / decrease in circulating immune cells in the blood; The present invention relates to a BO-11X composition (or a BO-11Xm composition), preferably a BO-112 composition (or a BO-112m composition), as defined herein for use in the treatment of a cell proliferation disorder characterized by abnormal growth of human or animal cells, comprising

[0120] This approach is useful for evaluating administration of BO-11X formulations such as BO-112 and can be further developed according to available techniques for imaging to evaluate, for example, tumor burden and / or response (see also Example 3).

[0121] In other embodiments, such as those summarized in FIG. 14 and FIG. 15, the present invention provides a method for treating a cell proliferation disorder characterized by abnormal growth of human or animal cells, comprising: (i) a BO-11X composition (or a BO-11Xm composition), preferably a BO-112 composition (or a BO-112m composition), as defined herein, or (ii) a preparation obtainable by treating cells or tissues derived from a subject (patient) ex vivo with a BO-11x composition (or a BO-11Xm composition), preferably a BO-112 composition (or a BO-11Xm composition), as defined herein; And, The composition is administered to the subject (patient) through the following steps: (i) at least one treatment with the composition or formulation, followed by (ii) tracking (analyzing) the medical condition of said subject (patient) and / or tracking gene expression in their tumor, cancer and / or immune cells, and / or with or subsequent to the assessment of (ii,a) cellular infiltrates (e.g., CD8 and / or CD4 positive T cells) in tumor biopsies, (ii,b) necrosis and / or apoptosis of cancer cells in tumor biopsies, or (ii,c) increase / decrease in circulating immune cells in the blood. (iii) at least one treatment with said composition and / or said formulation, and / or standard of care protocol, and / or anti-cancer drug or treatment (already approved or in a clinical investigation protocol) to which the subject (patient) is resistant, unresponsive or poorly responsive, and administering the compound according to a process comprising: The compositions or formulations may be used in steps (i) and (iii) for treatment with the compositions and / or formulations using the same or different doses, means of administration (intratumoral or subcutaneous / intramuscular) or regimens. More preferably, the standard of care, drug in clinical development, or other treatment to which the subject (patient) is resistant, unresponsive or poorly responsive is radiotherapy, chemotherapy, anti-PD-1 / PD-L1 therapy (or other immune checkpoint inhibitors), cancer antigen-based vaccination, or cell therapy (including CAR-T therapy). Preferably, the gene expression comprises mRNA and / or protein expression of a specific set of proteins.

[0122] In another embodiment, the present invention provides a BO-11X composition (or a BO-11Xm composition), preferably a BO-112 composition, for use in the treatment of a cell proliferation disorder characterized by abnormal growth of human or animal cells, comprising: (I) at least one (or a first) intratumoral injection of the composition; (II) at least one (or a second) subcutaneous or intramuscular injection of the composition; and wherein said at least one intratumoral injection is administered prior to said at least one subcutaneous or intramuscular injection.

[0123] Similarly, the present invention relates to a method for treating a cell proliferation disorder in a human or animal subject (patient) characterized by abnormal cell growth, comprising administering to said subject a BO-11X composition (or a BO-11Xm composition), preferably a BO-112 composition (or a BO-112m composition): (I) at least one (or first) intratumoral injection of the composition; (II) at least one (or a second) subcutaneous or intramuscular injection of the composition; wherein said at least one intratumoral injection occurs prior to said at least one subcutaneous or intramuscular injection.

[0124] Alternatively, a dosing regimen or corresponding method of treatment for a BO-11X composition (or a BO-11Xm composition) in a human or animal subject (patient) suffering from a cell proliferation disorder characterized by abnormal cell growth, comprising: (i) at least a first intratumoral injection in a first lesion; (ii) at least a second intratumoral injection in the same lesion or, if no longer present, in one or more additional lesions; may include.

[0125] In the composition for the above use and in the above treatment method, it is preferred that the subsequent intratumoral injection is performed at least 24 hours after the at least one intratumoral injection, more preferably at least 48 hours after 2 to 4 intratumoral injections, and even more preferably at least 1 week after 4 intratumoral injections. It is even more preferred that the application of the at least one intratumoral injection is repeated at equal or different time intervals in the composition for the above use and in the above treatment method.

[0126] These dosing regimens (or corresponding treatment methods) include: (a) administering a BO-11X composition (or a BO-11Xm composition) before or after administration of a second therapeutic agent, which is administered by intratumoral or peritumoral, subcutaneous, or intramuscular injection in the same and / or other lesion(s); (b) administering a BO-11X composition (or a BO-11Xm composition) after determining whether the subject is resistant, insensitive, or has little (or no) response to the second therapeutic agent; (c) also administering to the subject the second therapeutic agent after administering the BO-11X composition (or the BO-11Xm composition) and determining whether there is a statistically significant increase in the number of circulating immune cells and / or a change in the expression of any of the genes in Table I (see Example 4); It may also include.

[0127] With regard to embodiments (b) and (c) above, it is preferred that the second therapeutic agent is selected from anti-CTLA4, anti-PD1, anti-PDL1, CAR-T cells, a cancer antigen vaccine, or an agent targeting regulatory T cells, a metabolic enzyme, DNA repair and / or replication, or a protein expressed by any of the genes in Table I.

[0128] Alternatively, the administration regimen of the BO-11X composition (or the BO-11Xm composition) may include ex vivo treatment of cells with such a composition. In this case, the BO-11X composition (or the BO-11Xm composition) is (i) obtaining cells from a subject; (ii) contacting the cell with the composition ex vivo; (iii) administering such cells to a subject; and The compound is used as a medicine by administering it to a subject according to a dosage regimen comprising:

[0129] The treatment of cell proliferation disorders characterized by abnormal cell growth in humans or animals as shown in all the above embodiments is preferably the treatment of cancer. In the composition for the above use and in the above treatment method, it is more preferred that the at least one (or any second or other additional) intratumoral, peritumoral, subcutaneous or intramuscular injection is performed at least 24 hours after the at least one (or first) intratumoral injection, even more preferred at least 48 hours after 2 to 4 intratumoral injections, even more preferred at least 1 week after 4 intratumoral injections. In the composition for the above use and in the above treatment method, it is even more preferred that the application of the at least one intratumoral injection is repeated at equal or different time intervals. It is preferred to repeat the application of at least one subcutaneous injection at equal or different time intervals and / or to repeat the intramuscular injection at equal or different time intervals. In the compositions for the above uses and in the above methods of treatment, it is even more preferred that the composition administered in at least one subcutaneous or intramuscular injection contains the same or a smaller amount of polyinosinic-polycytidylic acid (poly(I:C)) as in at least one intratumoral injection.

[0130] In some embodiments, the present invention provides for a treatment regimen for certain cancers with a BO-11X formulation (or a BO-11Xm formulation) and a second immunomodulatory agent (and optionally one or more additional therapeutic agents). For example, in some embodiments, a BO-11X formulation, e.g., BO-112, can be first administered to a patient to optionally normalize tumor vascularization by reducing or eliminating hypoxia. Alternatively, such first administration of a mBO-11X formulation, e.g., BO-112, can stimulate and / or increase tumor T lymphocytes (e.g., CD4+ and CD8+ T cells) and / or NK cells, and / or inhibit and / or decrease the recruitment of immune suppressive cells (e.g., myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs); tumor-associated neutrophils (TANs), M2 macrophages, and tumor-associated macrophages (TAMs)) to the tumor. In some embodiments, the treatment of the present invention may alter the ratio of M1 to M2 macrophages at the tumor site to favor M1 macrophages. The BO-11X formulation may, in some embodiments, induce long-lasting (i.e., more than temporary) vascular normalization. For example, the BO-11X formulation's vascular normalization may last for more than 1, or 2, or 3, or 4, or 5, or 6, or 7, or 14, or 21 days. Thus, in some embodiments, this long-lasting BO-11X formulation's vascular normalization (or generally, changes in immune cells infiltrating the tumor or circulating in the bloodstream) may allow for a sustained, tolerant tumor microenvironment that is more likely to be responsive to one or more immunomodulatory agents. That is, in some embodiments, the BO-11X formulation may enhance, rescue, or increase sensitivity to immunomodulatory agent therapy.

[0131] Alternatively, the BO-11X formulation (or BO-11Xm composition, such as BO-112 or BO-112m) is administered to the patient before or after the initiation of treatment with one or more immunomodulatory agents. For example, in some embodiments, the immunomodulatory agent targets one or more co-inhibitory molecules to reduce or eliminate immunosuppression. In this favorable situation, the BO-11X formulation (or BO-11Xm composition, such as BO-112 or BO-112m) is administered to stimulate the immune system, i.e., by removing the suppression. Alternatively, the immunomodulatory agent first targets one or more co-stimulatory molecules, and then the BO-11X formulation (or BO-11Xm composition, such as BO-112 or BO-112m) is administered to support this effect, for example, synergistically.

[0132] Additionally, as described herein, the BO-11X formulation and / or immunomodulatory agent may be combined with additional therapeutic agents, for example, in the context of a co-administration, treatment regimen, or combination drug.

[0133] In some embodiments, the BO-11X formulation (or BO-11Xm composition) and / or the immunomodulatory agent may be administered sequentially, optionally with an additional therapeutic agent. As used herein, the term "sequentially" refers to administration of the additional therapeutic agent and the BO-11X formulation and / or the immunomodulatory agent more than about 60 minutes apart. For example, the time between the additional therapeutic agent and the sequential administration of the BO-11X formulation and / or the immunomodulatory agent may be more than about 60 minutes, more than about 2 hours, more than about 5 hours, more than about 10 hours, more than about 1 day, more than about 2 days, more than about 3 days, or more than about 1 week. The optimal number of administrations may depend on the additional therapeutic agent administered and the metabolism, excretion rate, and / or pharmacodynamic activity of the BO-11X formulation and / or the immunomodulatory agent. Either the additional therapeutic agent or the agent of the invention may be administered first.

[0134] In some embodiments, the BO-11X formulation (or BO-11Xm composition) and / or immunomodulatory agent may be administered simultaneously, optionally with an additional therapeutic agent. As used herein, the term "concurrently" means that the additional therapeutic agent and the BO-11X formulation and / or immunomodulatory agent are administered about 60 minutes or less apart, such as about 30 minutes or less, about 20 minutes or less, about 10 minutes or less, about 5 minutes or less, or about 1 minute or less. The administration of the additional therapeutic agent and the BO-11X formulation and / or immunomodulatory agent may be by simultaneous administration of a single formulation (e.g., a formulation including the additional therapeutic agent and the BO-11X formulation and / or immunomodulatory agent) or separate formulations (e.g., a first formulation including the additional therapeutic agent and a second formulation including the BO-11X formulation and / or immunomodulatory agent).

[0135] Also, simultaneous administration does not require that the additional therapeutic agents being administered be administered to a subject by the same route of administration. Rather, each therapeutic agent may be administered by any suitable route, e.g., parenterally or non-parenterally.

[0136] Such combinations may result in synergistic and / or additive and / or potent effects at lower doses of the BO-11X formulation (or BO-11Xm composition) and / or immunomodulatory agent. For example, when a BO-11X formulation is combined with one or more immunomodulatory agents, the effective amount of the BO-11X formulation may be lower than in monotherapy. In some embodiments, for example, when a BO-11X formulation is combined with an immunomodulatory agent, the effective amount of the BO-11X formulation is a subtherapeutic dose, and when an immunomodulatory agent is combined with a BO-11X formulation, the effective amount of the immunomodulatory agent may be lower than in monotherapy. In some embodiments, when an immunomodulatory agent is combined with a BO-11X formulation, the effective amount of the immunomodulatory agent is a subtherapeutic dose. In some embodiments, when an immunomodulatory agent is combined with a BO-11X formulation and an additional therapeutic agent, the effective amount of the additional therapeutic agent is a subtherapeutic dose. The term "sub-therapeutic dose or amount" means a dose or amount of a pharmacologically active substance that is below the dose or amount of that substance that would be administered as a single substance to achieve a therapeutic effect. A sub-therapeutic dose of such a substance will depend on the subject and disease state being treated, the weight and age of the subject, the severity of the disease state, the duration of administration, and the severity of the disease state. It may vary depending on the method, etc., but can be readily determined by one of skill in the art. In one embodiment, a sub-therapeutic dose or amount of a chemotherapeutic agent is less than 90% of the approved full dose of the chemotherapeutic agent, such as that provided in the U.S. Food and Drug Administration approved labeling information for the chemotherapeutic agent. In other embodiments, a sub-therapeutic dose or amount of a chemotherapeutic agent is less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or even less than 10% of the approved full dose, e.g., 20%-90%, 30%-80%, 40%-70%, or another range included in the values ​​provided herein.

[0137] In some embodiments, the effective amount of the immunomodulatory agent is less than its effective amount used in monotherapy for the same cancer and / or in combination therapy with agents other than the BO-11X formulation for the same cancer. In some embodiments, the effective amount of the BO-11X formulation is less than its effective amount used in monotherapy for the same cancer or clinical condition and / or in combination therapy with agents (such as immunomodulatory agents) for the same cancer or clinical condition.

[0138] In some embodiments, the BO-11X formulation (or BO-11Xm composition) is combined with one or more immunomodulators (e.g., 1, or 2, or 3, or 4, or 5 immunomodulators) and optionally one or more additional therapeutic agents (e.g., 1, or 2, or 3, or 4, or 5 additional therapeutic agents). Such combinations may result in synergistic and / or additive and / or potent effects at lower doses of the BO-11X formulation and / or the immunomodulator and / or the one or more additional therapeutic agents. The coadministration may be simultaneous or sequential. In addition, the pharmaceutical composition comprising the BO-11X formulation and / or the immunomodulator may include an additional therapeutic agent (e.g., in a combination formulation). That is, in some embodiments, any two or more of the agents disclosed herein may be combined. Furthermore, in some embodiments, the BO-11X formulation and / or the immunomodulator may be administered to a patient undergoing treatment with one or more additional therapeutic agents. Additionally, in some embodiments, the BO-11X formulation and / or immunomodulatory agent may replace a patient's current treatment with one or more additional therapeutic agents.

[0139] Adjuvant therapy, also called adjuvant care, is a treatment that includes primary, ... or is a treatment given in addition to an initial treatment. As a non-limiting example, adjuvant therapy may be an additional treatment given after surgery, usually when all detectable disease has been removed but there remains a statistical risk of recurrence due to occult disease. In some embodiments, the agents described herein are used as adjuvant therapy in the treatment of cancer. In some embodiments, the therapeutic agents described herein are applied as neoadjuvant therapy prior to resection. In certain embodiments, neoadjuvant therapy refers to a treatment to shrink and / or downgrade a tumor prior to any surgery. In some embodiments, neoadjuvant therapy refers to the administration of the therapeutic agents described herein to a cancer patient prior to surgery or other procedure that allows for removal of the tumor.

[0140] In some embodiments, the therapeutic agents described herein are useful as maintenance therapy following initial treatment with a first-line therapy, including but not limited to any of the additional therapeutic agents of the present disclosure.

[0141] In some embodiments, the present invention provides therapeutic regimens or methods for treating cancer or tumor in a subject comprising administering, simultaneously or sequentially, a therapeutically effective amount of a BO-11X formulation and / or an immunomodulatory agent and one or more additional therapeutic agents described herein. In some embodiments, the present invention provides therapeutic regimens or methods for treating cancer or tumor in a subject comprising administering, simultaneously or sequentially, a therapeutically effective amount of a BO-11X formulation and / or an immunomodulatory agent and one or more anti-cancer agents described herein, including but not limited to chemotherapeutic agents. Suitable chemotherapeutic agents for use in the methods of the present invention include the BO-11X formulation and / or an immunomodulatory agent and one or more additional therapeutic agents described herein. The chemotherapeutic agents may include those described in the document. In certain embodiments, the chemotherapeutic agent is one or more of 5-fluorouracil (5-FU), doxorubicin, gemcitabine, paclitaxel, and cisplatin. As an example, in some embodiments, the present invention provides for combining the BO-11X formulation and / or the immunomodulator with one or more common cancer treatment regimens (non-limiting examples include FOLFOX, FOLFIRI, IFL, FL (Mayo), QUASAR, Machover schedule, CAF, CMF, ECF, and FEC).

[0142] In some embodiments, the additional therapeutic agent is an anti-hyperproliferative agent, including but not limited to, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, cisplatin, VP16, enediyne, taxol, vincristine, vinblastine, carmustine, melphalan, cyclophosphamide, chlorambucil, busulfan, lomustine, 5-fluorouracil, gemcitabine, BCNU, or camptothecin.

[0143] Additionally, the additional therapeutic agent may further include the use of radiation. Additionally, the treatment method may further include the use of photodynamic therapy.

[0144] Salts, Pharmaceutical Compositions and Dosages In some embodiments, the present invention provides the formulations, compositions (formulations and compositions are used interchangeably in the present invention) described herein, as well as pharma- ceutically acceptable esters, prodrugs, salts, solvates, enantiomers, stereoisomers, active metabolites, cocrystals, and other physiologically functional derivatives thereof.

[0145] In one aspect, the present invention provides an agent as described herein and a pharma- ceutically acceptable carrier or excipient. The pharmaceutical composition may be in any suitable form appropriate for the desired use and route of administration. The pharmaceutical excipient may be a liquid, such as water and oil, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. The pharmaceutical excipient may be, for example, saline, gum arabic, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In one embodiment, the pharma- ceutically acceptable excipient is sterile when administered to a subject. When any agent as described herein is administered intravenously, water is a useful excipient. Saline solutions and aqueous solutions of dextrose and glycerol may also be employed as liquid excipients, particularly injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences (ed. Allen, Loyd V., Jr; 22nd ed., 2003). 012).

[0146] In addition, the pharmaceutical composition or formulation of the present invention may contain adjuvants such as preservatives, wetting agents, emulsifying agents, pH buffering agents, and dispersing agents. In addition, auxiliary, stabilizing, thickening agents, lubricants, and coloring agents may be included. Prevention of microbial activity may be ensured by including various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenolic acids, and the like. The pharmaceutical composition may also contain isotonic agents, such as sugars, sodium chloride, and the like. If necessary, the pharmaceutical composition may also contain a solubilizing agent. The agent may also be delivered by a suitable vehicle or delivery device known in the art. The composition for administration may also contain a local anesthetic, such as lidocaine, to reduce pain at the site of injection.

[0147] The pharmaceutical composition or formulation of the present invention may be in the form of a solution, suspension, emulsion, droplet, tablet, pill, pemphigoid, or the like. The pharmaceutical composition may be in the form of a tablet, a capsule, a capsule containing liquid, a powder, a sustained release agent, a suppository, an emulsion, an aerosol, a spray, a suspension, or any other form suitable for use.Thus, the compositions described herein may be contained in a capsule, a tablet, a pill, a caplet, a bottle, an ampoule, a sachet, a syringe, a cartridge, a nebulizer, or other container.In one embodiment, the pharmaceutical composition is in the form of a capsule.In another embodiment, the pharmaceutical composition is in the form of a tablet.

[0148] In some embodiments, administration of any of the described agents and compositions is any one of oral, intravenous, and parenteral. In some embodiments, routes of administration include, for example, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intranasal, intracerebral, intrahepatic, intrapancreatic, intravesicular, intravaginal, transdermal, rectal, by inhalation, or topically, for example, to the ear, nose, eye, or skin. In some embodiments, administration is oral or by parenteral injection. The mode of administration may be at the discretion of the medical practitioner and depends in part on the medical condition at the site and / or concurrent treatments (e.g., chemotherapy, radiation therapy, or combinations with antibodies, vaccines, and other cancer-targeting drugs). In some embodiments, administration results in the release of any agent described herein into the bloodstream.

[0149] Any of the agents, pharmaceutical compositions and / or formulations described herein may be administered orally. Such agents and / or pharmaceutical compositions may also be administered by any other convenient route, such as intravenous infusion or bolus injection, absorption through epithelial or muco-cutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), or may be administered together with additional therapeutic agents. Administration may be systemic or local. Various delivery systems, such as encapsulation in liposomes, microparticles, microcapsules, capsules, etc., are known and may be used. In specific embodiments, it may be desirable to administer locally to the area requiring treatment.

[0150] In one embodiment, the agents described herein and / or the pharmaceutical compositions and / or formulations described herein are formulated in accordance with routine procedures as compositions adapted for oral administration to humans. Solid dosage forms for oral administration include, for example, capsules, tablets, pills, powders, and granules. Such dosage forms may contain inert pharma- ceutically acceptable excipients or carriers, such as sodium citrate, dicalcium phosphate, and / or a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, silicic acid, microcrystalline cellulose, and Bakers Special Sugar; b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone; c) humectants, such as glycerol; d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium carbonate, cross-linked polymers, such as crospovidone (cross-linked polyvinylpyrrolidone), croscarmellose sodium (cross-linked sodium carboxymethylcellulose), sodium starch glycolate; e) solution retarders, such as paraffin. The active agent is mixed with at least one of the following excipients: a) a tertiary ammonium agent; b) an absorption enhancer, such as a quaternary ammonium agent; c) a wetting agent, such as cetyl alcohol and glycerol monostearate; d) an absorbent, such as kaolin, bentonite clay, and e) a lubricant, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, glyceryl behenate, and mixtures of such excipients. Those skilled in the art will recognize that a particular excipient may have more than one function in an oral dosage form. In addition, in the case of an oral dosage form, such as a capsule or tablet, the dosage form may include a buffering agent.

[0151] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active agent, the liquid dosage form may contain, for example, water or other solvent. Inert diluents, solubilizers and emulsifiers commonly used in the art, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof. Suitable dosage forms for parenteral administration (e.g., intravenous, intramuscular, intrahepatic, intrapancreatic, intraperitoneal, subcutaneous and intraarticular injection and infusion) include, for example, solutions, suspensions, dispersions, emulsions and the like. The above dosage forms may also be manufactured in the form of sterile solid compositions (e.g., lyophilized compositions) that can be dissolved or suspended in a sterile injectable medium immediately before use. The above dosage forms may include, for example, suspending agents or dispersing agents known in the art. The pharmaceutical composition of the present invention for parenteral injection includes pharma- ceutical acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions immediately before use.Examples of suitable aqueous or non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.Proper fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by using surfactants.

[0152] Any of the agents described herein and / or any of the pharmaceutical compositions described herein can be administered by controlled or sustained release means or by delivery devices known to those skilled in the art. Such dosage forms may be useful to provide controlled or sustained release of one or more active ingredients, for example, using hydropropylcellulose, hydropropylmethylcellulose, polyvinylpyrrolidone, Eudragit, other polymer matrices, gels, permeable membranes, osmotic systems, multi-layer coatings, microparticles, liposomes, microspheres, or combinations thereof to provide desired release profiles of varying rates. Suitable controlled or sustained release formulations can be easily selected for use with the active ingredients of the agents described herein. Thus, the present invention provides single unit dosage forms suitable for oral administration, such as, but not limited to, tablets, capsules, gelcaps, and caplets, adapted for controlled or sustained release.

[0153] The formulations containing the agents and / or pharmaceutical compositions of the present invention described herein are conveniently presented in unit dosage form and can be prepared by any method known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agent into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are made by uniformly and intimately bringing the therapeutic agent into association with liquid carriers, particulate solid carriers, or both, and then, if necessary, shaping the product into the desired formulation (e.g., by wet or dry granulation, powder blending, etc., followed by tableting using conventional methods known in the art).

[0154] It is understood that the actual dose of the drug described herein and / or pharmaceutical composition of the present invention administered according to the present invention may vary depending on the specific drug, the specific dosage form, and the mode of administration. Many factors that may change the action of BO-11X formulations (e.g., body weight, sex, diet, time of administration, route of administration, rate of excretion, condition of the subject, drug combination, genetic tendency, and reaction sensitivity) can be taken into consideration by those skilled in the art. Administration can be carried out continuously or in one or more separate doses within the maximum tolerated dose. The optimal administration rate for a given set of conditions can be confirmed by those skilled in the art using conventional dosage administration tests.

[0155] Individual doses of the agents described herein and / or pharmaceutical compositions of the invention may be administered, for example, in the form of about 0.01 mg to about 1000 mg of poly(I: The BO-11X formulation may be administered in a unit dosage form (e.g., tablet or capsule) containing poly(I:C) molecules, for example, the individual BO-11X formulations are formed by preparing a complex from about 0.01 mg to about 1000 mg of poly(I:C), preferably from about 0.5 mg to about 2.5 mg of poly(I:C), more preferably from about 1 mg to about 2 mg of poly(I:C) (including all values ​​and ranges therebetween). In some embodiments, the agents and / or pharmaceutical compositions of the invention described herein are administered in an amount of about 0.01 mg to about 1000 mg of poly(I:C) molecules in the BO-11X formulation daily, or from about 0.1 mg to about 10 mg daily (e.g., where the individual daily BO-11X formulations are formed by preparing a complex from about 0.01 mg to about 1000 mg, preferably from about 0.01 mg to about 10 mg of poly(I:C)) (including all values ​​and ranges therebetween).

[0156] In some embodiments, a suitable dosage of an agent and / or pharmaceutical composition of the invention is in the range of about 0.001 mg to about 10 mg of poly(I:C) molecules in a BO-11X formulation per kg of subject body weight, preferably 0.003 mg to about 10 mg of poly(I:C) molecules in a BO-11X or BO-11Xm formulation (calculated for the subject or, where appropriate, calculated for the subject's body weight), more preferably 0.005 mg to about 10 mg of poly(I:C) molecules in a BO-11X formulation per kg of subject body weight, and even more preferably Preferably, the poly(I:C) molecule in the BO-11X formulation is 0.01 mg to about 10 mg per kg of subject body weight (e.g., where each of the BO-11X formulations administered is formed by preparing a complex from about 0.005 mg to about 10 mg of poly(I:C)), and more preferably, about 0.003 mg to about 10 mg of poly(I:C) per kg of subject body weight, and more preferably, about 0.001 mg to about 10 mg of poly(I:C) per kg of subject body weight, including all values ​​and ranges therebetween. 01 mg to about 10 mg per kg of subject body weight, and all values ​​and ranges therebetween. In other embodiments, the suitable dosage of the BO-11X formulation and / or the immunomodulatory agent and / or the additional therapeutic agent is in the range of about 0.01 mg to about 10 mg per kg of subject body weight, or in the range of about 0.05 mg to about 1 mg per kg of subject body weight.

[0157] According to certain embodiments of the present invention, the medicaments and / or pharmaceutical compositions described herein may be administered, for example, more than twice a day, about once a day, about once every 2 days, about once every 3 days, about once a week, about once every 2 weeks, about once a month, about once every 2 months, about once every 3 months, about once every 6 months, or about once a year. In one embodiment, the suitable dosage of the medicaments and / or pharmaceutical compositions of the present invention ranges from 0.1 mg to 10 mg of poly(I:C) molecules in the BO-11X formulation per subject (patient) over a treatment cycle, preferably 0.5 mg to 2 mg of poly(I:C) molecules in the BO-11X formulation per subject, more preferably 0.6 mg to 1 mg per subject. In particular, when administering the compositions of the present invention by intradermal or intratumoral injection, the total amount of the composition can be adapted accordingly.

[0158] kit The present invention also provides kits that can simplify the administration of the agents and / or pharmaceutical compositions described herein. A kit is a collection of materials or components that includes at least one agent described herein. The exact nature of the components configured in the kit depends on its intended purpose. In one embodiment, the kit is configured for the purpose of treating a human subject.

[0159] Instructions for use may be provided with the kit. Instructions for use typically include clear language describing techniques to be employed for the use of the components of the kit to affect a desired outcome, such as treating or preventing cancer, gynecological disorders, or infectious diseases. Optionally, the kit may also include diluents, buffers, pharma- ceutically acceptable carriers, syringes, catheters, applicators, filters, needles (microneedles), pipetting or metering equipment. , other useful components such as taping materials, or other useful equipment that may be readily recognized by one of ordinary skill in the art. In particular, the kits may include devices for more precise (e.g., image-guided) intratumoral or peritumoral drug delivery, implantable (or non-implantable) drug-eluting devices in the form of matrices (including porous, biodegradable and / or polymeric structures and scaffolds), encapsulation systems, or other suitable packaging for clinical use.

[0160] Because the BO-11X or BO-11Xm compositions can be used directly, in combination with other compounds (e.g., vaccines, drugs, adjuvants, etc.), using various routes of administration, and / or involving the collection and analysis of cells or samples derived from a patient, the kits may include syringes (prefilled or not) for intratumoral, intramuscular and / or subcutaneous injection, vehicles for dilution, vials for storing biological material derived from a patient, and / or specific materials such as antibodies for detecting specific cell markers.

[0161] Section 1. 1. An aqueous composition comprising particles, comprising: (i) each of said particles comprises: (a) polyinosinic-polycytidylic acid (poly(I:C)), or a salt or solvate thereof; at least 40% of the poly(I:C) molecules contained in the particles have at least 850 base pairs, and at least 50% of the poly(I:C) molecules contained in the particles have 400 to 5,000 base pairs; (b) a water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine, or a salt thereof and / or a solvate thereof; The linear polyalkyleneimine has an average molecular weight of 17 kDa to 23 kDa; The complex includes (ii) at least 90% of the particles have a unimodal size distribution less than 300 nm; (iii) the particles have a z-average diameter of 80±20 nm as measured by ISO 22412:2017 and a particle size polydispersity index of less than 1.5; (iv) the composition comprises polyinosinic-polycytidylic acid (poly(I:C)) at a concentration of at least 0.5 mg / mL; (v) the composition has a pH of 2 to 4 and an osmolality of 200 mOsm / kg to 600 mOsm / kg; (vi) the composition has a zeta potential according to ISO 13099-2:2012 of 35 mV to 50 mV; Aqueous composition. Section 2. Item 1. The composition according to item 1, wherein the particles have a median diameter (D50%) of 85±20 nm. Section 3. The particles include (i) at least 10% of the poly(I:C) molecules have less than 400 base pairs, at least 40% of the poly(I:C) molecules have at least 850 base pairs, at least 70% of the poly(I:C) molecules have between 400 and 5000 base pairs, and between 20% and 45% of the poly(I:C) molecules have between 400 and 850 base pairs; or (ii) 5% to 60% of the poly(I:C) molecules have less than 400 base pairs, 15% to 30% of the poly(I:C) molecules have between 400 and 850 bases, 10% to 70% of the poly(I:C) molecules have between 850 and 5000 base pairs, and 0% to 10% of the poly(I:C) molecules have more than 5000 base pairs. Item 3. The composition according to item 1 or 2. Section 4. Item 4. The composition according to any one of Items 1 to 3, wherein the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine is a linear polyethyleneimine. Section 5. Item 5. The composition according to any one of items 1 to 4, wherein the particle size polydispersity index is in the range of 0.2 to 0.3. Section 6. The composition according to any one of items 1 to 5, further comprising at least one pharma- ceutically acceptable carrier, organic solvent, excipient, and / or adjuvant. Section 7. Item 9. The composition according to any one of items 1 to 8, further comprising at least one compound selected from an organic compound, an inorganic compound, a nucleic acid, an aptamer, a peptide, or a protein. Section 8. The composition according to any one of items 1 to 7, further comprising non-coding RNA or RNA encoding a protein. Section 9. The composition according to any one of items 1 to 8, further comprising glucose or mannitol at a concentration of 1% to 10% (weight / volume). Section 10. Item 10. The composition according to any one of items 1 to 9, wherein the aqueous composition has a pH of 3.0±0.2 and an osmolality of 300 mOsm / kg to 310 mOsm / kg. Section 11. Item 11. The aqueous composition according to any one of items 1 to 10, wherein the particles are formed at a ratio of the number of moles of nitrogen of the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine to the number of moles of phosphorus of the poly(I:C) molecule of 2.5 to 4.5. Section 12. Item 12. The composition of item 11, wherein the particles are formed by separately injecting a solution containing the poly(I:C) molecules and a solution containing the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine in a mixing chamber. Section 13. Item 13. The composition according to item 11 or 12, which is formed by adding glucose or mannitol at a concentration of 1% to 10% (weight / total volume of the composition). Section 14. Item 14. The composition according to item 13, wherein glucose is added to the solution containing poly(I:C). Section 15. Item 14. The composition according to item 13, wherein the solution containing the poly(I:C) molecule and the solution containing the water-soluble, linear homopolyalkyleneimine or heteropolyalkyleneimine are injected separately at a flow rate of 1 mL / min to 50 mL / min for either solution, and / or are mixed at a speed of 50 rpm to 600 rpm. Section 16. A composition obtainable by freeze-drying the aqueous composition according to any one of items 1 to 15. Section 17. 17. The composition according to any one of items 1 to 16, which is used as a medicine. Section 18. Item 18. The composition according to item 17, wherein the medicament is an injectable aqueous composition optionally containing a pharma- ceutically acceptable carrier, excipient, and / or adjuvant. Section 19. Item 17. The composition according to any one of items 1 to 16, which is used for treating a cell proliferation disorder characterized by abnormal cell growth in a human or animal. Section 20. 20. The composition of claim 19, wherein the cell proliferation disorder is cancer or a gynecological disorder characterized by abnormal growth of cells of the reproductive organs of a female mammal. Section 21. Item 21. The composition according to item 19 or 20, which is used for injection into a tumor or around a tumor. Section 22. 21. The composition according to item 19 or 20, which is used at the skin level or for injection into an internal organ or tissue. Section 23. 21. The composition of claim 19 or 20, used in combination with a second therapeutic agent selected from anti-CTLA4, anti-PD1, anti-PDL1, CAR-T cells, a cancer antigen vaccine, or an agent targeting regulatory T cells, a metabolic enzyme, DNA repair and / or replication, or a protein expressed by any of the genes in Table I. Section 24. 21. The composition according to item 19 or 20, which is used in combination with a second therapeutic agent to reduce the dosage and / or frequency of administration of said second therapeutic agent. Section 25. 21. The composition according to paragraph 19 or 20, which is used in combination with a second therapeutic agent to treat patients who are resistant, insensitive, or have little (or no) response to the second therapeutic agent. Section 26. A pharmaceutical composition comprising: (i) at least a first intratumoral injection; (ii) at least a second subcutaneous or intramuscular injection; wherein the at least one intratumoral injection is administered prior to the at least one subcutaneous or intramuscular injection, and the composition is the composition according to any one of items 1 to 16. Section 27. A pharmaceutical composition comprising: (i) at least a first intratumoral injection in a first lesion; (ii) at least a second intratumoral injection in one or more additional lesions; and 17. A pharmaceutical composition which is administered to a subject according to an administration regimen comprising the steps of: Section 28. Item 28. The pharmaceutical composition according to item 26 or 27, which is administered before or after administration of a second therapeutic agent, and the second therapeutic agent is administered by intratumoral or peritumoral injection, subcutaneous injection, or intramuscular injection in the same and / or other lesion(s). Section 29. Item 29. The pharmaceutical composition of item 28, wherein the second therapeutic agent is administered to the subject after determining whether the subject is resistant, insensitive, or has little (or no) response to the second therapeutic agent. Section 30. Item 29. The pharmaceutical composition according to Item 28, wherein the second therapeutic agent is administered to a subject after administration of the composition according to any one of Items 1 to 16 and determining whether a statistically significant increase in the number of circulating immune cells and / or a change in the expression of any of the genes in Table I is observed. Section 31. 31. The pharmaceutical composition of claim 29 or 30, wherein the second therapeutic agent is selected from anti-CTLA4, anti-PD1, anti-PDL1, CAR-T cells, a cancer antigen vaccine, or an agent targeting regulatory T cells, a metabolic enzyme, DNA repair and / or replication, or a protein expressed by any of the genes in Table I. Section 32. Item 32. The pharmaceutical composition according to any one of Items 26 to 31, wherein the pharmaceutical use is for the treatment or prevention of a cell proliferation disorder characterized by abnormal cell growth in humans or animals. Section 33. Item 32. The pharmaceutical composition according to any one of Items 26 to 31, wherein the medical use is for treating or preventing bacterial infection or viral infection. Section 34. Item 32. The pharmaceutical composition according to any one of items 26 to 31, wherein any of the second or other additional intratumoral, peritumoral, subcutaneous or intramuscular injections is administered at least 24 hours after the at least first intratumoral injection. Section 35. A pharmaceutical composition comprising: (i) obtaining cells from a subject; (ii) contacting the cell with the composition ex vivo; (iii) administering such cells to the subject; and 17. A pharmaceutical composition which is administered to a subject according to an administration regimen comprising the steps of: Section 36. Item 36. The pharmaceutical composition according to Item 35, wherein the pharmaceutical use is for the treatment or prevention of a cell proliferation disorder characterized by abnormal cell growth in humans or animals. Section 37. Item 36. The pharmaceutical composition according to item 35, wherein the pharmaceutical use is for treating or preventing bacterial or viral infection. Section 38. Item 38. The pharmaceutical composition according to any one of Items 35 to 37, wherein the cells are isolated from blood, tissue or tumor. Section 39. Item 39. The pharmaceutical composition according to any one of items 35 to 38, wherein the cells are selected for expression of one or more markers before and / or after exposure to the composition. EXAMPLES

[0162] Example 1: Structural characterization and initial in vitro functional validation of jetPEI-based poly(I:C) formulations (BO-11X formulations) Materials and Methods Poly(I:C) preparation Single-stranded polyinosinic acid (poly(I)) molecules and polycytidylic acid (poly I) molecules used to generate double-stranded polyinosinic-polycytidylic acid (poly(I:C)] molecules were obtained from commercial providers such as Tide Group, Carbogen, Hangzhou Fst Pharmaceutical Co, or Invivogen. Depending on the supplier and batch, the particle size distribution for poly I(C) molecules is defined as follows: less than 400 bases, 20%-82% (e.g., by detailed testing using preparations exhibiting 33%, 43%, 50%, 70% or 73%s); 400 bases-850 bases, 15%-40% (e.g., by detailed testing using preparations exhibiting 20%, 27%, 30%, 34%, or 37%); 850 bases-5000 bases, 3%-50% (e.g., by detailed testing using preparations exhibiting 5%, 6%, 13%, 30%, 34%, 42%, or 48%); more than 5000 bases, 1% or less (usually absent). Depending on the supplier and batch, the particle size distribution for poly(I) molecules is defined as follows: less than 400 bases, 80%-99% (e.g., with detailed testing using preparations exhibiting 81%, 86%, 91%, 95%, or 98%); 400 bases-850 bases, 1%-20% (e.g., with detailed testing using preparations exhibiting 6%, 8%, 12%, or 17%); 850 bases-5000 bases, 0%-5% (e.g., with detailed testing using preparations exhibiting 3%, 1% or less); and more than 5000 bases, 1% or less (usually absent). Additionally, the criteria for manufacturing the BO-11X formulation for application to poly(I) and poly(C) powders or solutions include maximum absorbance (at wavelengths of 248±1 nm and 268±1 nm for poly(I)Id poly(C), respectively), endotoxin content (10EU / m- or less), pH (6.0-8.0), and sedimentation coefficient (4S or more).

[0163] Batch poly(I) and poly(C) preparations were obtained, annealed and purified as described in International Application PCT / EP2016 / 078078. In short, poly(I) and poly(C) preparations were obtained using powdered poly(C) separately in the same manner and at the same concentrations. To further improve the quality of the starting solutions, membranes with a 300 kDa cutoff or a 500 kDa cutoff (Pellicon 2 cassettes, Millipore) were used. Additional steps of filtration may be performed. The permeates of these filtration steps are concentrated. The monomers were then separated on a 30 kDa membrane (Pellicon 2 cassette, Millipore). The retentate obtained for each solution was concentrated. Mix with a buffer solution (e.g. 10x PBS). Determine the optical density of both solutions to calculate the concentration based on 1:1 stoichiometry for the subsequent annealing step, and adjust the total volume accordingly before the annealing step. Incubate the poly(I) solution at 55°C to 62°C for 30 minutes. The solution was mixed with the poly(C) solution molecules and stirred. The resulting solution was slowly cooled to room temperature over approximately 3 hours to anneal the single-stranded molecules and generate poly(I:C) molecules, and finally filtered through a G3 glass pore filter (pore size approximately 15 μm to 40 μm).

[0164] This annealing process produces a solution containing a pool of different double-stranded poly(I:C) molecules, which is then applied onto a chromatographic GPC column. Chromatography was performed using a 5 cm diameter Omnifit glass column packed with 700 ml of a slurry of Toyopearl HW-65F in 40 mM sodium phosphate buffer. The slurry was allowed to settle slowly, and then washed with 40 mM sodium phosphate buffer (pH = 6.9) at a flow rate increased from 10 mL / min to 60 mL / min. The column was placed in a preparative HPLC device consisting of two feed pumps, a UV detector, a sampling valve, and a computer. The reaction mixture from the annealing was loaded onto the column and eluted with 40 mM sodium phosphate buffer (flow = 50 mL / min, pH = 6.9). The target fraction was obtained when the UV signal was between 100 mV and 1250 mV and was subjected to further processing using four dilution desalting cycles, and a tangential flow device (TFF, Millipore's Pell icon 2, regenerated cellulose, 0.1m each 2 The retentate and wash solutions were filtered through the membrane to obtain clear, colorless solutions, which were desalted using isopropanol, freeze-dried, and lyophilized at room temperature (1 mbar for approximately 5 days). Poly(I:C) preparations were prepared according to the following exemplary process: The process can be obtained by heating the poly(C) solution at 61° C.-66° C. for 1.5 h before mixing it with the poly(I) solution and stirring at 55° C.-58° C. for 70 min, after which the mixture was cooled and filtered through a 0.2 μm membrane.

[0165] Various commercially available in vivo-Jet PEIs (with average molecular weights comprised between 8.3 kDa and 22.5 kDa, with a polydispersity index of less than 1.5 determined from the polydispersity index of PEOX (polyethylene oxide, precursor of PEI) by gel permeation chromatography (GPC: SOP GPC-0044), and sterile filtered through a 0.2 μm filter) were obtained from PolyPlus (catalog number 201-50G).

[0166] Some conditions applicable to the chromatography and / or filtration steps, the absence or presence of a freezing step, together with the buffer and the annealing time, were adapted against further solution viscosity reduction or complex precipitation. Either mannitol or glucose is used as an excipient in the final formulation. Solution 1 containing JetPEI is obtained either by using JetPEI in a concentrated liquid preparation or by solubilizing a solid bulk preparation of JetPEI (with a molecular weight comprised between 17 kDa and 23 kDa) in a volume of sterile water for injection to reach 150 mM and mixing to obtain a homogenous solution. A further dilution step is performed to reach a concentration of 11.25 mM to 11.7 mM before the final dilution to 5.62 mM to 5.85 mM in the final vial. Solution 2 contains poly(I:C) molecules and glucose monohydrate in an amount that upon mixing with JetPEI provides a solution containing 5% glucose (weight / total volume of the composition) and 0.5 mg to 0.7 mg of poly(I:C) per mL of total volume of the composition, thereby complexing the poly(I:C) with the JetPEI.

[0167] Solution 1 and solution 2 were mixed at 0.2 The two solutions are sterilized separately using double filtration through a 0.2 μm filter (Sartopore™ 2 150 0.2 μm, fully qualified as a sterilizing grade filter (according to ASTM F-838-05 guidelines)). The automated mixing of the two solutions is carried out in the following sequential process: The following processes were carried out in each vial: (i) Solution 1 was pumped into the vial using a Watson-Marlow pump to dispense 5.95 g to 6.05 g (6 mL; density: 1 g / mL). al, and (ii) add solution 2 onto solution 1 using a 1.8 mm inner diameter tube connected to a G20-0.9 μm needle using a Flexicon pump at a speed of 550 rpm to dose 6.08 g to 6.40 g (6 mL). Results may be improved by the use of a T-piece mixer. In case of aggregation of particles (e.g., in the size range of 1 μm to 100 μm or more) that may still be present by visual inspection at the end of the manufacturing process (or during its storage) due to electrostatic interactions, the product can be filtered through a 0.8 μm filter prior to use (e.g., before its injection) without thereby altering either the biological properties or the monomodal size distribution of the particles in the composition. For example, the BO-112 formulation may be filtered through a Minisart syringe filter (Sartorious) with an exclusion size of 0.8 μm. The vials (containing various volumes of the BO-112 formulation, e.g., 1 mL, 2 mL, 5 mL, 10 mL or more) are sealed with sterile, pyrogen-free rubber stoppers, crimped with aluminum capsules, and individually labeled. These vials may be used directly for injection or their contents may be diluted with an appropriate vehicle prior to use.

[0168] By chromatography or agarose gel, and unlabeled or 32Preparations of [P]-labeled poly(I) and poly(I:C) were used to characterize and compare the size of the poly(I:C) molecules present in the BO-11X preparation. Briefly, 1 μg of poly(I) and poly(I:C) (PBS) were loaded onto an agarose gel and electrophoresed for 1 h at 80 volts in TBE buffer. Depending on the size distribution of the initial poly(C) and poly(I) molecules, the size distribution of the poly(I:C) molecules present in the BO-11X preparation was also determined by chromatography to be as follows: less than 400 bases, 7% to 57% (further tests performed with the preparations show values ​​included in the 10% to 30%, e.g. 11%, 15%, 17%, 21%, 26% or 28%); 400 bases to 850 bases, 20% to 45% (further tests performed with the preparations show values ​​included in the 10% to 30%, e.g. 11%, 15%, 17%, 21%, 26% or 28%); Further tests carried out with preparations give values ​​comprised between 20% and 30%, for example 23%, 25% or 27%; 850 bases to 5000 bases, 20% to 70% (further tests carried out with preparations give values ​​comprised between 40% and 60%, for example 42%, 45%, 52%, 53% or 55%); and above 5000 bases, 0% to 9% (further tests carried out with preparations give values ​​comprised between 0% and 5%, for example 3%, 1% or 0%). The sizes of the various batches of Poly(I) and Poly(C) preparations were evaluated by chromatography and compared.

[0169] The BO-112 compositions are made and tested at the concentrations and particle size distributions described for the BO-11X formulation in International Application PCT / EP2016 / 078078. The BO-112 compositions are provided as vials containing poly(I:C) at concentrations between 0.5mg / mL and 0.8mg / mL. The stability of the BO-112 compositions in these vials was confirmed after storage at 2°C to 8°C for one year.

[0170] Commercially available poly(I:C)-containing formulations Poly-ICLC is a poly(I:C) preparation stabilized with polylysine and carboxymethylcellulose (Ewel C et al., 1992, Patent Document 12). LyoVec-HMW( Poly(I:C) preparations with the corresponding high molecular weight (HMW; catalog name tlrl-pic) and low molecular weight (LMW; catalog name tlrl-picw) are available from Invivogen.

[0171] analysis technology Values ​​for the zeta-average (z-average) diameter and polydispersity index of JetPEI / Poly(I:C) particles in separate BO-11X preparations (0.5 mg / mL to 0.8 mg / mL, diluted for cell line and other assays at a Poly(I:C) concentration of 1.0 μg / mL) were calculated using the particle was determined according to ISO 22412 using a Zetasizer Nano ZS according to the manufacturer's instructions, based on the assumption that the particles are spherical. In general, dynamic light scattering (Nanosizer technology) is applied using v7.11 software.

[0172] In vitro characterization of BO-11X formulation According to the literature describing the properties of BO-110 complexes on the human melanoma cell line SK-MEL-103 and the human pancreatic cancer cell line c (Non-Patent Document 16; Non-Patent Document 17; Patent Document 16), different poly(I:C)-based formulations were tested using human melanoma cells, human pancreatic cells or human melanocytes. Briefly, cell viability assays were performed on adherent cells at least 12 hours before treatment. The percentage of cell death at the indicated time and treatment concentration was estimated by a standard trypan blue exclusion assay on floating and adherent cells that were pooled, stained with 0.4% trypan blue solution (Gibco Laboratories, Grand Island, NY, USA) and scored under a light microscope (a minimum of 100-500 cells were counted per treatment). Each formulation was tested for a period comprised between 12 hours and 48 hours, with concentrations of poly(I:C) molecules in the different formulations comprised between 0.3 μg / ml and 2.5 μg / ml.

[0173] The death-inducing activity of BO-112 was examined in normal melanocytes. , and cell lines derived from melanoma and glioblastoma, and compared with the isolated components, namely poly(I:C) molecules and linear PEI (JetPEI; Polyplus). Normal melanocytes were isolated from the foreskin of asymptomatic donors. Melanoma cells SK-Mel-28, SK-Mel-103 and UACC62 (carrying mutations in p53, NRAS and BRAF, respectively) were obtained from established collections at ATCC or Memorial Sloan Kettering Cancer Centre (USA) and subjected to short tandem repeat (STR) profiling (GenePrint™ 10 System) for cell line authentication. Primary cells derived from melanoma patients were obtained and maintained using standard protocols. Cells were seeded in 96-well plates (6000 cells / well). Treatment with 0.5 μg / ml or 1 μg / ml poly(I:C) alone, BO-110 or BO-112 formulations for 24 or 40 hours, triplicates per experiment.

[0174] Characterization of tumor cell death The cutaneous melanoma murine cancer cell line B16-F10 (ATCC code CRL-6475) was obtained from the established collection at ATCC. B16-OVA cells (derived from B16-F10 cells) were purchased from the Center for Applied Medical Research (Centro de Investigacion Medica Aplicada) (STEM). The IFN-insensitive B16 cell line was obtained from Invivogen (B B16-Blue™ IFN-γ cells, catalog number bb-ifng; B16-Blue™ IFNα / β cells, catalog number bb-ifnt1) were maintained as instructed by the manufacturer. Characterization of tumor cell death (apoptosis, necrosis, immunogenic cell death) induced by BO-112 formulations was investigated and compared with isolated poly(I:C) and other TLR ligands (LPS specific for TLR4). B16-OVA cells (10 5cells / well) alone or with ultra-pure LPS (0.25 μg / mL and 1 μg / mL, InvivoGen, The cells were cultured for 48 hours with BO-112 formulations (0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml) or with poly I:C alone (0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml) (San Diego, Calif.). The rates of cell apoptosis and necrosis were analyzed by flow cytometry using combined staining with Annexin V and 7ADD (live cells: 7ADD negative, Annexin V negative; cell necrosis: 7ADD positive, Annexin V negative; early apoptosis: 7ADD negative, Annexin V positive; late apoptosis: 7ADD positive, Annexin V positive). The effect of BO-112 on the induction of immunogenic cell death was analyzed by flow cytometry by detecting the cell surface expression of MHC-1, CD95, and calreticulin. For flow cytometry, For the analysis, samples were acquired on a Gallios cytometer (Beckman Coulter) and data were were analyzed with Kaluza flow analysis software (Beckman Coulter).

[0175] PARP activation In addition, we investigated the effect of BO-112 formulations on the activation of poly ADP-ribose polymerase (PARP), an enzyme involved in DNA repair, genomic stability, and programmed cell death. MC38 colon adenocarcinoma (Cellosaurus code CVCL_B288, Kerafast catalog number ENH204) and 4T1 breast cancer cells (ATCC code CRL-2539) were obtained from established cell collections such as ATCC. Each cancer cell line (3 × 10 6 ) were stimulated with BO-112 (0.5 μg / mL) and PARP activation was analyzed in cell lysates at 0, 16 and 24 hours by Western immunoblotting using a PARP monoclonal antibody (clone C-2-10, ThermoFisher Scientific). , identified a 116 kDa protein corresponding to PARP and an 85 kDa apoptosis-inducing cleavage product.

[0176] result International application PCT / EP2016 / 078078 discloses protocols and experimental data for the initial development and characterization of BO-11X formulations, leading to increased cytotoxicity of BO-11X formulations against cancer cells compared to BO-110 conjugates described in the literature and obtained on a laboratory scale (Non-Patent Document 16, Non-Patent Document 17, Patent Document 16). Data on the BO-11X manufacturing process under GMP conditions for process and formulation and on the obtained poly(I:C)-containing formulations were compared with data disclosed in the literature.

[0177] FIG. 1A provides an overview of such a process for producing a first type of BO-11X formulation, designated as BO-112 formulation, in which the bulk material (i.e., a double-stranded poly(I:C) molecule produced by annealing single-stranded molecules of poly(I) and poly(C)) is first mixed with an excipient such as glucose in a solution that is sterilized by filtration separately from the solution containing the polymer with the function of carrier (i.e., JetPEI). These two bulk preparations are then appropriately mixed in each vial to produce a number of structurally and functionally comparable pharmaceutical preparations required for drug toxicology research and clinical applications. This process can also be provided by adding poly(I:C) formulations in which further compounds (such as immune-related adjuvants or other therapeutic compounds) are present in the particles formed in step 1 (and thus in the final formulation), in particular such therapeutically relevant compounds together with (or instead of) an excipient such as glucose, giving an example of a BO-11Xm formulation that can be designated as BO-112m.

[0178] At least some of these reproducibility and criteria can be compared with other poly(I:C)-containing formulations with known anticancer activity. At the level of poly(I:C) molecular size, the poly(I:C) molecules contained in commercially available Lyovec-HMW and Lyovec-LMW encompass a size range that is clearly different from that provided by the manufacturing process of BO-11X (HMW is almost entirely above 0.85 kb, LMW is almost entirely below 0.85 kb). This size difference of poly(I:C) molecules may depend on the different manufacturing processes and / or the carriers associated with poly(I:C) molecules in the complex. The Z-average values ​​of complexes within the poly(I:C)-based complexes in Poly-ICLC (containing polylysine and carboxymethylcellulose) and LyoVec-HMW / LyoVec-LMW (which, according to the manufacturer, contain the cationic lipid-based transfection reagent di-tetradecylphosphoryl-N,N,N-trimethylmethanaminium chloride, or DTCPTA, and the neutral lipid 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, or DiPPE) were compared with those of the BO-112 formulation, demonstrating that these commercial formulations showed a much larger (majority of 100-fold) distribution of complexes for LyoVec-LMW with at least a bimodal distribution. The results show that the commercial preparations contain complexes (>200 nm) when subjected to freeze / thaw cycles (FIG. 1B). When this analysis is performed after freeze / thaw cycles, these commercial preparations also appear less stable, with variability not observed for BO-112. Indeed, while the BO-112 preparations have a Z-average diameter (d.nm) of 100±50 nm (e.g., 82.5 nm) not exceeding 400 nm, the LyoVec-based and poly-ICLC preparations have Z-average values ​​significantly higher than 300 nm, confirming that commercially available poly(I:C) is provided as preparations that are either heterogeneous in composition or contain large particles that are poorly functionally characterized and whose size changes during freeze / thaw cycles.

[0179] This approach can be automated to provide BO-11X formulations (such as BO-112 formulations) with even more uniform characteristics. This manufacturing procedure not only prevents having free JetPEI or poly(I:C) molecules in solution that are not complexed within the BO-112 formulation, but also allows for a controlled average diameter and unimodal size distribution of the complexes in the BO-112 formulation, such that the Z-average can be adjusted from 30 nm to 150 nm. Furthermore, this approach can be adapted to include poly(I:C) molecules of different size distributions, as well as other polyribonucleotides (poly(A), poly(G) and / or poly(U)) that have different sizes, size distributions, and / or present single-stranded and double-stranded regions.

[0180] International application PCT / EP2016 / 078078 also discloses that commercially available poly(I:C) is provided as preparations that are either heterogeneous in composition or contain large particles that are poorly functionally characterized and whose size changes during freeze / thaw cycles. Indeed, hyperchromicity can also be used to evaluate the stability of BO-112 formulations, particularly double-stranded poly(I:C) molecules within particles, as a result of temperature (or other conditions) changes that determine the separation between poly(I) and poly(C) chains. BO-112 formulations showed very low hyperchromatic effects, with a difference in transmittance at 260 nm of less than 0.2 or less than 0.1. Also, the stability of frozen BO-11X vials at -20°C for various times was evaluated and confirmed up to at least one month.

[0181] Filtration and freezing of the BO-112 formulation prior to administration does not promote substantial changes to the cytotoxic properties or stability of the particles within the composition relative to the original BO-112 formulation (e.g., the composition maintains a hydrodynamic diameter with a D90% of less than 250 nm, a Zeta potential of greater than 30 mV (e.g., 40 mV-50 mV), a Z-average of 30 nm-150 nm, compatibility with the use of glucose as an excipient, a polydispersity value comprised between 0.1 and 0.6, and other applicable standards according to the European Pharmacopoeia).

[0182] Thus, BO-11X formulations such as BO-112 formulations are formulations that present a high level of stability and reproducibility for particles formed by poly(I:C)-JetPEI complexes with a Z-average diameter (d.nm) of less than 200 nm (if not less than 100 nm), which is not observed for commercially available poly(I:C) formulations based on other carriers and manufacturing methods. The resulting BO-112 formulations present BO-112 complexes with a monomodal size distribution and that do not contain visible particles (i.e., do not contain a large number of particles exceeding the limit required by the European Pharmacopoeia 2.9.20) even if the final solution is not filtered through 5 μm after mixing the bulk solutions 1 and 2. The BO-112 formulations can be filtered through a 0.8 μm filter prior to use (e.g., before its injection) without thereby altering either the biological properties or the monomodal size distribution of the particles within the composition. For example, the BO-112 formulation may be filtered through a Minisart syringe filter (Sartorious) with an exclusion size of 0.8 μm. Mixing conditions may be adapted, inter alia, by adjusting the mixing speed from 50 rpm to 600 rpm and / or the flow rates from 1 mL / min to 50 mL / min for either the Poly(I:C) or JetPEI solutions.

[0183] In general, BO-11X preparations (and in particular BO-112 preparations) have the following main characteristics: colorless, no visible particles, an osmolality comprised between 220 mOsm / kg and 340 mOsm / kg, a pH comprised between pH 2 and pH 4 (e.g. 2.7-3.4), an optical rotation between +1500 and +3750, a zeta potential of 30 mV or more, a unimodal size distribution of particles having a Z-average diameter (nm) between 30 nm and 250 nm (e.g. 30 nm to 150 nm), but preferably between 60 nm and 130 nm, and at least 40%, 50% or 60% of such double-stranded polyribonucleotides have a size greater than 0.85 Kb, and at least 70% of such double-stranded polyribonucleotides have a size comprised between 0.4 Kb and 5 Kb, comprising poly(I:C) molecules. Characteristics such as particle size distribution may be tuned by using a T-piece mixer in combination with different flow rates for both Solution 1 and Solution 2. When such rates are above 20 mL / min (e.g., 30 mL / min), the turbidity of the resulting BO-112 formulation decreases in parallel with a decrease in the Z-average particle size and size distribution around this value, while remaining unimodal, presumably due to a change in the flow regime.

[0184] An exemplary BO-112 formulation is provided as a vial containing particles with a Z-average diameter of 45±5 nm to 81±5 nm (e.g., 73±5 nm), with at least 50% of the particles smaller than 85±20 nm, a polydispersity of 0.25, a zeta potential of 38 mV, and a pH of 3.1. These structural properties, which are maintained after freeze / thaw cycles at -20°C or extensive exposure at room temperature, can be adjusted in separate batches to maintain the criteria within a specific range of values. In particular, more preferred ranges are defined when comparing GMP and non-GMP batches for physicochemical and functional properties, as well as more reproducible and effective criteria for evaluating BO-112 formulations (and BO-11X formulations in general). For example, a therapeutically and biologically effective BO-112 formulation may present particles with a Z-average diameter of 100±50 nm or 80±20 nm (e.g., 76 nm, 89 nm or 96 nm), with a potential z comprised between about 35 (or 40) mV and 50 mV (e.g., 39 mV, 46 mV or 50 mV) or between about 40 mV and 45 mV (e.g., 43 mV), with at least 90% of the particles having a diameter of less than 250 nm or 200±50 nm (e.g., 170 nm, 172 nm, 174 nm, 216 nm, 218 nm, 220 nm), and a polydispersity of 0.2 to 0.3 (e.g., 0.21, 0.23 or 0.25). Additional criteria can relate to characteristics measured in the aqueous composition such as the presence of less than detectable or irrelevant monomeric inosinic acid (e.g., less than 1 μg / mL, 0.5 μg / mL, 0.2 μg / mL or 0.1 μg / mL), an osmolality comprised between 300 mOsm / kg and 310 mOsm / kg, an ionic strength of less than 5 mM, or preferably less than 1 mM (e.g., 0.7 mM, 0.76 mM, 0.78 mM or 0.80 mM). These values ​​may change after storage at low temperature (e.g., 5° C.±3° C.), but should still remain within these ranges.

[0185] The concentration of poly(I:C) and particles in the vial can be adapted according to the final application. However, to maintain the stability of the poly(I:C)-based and PEI-based complexes in the composition, the vial should contain BO-11X at a concentration of more than 0.1 mg / mL poly(I:C), and in some cases more than 0.5 mg / mL poly(I:C) molecules, which stabilizes the zeta potential and aggregation characteristics and allows for uniform and effective use of the BO-11X formulation. The vial can be prepared for single use (containing 4 mL, 2 mL, 1 mL or less volume of BO-11X composition) as well as larger batch formulations (containing 5 mL, 10 mL, 15 mL or more volume of BO-11X composition) that can be divided into two, three, five or more aliquots for single use administered over the course of a treatment period (3 days, 5 days, 7 days, 10 days, 15 days, 30 days or more).

[0186] When the cytotoxic activity of the BO-112 formulation was compared to the commercial formulation, the latter was less effective in killing cancer cells in at least two in vitro models (Figures 2A and 2B). It appears not to be the case. The cytotoxic activity of the BO-11X preparation can be measured and verified for further use in various types of cancer cell lines representing various cancer indications. These effects can also be examined by measuring the expression and / or secretion of proteins known to potentially alter and improve cellular responses to cancer cells. For example, the BO-112 preparation induces interferon-beta expression in melanoma cell lines over a period of at least 24 hours more efficiently than poly-ICLC (Figure 2C). This in vitro evidence can be used not only to evaluate which types of cancers can be more effectively treated by administering the BO-11X preparation, but also to evaluate which other cancer treatments (such as cell-based or antigen-based vaccines, adjuvants, antibodies, chemotherapeutic drugs, radiation therapy, cell therapy, immunotherapy, epigenetic therapy, or inhibitors of enzyme activity such as kinases or metabolic enzymes) can work more effectively when administered in combination with the BO-11X preparation (e.g., by reducing the dosage, frequency and / or duration of treatment with this other approach).

[0187] Indeed, the specificity of such cytotoxic effects by the BO-11X formulation on cancer cell lines, but not on normal primary cells (previously described for the laboratory-scale BO-110 formulation; 17) was confirmed in vitro by comparing activity with appropriate compound and cell controls (Figure 3). LNeither the poly(I:C) molecule alone significantly affects the viability of tumor cells (melanoma or glioma). Only when linear PEI and poly(I:C) molecules are complexed as provided in the BO-112 formulation is a significant killing of tumor cells observed without affecting the viability of normal melanocytes. Cell-based assays for in vitro cytotoxicity can be part of the validation and grading of batches of BO-112 formulations prior to further (pre)clinical use. Such assays can be based on the effect on human melanoma cell lines (such as SK-Mel-19, SK-Mel-28, SK-Mel-103 and SK-Mel-147 cells) after 24, 36 or 48 hours of exposure to batches of BO-112 formulations at one, two or more standard concentrations (e.g., 0.35 μg / mL, 0.5 μg / mL, 0.85 μg / mL, 1.0 μg / mL or 1.5 μg / mL; with or without prior filtration through a 0.8 μm filter) in culture medium, using vehicle or other particle-free solutions with comparable standards (such as osmolality, pH or ionic strength) as negative controls, and SDS or other biological or chemical cytotoxic agents.

[0188] Overall, the poly(I:C), particle, composition and cytotoxicity based criteria applied to the creation and validation of the BO-11X formulation (and in particular the BO-112 formulation) make this poly(I:C) formulation a structurally distinct and functionally improved formulation compared to previous poly(I:C) based formulations that are commercially available (see drawings) and / or described in the literature (Non-Patent Document 2, Patent Document 16, Patent Document 9). With regard to these latter publications, these non-GMP poly(I:C) based formulations have substantially larger sizes, higher N / P ratios, additional chemical complexities during manufacture, and require the addition of groups such as PEG (with protective activity) and / or EGF peptides (for cell targeting) to achieve the desired level of cytotoxicity using particle-containing solutions with limited specificity for cancer cells expressing cell surface antigens such as EGFR.

[0189] The above observations confirmed that cell lines derived from melanoma patients exposed to the BO-112 composition not only specifically and more strongly reduced the viability of cancer cells (when compared to other poly(I:C)-based formulations), but also induced interferon alpha / beta production by such cells (Figure 4). Furthermore, the BO-112 composition promoted tumor cell death (apoptosis and necrosis) and enhanced immunogenic cell death (ICD) to a much greater extent than comparable concentrations of LPS (a TLR4 agonist) or the corresponding poly(I:C) molecule (generally defined as a TLR3 agonist) (Figures 5A and 5B). The BO-112 formulation The stronger pro-apoptotic potency of BO-112, when compared to these TLR-specific agonists, has a significant impact not only on the elimination of cancer cells but also on the activation of effective anti-tumor immune responses. Indeed, a significant increase in the expression levels of ICD markers such as MHC-I, CD95 or calreticulin was observed after BO-112 stimulation (compared to untreated cells, LPS or poly I:C treated cells), confirming the strong potency of BO-112 formulations to induce anti-tumor immunity. Similar in vitro studies can be performed using tumor mouse models to guide in vivo studies and clinical development.

[0190] A similar cell-based approach was used to validate BO-11X, and particularly BO-112, formulations exposed to filtration and / or freezing, not only to confirm that the cytotoxic effect is qualitatively and quantitatively maintained in BO-112 preparations after such treatment, but also to assess the enhanced expression of cell death markers and / or cancer antigens or targets specifically recognized by immune cells or cancer drugs. For example, this approach can also be used to measure the reduction or decrease in expression (or degradation) of cell surface markers and biological targets of cancer drugs, such as receptors, kinases, enzymes, etc.

[0191] For example, aside from immune checkpoints, the activity of enzymes controlling DNA repair, such as poly(ADP-ribose) polymerase, may be affected by exposure of cells to BO-11X compositions, as observed for PARP1 in cell lines and fresh tumor specimens derived from autologous primary and metastatic head and neck squamous cell carcinomas in which the role of TLR3 signaling in metastatic progression was evaluated, with significant apoptosis observed as measured by cleaved PARP in primary and metastatic tumor samples, as well as in related cell lines, after exposure to poly(I:C) molecules (Umemura N. et al., 2012). Figure 6 shows that PARP cleavage is associated with BO- This was also observed when BO-112 formulation was administered to 4T1 breast cancer and MC38 colon cancer cell lines, and the clinical use of PARP inhibitors, whose clinical applications are limited by resistance mechanisms in patients, in combination therapy to broaden the therapeutic utility of PARP inhibitors, as shown in the previous figures for anti-PD1 or anti-PD-L1 (Lim J and Tan D, 2017). It is shown that it can be used to improve the use.

[0192] A deeper analysis of these in vitro data to guide clinical development can be performed using the production and comparison of different BO-11X formulations, different administration regimens, and / or different preclinical models involving conditions related to diseases such as cancer. In particular, additional studies can include the determination of the effect of the BO-11X formulation on the activity, expression, and / or concentration of mRNA and / or corresponding protein in biological material (such as blood or biopsy material) and cells obtained from patients (cancer cells, immune cells or other cell types). The properties of the BO-11X formulation can be evaluated in human cells (primary tumor cells, cell lines or genetically modified cells) when cultured in vitro and tested ex vivo, and / or when injected into mice, where more complex immunological mechanisms can be explored. Characterization of such activity and associated changes in gene expression and potential mechanisms of action can allow for the definition of optimized administration routes and regimens, combinations with other drugs, follow-up treatments and / or patient populations applicable to the BO-11X formulation, as summarized in Example 3.

[0193] Example 2: Functional characterization of BO-11X formulations in animal models Materials and Methods BO-11X formulation and other compounds BO-112 formulations were obtained as described in Example 1 and were administered at 0.05 mg / Kg in 5% glucose PBS solution (vehicle; reference: BE14-516F, Lonza, France). It was diluted in three different concentrations according to the dosage per kilogram of animal body weight: 0.5mg / Kg and 2.5mg / Kg.

[0194] A mouse anti-PD-L1 antibody (InVivoPlus, clone 10F.9G2) was selected for combination with the immunotherapy compound. A rat-IgG2b antibody (clone LTF-2, BioXCell) was used as an isotype control. For daily injections into mice, anti-PD-L1 and rat-IgG2b (RIgG) antibodies were diluted in vehicle to a final concentration of 1.5 mg / ml.

[0195] Mouse anti-CD4 (clone GK1.5) and anti-CD8α (clone 2.43), as well as rat-IgG2b (clone LTF-2) antibodies (all from BioXCell) were used for T cell depletion. Mice were given three initial doses of anti-CD4 or anti-CD8α (300 μg / mouse), or rat-IgG2b (100 μg / dose) antibodies, followed by a maintenance dose of 100 μg / mouse.

[0196] Mouse cell lines B16-F10 (cutaneous melanoma, ATCC code CRL-6475) and derived B16-OVA; MC38 (colon adenocarcinoma, Cellosaurus code CVCL_B288, Kerafast catalogue no. ENH204); 4T1 (breast carcinoma, ATCC code CRL-2539) were obtained from established collections at ATCC or from the Applied Medical Research Centre (Navarra, Spain) and, where possible, were subjected to short tandem repeat (STR) profiling (GenePrint™ 10 System) for cell line authentication. IFN-insensitive B16 cell lines were obtained from Invivogen (B16-Blue™ IFN-γ cell line). B16-Blue™ IFNα / β cells, Catalog No. bb-ifng; The samples were analyzed using the same protocol as described above, with the exception of the 10-μg / mL ELISA kit (code number bb-ifnt1) and maintained as directed by the manufacturer.

[0197] Animal models for human cancer The cell lines indicated above were injected subcutaneously (sc) into the right flank of 8- to 10-week-old female C57BL / 6 mice (5 × 10 5 ~1×10 65 For abscopal studies, a second sc injection (3 × 10 5 cells) was administered to the left flank (immediately after the first injection of tumor cells to the right flank, simultaneous injection model). For rechallenge studies, a second s.c. injection (2.5–5 × 10 5 Cells) were administered into the left flank of tumor-free mice that responded to BO-112 treatment. Tumors were measured weekly with calipers until sacrifice, and volumes were calculated (length × width). 2Survival was assessed by Kaplan-Meier analysis.

[0198] BO-112 Administration and Other Compounds Tumor volume 80mm 3 ~100mm 3 BO-112 treatment was initiated at this time. BO-112 and vehicle were administered intratumorally by a single direct injection into the tumor mass on the right flank (BO-112 dosing schedule (2 doses / week for 3 weeks)). Anti-PD-L1 and rat-IgG2b antibody dosing was administered intraperitoneally starting with the second dose of BO-11X and continued on the same schedule as BO-112. Anti-CD4, anti-CD8α and rat-IgG2b mAbs were administered intraperitoneally. The initial dose was injected the day before the start of BO-112 dosing and continued throughout the experiment. The exact schedule of dosing (BO-112 and other compounds) for all experiments is shown in the figures.

[0199] Immune Response Research The influence of different T cell subsets on the BO-112 antitumor effect was investigated by T cell depletion experiments in the MC38 mouse tumor model. Anti-CD4 or anti-CD8α antibodies were administered systemically to MC38 tumor-bearing mice (starting before BO-112 treatment). The dose, administration and schedule of BO-112, anti-CD4 or anti-CD8α antibodies were previously described. Tumors were measured weekly with calipers until sacrifice, and volumes were calculated (length × width). 2 T cell activation and priming induced in vivo by BO-112 therapy were Tumors and draining lymph nodes were excised, tumors were digested (collagenase / dispase digestion medium), filtered, and all samples were processed to obtain single cell suspensions. Standard protocols for flow cytometry surface and intracellular staining were performed using the following fluorochrome-conjugated antibodies: anti-CD4, anti-CD8, anti-CD45, anti-PD-1, anti-IFNγ, anti-CD137 (Biolegend). Antigen-specific CD8 against OVA or Trp2 were used. + T cells were analyzed (iTAg Tetramer / PE - H-2Kb, BML international Corporation). Samples were acquired using a Gallios cytometer (Beckman Coulter) and data were analyzed with Kaluza flow analysis software (Beckman Coulter). Ta.

[0200] The cell death-inducing activity of BO-112 was tested in IFN-unresponsive mouse cancer cells by MTS assay (CellTiter 96™ AQueous Non-Radioactive Cell Proliferation Assay, Promega). IFN-γ (IFN-α / β unresponsive) cells (5000 cells / well; 96 flat-well plates, 8 replicates per condition) were cultured in vitro with either poly(I:C) alone (0.5 μg / mL), the BO-112 formulation (0.5 μg / mL), or 2',3'-cyclic GMP Sting agonist (7 μg / mL; InvivoGen, San Diego, CA) as described in the figures. The cells were incubated with E. coli (EgO) for 24, 48 or 72 hours depending on the experiment. The absorbance (OD492nm) was measured in an ELISA reader. The % dead cells refers to untreated cells (0%).

[0201] result The in vivo anti-cancer efficacy of BO-112 formulations was investigated in an immunocompetent mouse line implanted with murine melanoma cells. Mice were treated with either PBS solution or three different concentrations of BO-112 formulations (preferably 0.05 mg / kg, 0.5 mg / kg, or 2.5 mg / kg administered intratumorally) in combination with a murine anti-PD-L1 antibody (preferably administered systemically) for three weeks and compared to vehicle alone (Figure 7A). Anti-PD-L1 antibody in combination with vehicle did not significantly increase survival when compared to vehicle alone. All three BO-112 formulation combinations tested with anti-PD-L1 (and possibly independent of such antibody) significantly increased mouse survival compared to vehicle or anti-PD-L1 alone. Furthermore, survival was significantly increased with the combination of 2.5 mg / kg BO-112 formulation + anti-PD-L1 compared to lower doses of BO-112 formulations (Figure 7B). Indeed, the BO-112 formulation administered alone clearly reduced tumor growth in this model (Figure 7C and Figure 7D). The effect of this combination was also tested in a similar model on the abscopal effect of intratumoral injection in a mouse model of melanoma, where the BO-112 formulation reduced the size of not only the injected tumor masses but also the non-injected tumor masses, confirming the local and systemic antitumor effect of the BO-112 formulation (Figure 8).

[0202] Anti-PD-L1 antibodies are important and validated anti-cancer drugs and mediators of effective immune responses against cancer cells. Our experiments demonstrate that BO-11X conjugates can be used in combination with other anti-cancer drugs, and that the combination of BO-11X compounds with other anti-cancer drugs, such as anti-PD1, has superior efficacy to the anti-cancer drug alone, resulting in a significant increase in survival and anti-tumor efficacy. Furthermore, improvements in survival (or immune memory cells, and more generally systemic therapeutic response) correlate with increasing doses of the BO-11X formulation for the combination, supporting that an additional benefit in survival is mediated by the BO-11X formulation. This in vivo anti-cancer efficacy of the BO-112 formulation was also confirmed in the absence of anti-PD-L1 or any other treatment in both 4T1 (Figure 9) and MC38 (Figure 10) models for breast and colon cancer, respectively. BO-112 not only reduced tumor growth in a 4T1 breast cancer model, but also in an MC38 colon cancer model, using two different approaches: The use of IgG4-dependent immunization (with or without rechallenge with IgG4; Figures 10 and 11) also improved mouse survival.

[0203] Thus, BO-11X formulations (alone or in combination with other anti-cancer agents, such as antibodies, immunotherapy or chemotherapy, which may be administered using the same or different routes) can be used to treat melanoma and other cancer indications, particularly those that allow for peri- or intratumoral injection, such as pancreatic, endometrial, ovarian, renal, hepatocellular or colon cancer. Additionally, BO112 induces systemic immunity by promoting immune cell memory, allowing for its use as a single therapeutic agent.

[0204] In this area, specific biological pathways may be targeted, as shown by the combined effect of immunomodulatory monoclonal antibodies targeting PD-1, CTLA4, PD-L1 or CD137, and poly(I:C) preparations, enhancing the activity of dendritic cells (Sanchez-Paulete AR et al., 2015). Identification of the mechanism of action and function may lead to the most appropriate dosage, dosing schedule, combination with other drugs or therapies, and indications for BO-11X formulations. To this end, Duewell P et al., 2015 discloses alternative animal models of disease that can be used to test the compositions of the present invention for immunotherapy of pancreatic cancer.

[0205] To assess how such treatment improves mouse survival in relevant models (such as mouse melanoma, breast cancer, ovarian cancer, leiomyosarcoma, endometrial cancer or pancreatic cancer models) with or without co-administration of additional drugs or vaccines, in vivo studies can be performed with intratumoral (it) administration of a range of concentrations of poly(I:C) molecules (such as 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 2.5 mg / kg or 5 mg / kg) to measure the therapeutic effect of BO11X formulations on tumor growth (at local and / or distant locations) and anti-tumor immune responses. At the same time, dose-response studies on specific biological activities induced by BO-11X treatment can be evaluated in parallel ex vivo using human or animal samples at the level of apoptosis induction (by caspase-related glow), immunogenic cell death induction (e.g. expression of MHC-I, calreticulin, CD95 or HMGB1), secretion of chemokines / cytokines in body fluids (e.g. secretion of IL-6 and IP-10), activation and / or proliferation of cells in vitro (e.g. associated with upregulation of CD40, CD86, CD69 for appropriate cell types). These studies can be performed using cells directly involved in the disease (e.g. tumor cells, epithelial cells, endothelial or epithelial cells) or cells indirectly involved after performing some immune activity or immune modulating activity in the tumor, lymphoid organs or blood (e.g. human peripheral blood mononuclear cells, NK cells, B cells, CD4+ / CD8+ T cells, dendritic cells). These studies may also cover the effects of BO-11X treatment using different routes of administration, such as subcutaneous or intramuscular administration, to establish different schedules for BO-11X clinical use, as well as the suitability of BO-11X as an adjuvant in cancer-related and / or infectious disease-related vaccinations.

[0206] These studies can be further linked to the identification of molecules that can be used as biomarkers to predict the response (or lack of response) to BO-11X in order to stratify disease stages and / or patient populations to BO-11X treatment. In particular, analysis of BO-11X activity can be performed by comparing the qualitative and / or quantitative characteristics of immune cells (NK cells, B cells, CD4+ / CD8+ T cells, etc.) and tumor growth kinetics in animal models where changes in specific cell markers and (sub)populations can also be measured when specific cell types are depleted or activated in combination with BO-11X administration (e.g., by co-administration of T cell depleting or activating antibodies, viral, bacterial or cancer antigens, cell-based therapies such as adoptive T cell therapy, or compounds with adjuvant properties).

[0207] The involvement of specific immune cells can be investigated in cancer animal models similar to those described previously, where treatment with BO-112 formulations is evaluated for immune cell depletion or the presence of specific immune cell populations in tumors after administration of the BO-112 formulation. Depletion of CD4 positive T cells improves the efficacy of the BO-112 formulation, suggesting the clinical potential of combination therapy of BO-112 with drugs targeting CD4 Tregs (Figures 12A and 12B). Depletion of CD8 positive T cells appears to reduce the antitumor effect of the BO-112 formulation on mouse tumor models, confirming the involvement of adaptive immune responses in the BO-112 antitumor-mediated effects. Furthermore, the representation of specific cell populations in tumor-infiltrating lymphocytes is altered by intratumoral injection of the BO-112 formulation, with not only CD45 / CD8 positive T cells, but also a significant increase in positivity for CD137, OVA and Trp2 tetramer, PD-1, and interferon gamma expression in CD8 positive cells, and these effects are partially confirmed in CD4 positive cells. In the same model, specific CD8+ T cells against the endogenous tumor antigen Trp2 were also increased in tumor-draining lymph nodes (FIGS. 12C and 12D).

[0208] These data confirm that BO-112 formulations can promote adaptive immune responses against tumors and induce systemic immunity. The potent effects of BO-112 in inducing tumor cell death and promoting T cell infiltration and activation provide evidence for clinical combination with drugs targeting complementary mechanisms of tumor progression such as immunosuppression (Chen DS and Mellman I, 2013 ). Activation of CD4+ and CD8+ T cells in tumors following BO-112 therapy demonstrates activation of the IFN signaling pathway. IFNγ not only plays a pivotal role in antitumor systemic and local immunity, but also induces PD-L1 expression in cancer cells, a mechanism described to impair local tumor immunity and promote immunosuppression (Abiko K et al., 2015). Intratumoral administration of BO-112 in various mouse tumor models induces PD-L1 expression in tumor cells, supporting the rationale for combination therapy of BO-112 with drugs targeting PD-1 / PD-L1. Promising combinations include drugs targeting other immune checkpoint inhibitors such as CTLA4, Tim-3, LAG3, or IDO to unblock immune suppression induced by tumor cells and / or the tumor microenvironment.

[0209] The potent direct cytotoxic effect of BO-112 formulations on tumor cells is detected even in cells that do not respond to IFN, with relevant clinical implications for patient selection and BO-112 treatment. BO-112 formulations appear to induce tumor cell death independent of the ability of cancer cells to respond to interferon as well (Figure 13). Loss-of-function mutations in IFN-gamma receptor signaling or antigen presentation machinery mediate some cases of primary and acquired resistance to PD-1 blockade therapy (Zaretsky J et al., 2016). Activation of the RIG1 / MDA5 pathway by BO-112 in tumors may provide a strategy to overcome IFN-γ resistance and resensitize tumors to autologous CD8+ T cell therapy. Early chromosomal abnormalities predispose certain tumor types to the acquisition of IFNγ and T cell resistance, and therefore screening patient metastases for chromosomal abnormalities and gene mutations prior to immunotherapy to define the risk of developing resistance may be useful in selecting patients who will benefit from BO-112 therapy.

[0210] The literature has shown that human tissue specimens for cells in tumors (including melanoma, invasive breast cancer, prostate adenocarcinoma, lung adenocarcinoma, and colon adenocarcinoma) have been shown to contain JAK1 and JAK2 mutations, including loss-of-function alterations (homodeltions, truncating mutations, or downregulation of the gene or protein) of either JAK1 or JAK2 that are predicted to reduce JAK1 or JAK2 signaling. We provide some evidence that BO-112 has alterations in IL-1 and JAK2, which may be useful in selecting patients who would benefit most from BO-112 therapy, taking into account the tumor mutation burden.

[0211] Example 3 Clinical study using BO-112 formulation Preclinical studies on administration of BO-112 in animal models can be used as a basis for the establishment of clinical studies administering BO-112 (e.g., by intratumoral delivery) for safer and more focused enhancement of local and systemic antitumor effects. The potential of intratumoral administration of BO-112 as an immunomodulatory treatment and its toxicity / safety profile are analyzed in this first in human proof-of-concept clinical trial (NCT02828098). Patients with cancer lesions accessible for intratumoral injection, such as malignant solid tumors and palpable cutaneous / subcutaneous or lymph node metastases (>1 cm) and able to obtain biopsies, are treated with BO-112 using intratumoral injections at various dose levels (0.6 mg to 1 mg of poly(I:C) content in each dose, 1 to 3 weekly doses) starting with BO-112 preparations containing poly(I:C) molecules at a concentration of at least >0.5 mg / mL. Injected lesions are biopsied prior to the start of treatment and 7-14 days after the last dose, or alternatively, for example, 6 weeks. Patients are evaluated in parallel for clinical relevance and indications of innate or adaptive immune system responses and signaling pathways. BO-112 pharmacokinetics and circulating cytokines such as type I interferons, TNF-alpha, and IL-6 are also evaluated in plasma.

[0212] Preliminary results indicate that patients experienced no relevant toxicity apart from two episodes of thrombocytopenia that resolved without treatment. BO-112 was not detectable in the bloodstream after intratumoral delivery. For BO-112, both statistically and therapeutically relevant changes were identified in all patients for at least one of the following tumor-related criteria: size of injected tumor, appearance or absence of metastasis, apoptosis and necrosis of cancer cells (indicating immunogenic cell death induced in tumors by BO-112 formulations), increase in CD4-positive tumor-infiltrating T cells, increase in CD8-positive tumor-infiltrating T cells, increase in circulating immune cells (NK cells, dendritic cells, monocytes, and / or regulatory T cells, including total populations or specific subpopulations displaying specific markers such as CD16 or PD-1).

[0213] When BO-11X formulations (or BO-11Xm formulations) are administered clinically by intratumoral injection, apoptosis and / or necrosis are observed in the tumor, possibly as a result of a direct antitumor effect (e.g., by promoting presentation of tumor antigens to dendritic cells) in combination with activation of antitumor responses by other cells endogenous to the tumor, a cascade that may also result in recruitment and / or activation of immune cells, particularly CD4+ and CD8+ T cells, to the tumor mass, promoting immune effects against the tumor and contributing to the cytotoxic effects of BO-11X. Systematic changes in immune cell populations such as CD8, CD4, CD4 Treg, NK T, NK, CD16+ monocytes or DCs are also induced, which may be capable of enhancing both primary and memory antitumor responses.

[0214] The BO-11X formulation (or BO-11Xm formulation) can also be administered in one or more treatment cycles as a single agent or in combination with other anti-cancer therapies (with or without chemotherapy and radiotherapy), such as checkpoint inhibitors or other cancer immunotherapeutics, given at different frequencies, by other administration routes in regimens including but not limited to subsequent intratumoral injections, alternative administration routes such as subcutaneous or intramuscular administration (FIGS. 14A and 14B, including anti-CTLA4, anti-PD-1 or anti-PD-L1 co-therapy). A cycle of BO-11X treatment can be established as a defined number of intratumoral injections (1 to up to 4 or more consecutive injections over 1, 2, 3, 4 or more weeks) into the same or different tumor lesions.

[0215] In the second part of the first-in-human clinical trial mentioned above, patients who do not respond to treatment with anti-PD1 antibodies will receive multiple doses of BO-112 in addition to continued treatment with anti-PD1 antibodies (see Figure 14B). Clinical response to treatment as measured by total tumor burden based on imaging, and biological activity as determined in tumor tissue and circulating immune cells will be evaluated during the study (see Figure 15).

[0216] This can be followed by multiple intramuscular or subcutaneous injections (1 to up to 7 or more consecutive injections over 1, 4, 7, 15 or more weeks), and such cycles can be repeated with the same regimen (or with more time between injections) depending on patient response. These intramuscular or subcutaneous BO-11X formulations are optionally diluted prior to administration to obtain a lower dose of poly(I:C) molecule compared to intratumoral injection (e.g., 50%, 25%, 10%, 5%, 1% of the dose injected into the tumor), but still maintain the initial therapeutic and / or immunomodulatory effects of intratumoral injection. In addition to the above parameters, clinical response can also be assessed by physical examination, CT scan, MRI scan, or other imaging methods to assess tumor burden.

[0217] Alternatively, the BO-11X formulation (or BO-11Xm formulation) can be administered ex vivo using cells isolated from a patient to improve the maturation, potency, and / or activation of specific immune cells, particularly dendritic cells (Figure 14C). This approach can be applied to in vitro maturation of dendritic cells as described in the literature for applications related to neoantigens, adoptive T cells, cell lysates, cancer, gynecological diseases and / or infections (Vanderlocht J et al., 2010; Gallois A and Bhardwaj N, 2013; Da Silva DM et al., 2015; Fritsch EF et al., 2014; Gonzalez FE et al., 2014; Tai LH et al. 2013; Hammerich L et al., 2015; Hervas-Stubbs S et al., 2012; Ochoa MC et al., 2017; Osada T et al., 2015; Perica K et al., 2015). Also, in this case, these in vitro maturation The BO-11X formulation in the vitro / ex vivo method is optionally diluted prior to administration to obtain a lower dose of poly(I:C) molecule compared to intratumoral injection (e.g., 50%, 25%, 10%, 5%, 1% of the dose injected intratumorally, but optionally within the range of doses and concentrations used to validate the BO-11X formulation in the cell line model disclosed in Example 1). These doses can be administered with or without subsequent cycles of BO-11X treatment in the same patient and still provide therapeutic and / or immunomodulatory effects appropriate for such treatment approaches.

[0218] Using any of the above-listed administration routes and regimens, the BO-11X formulation (or BO-11Xm formulation, such as the BO-112 formulation) can be validated in patients taking into account one or more combined criteria measured using biopsies, blood samples, and / or other clinical criteria (see above and FIG. 15A). Thus, apart from direct assessment of tumor size and metastasis, the therapeutic efficacy of the BO-11X formulation can be determined in a manner that evaluates at least one of the following three general criteria: direct cytotoxicity against cancer cells (apoptosis and necrosis of cancer cells), increase in tumor-infiltrating immune cells (such as CD4-positive and / or CD8-positive tumor-infiltrating T cells), increase in immune cells circulating in the blood (such as lymphocytes, NK cells, monocytes, dendritic cells, macrophages, total population or specific subpopulations of B cells), and / or shows some differential expression (as determined by RNA sequencing or other large-scale sequencing approaches) before versus after treatment only in either responding or non-responding patients.

[0219] This validation process may include tracking at the molecular level, for example by screening the mRNA and / or protein expression of a set of specific proteins, to ascertain not only the efficacy of the treatment, but also whether BO-11X (or BO-11Xm) administration has enhanced the patient's response, so that other treatments (previously found to be ineffective) can be applied. Examples of such signatures and alternative regimes that can be identified in patients treated with BO-11X or BO-11Xm can be found in the literature, for example in terms of interferon expression and / or other markers to be identified, as well as acquired resistance to PD-1-based therapy for the potential salvage of the patient (Zaretsky J et al., 2016, Masucci G et al., 2016). Thus, safety, efficacy and immunobiological data can be used to determine whether BO-11X (or BO-11Xm) administration has enhanced the patient's response, so that other treatments (previously found to be ineffective) can be applied. The data provide a basis for selecting a dose of BO-11X (or BO-11Xm) for future clinical trials using BO-11X formulations such as BO-112 alone and / or in combination with other drugs, standard treatment protocols, or immunotherapies that may provide additional therapeutic benefit (Figure 15B).

[0220] The therapeutic efficacy of the BO-112 formulation is under clinical evaluation with two initial examples further demonstrating relevant clinical efficacy (Figures 16 and 17). These preliminary results confirm the efficacy of BO-112 in reducing cancer lesions and demonstrate the safety and intended biological effects with or without co-administration of anti-CTLA4, anti-PD1 and / or anti-PD-L1 antibodies, along with the potential effect of addressing cancer patient refractoriness to checkpoint therapy and inducing immunogenic cell death and anti-tumor immunity. Furthermore, these preliminary results show that patients did not experience clinically relevant toxicity, except for two cases of thrombocytopenia, both of which recovered (one with platelet transfusion and the other without treatment). BO-112 was not detectable in the bloodstream after intratumoral delivery. BO-112 demonstrated therapeutically relevant changes in all patients with respect to at least one of the following tumor-related criteria: size of injected tumors, apoptosis and necrosis of cancer cells, increase in CD4 positive tumor-infiltrating T cells, increase in CD8 positive tumor-infiltrating T cells, increase in circulating immune cells (NK cells, dendritic cells, monocytes, and / or regulatory T cells, including total populations or specific subpopulations displaying specific markers such as CD16 or PD-1).

[0221] Example 4 Evaluation of the biological effects of administration of BO-112 formulations in patients Materials and Methods Pre- and post-treatment biopsies are obtained from injected metastatic lesions to analyze apoptosis, necrosis, immune infiltrates and inflammatory gene RNA expression signatures (e.g., using Nanostring's platform and specific panels of human genes such as those listed by manufacturers such as PanCancer Pathways, PanCancer Immune Profiling or PanCancer Progression Panel). Pharmacokinetics, serum cytokines and circulating immune cells are subsequently examined in pre- and post-treatment blood samples.

[0222] Using nSolver analysis software (NanoString, Inc.), counts were first normalized to the geometric mean of the negative controls added to the assay to correct for experimental variability. The geometric mean was then used to calculate a normalization factor for the positive controls, and finally normalized to the housekeeping genes incorporated into the Human Immunology panel. Detailed normalization analysis guidelines can be found on the NanoString Technologies website. (http: / / www.NanoString.com). Normalized data was measured as counts. Normalized data from the Solver procedure were log-transformed (base 2) for the 750 endogenous genes.

[0223] nCounter chip data for 12 patients was obtained pre- and post-treatment. Differential expression was assessed using paired t-tests for each gene. The design matrix used was:

number

[0224] result Initially, gene expression studies using cells obtained from patients treated with BO-112 allowed the identification of down- or up-regulation of a limited number of genes, as summarized in Table I.

[0225] [Table 1]

[0226] Genes were selected and (log2) fold change, p-value and adjusted p-value are presented. From this analysis, 23 genes were found to be differentially expressed in tumors (hence potentially including both cancer cells and infiltrating immune cells) pre- and post-treatment (p-value<0.05). The genes listed in Table I above can be associated with one or more GO (Gene Ontology) classes related to regulating (but preferably activating or increasing) the frequency, speed or extent of immune response or immune defense (against current or potential internal and / or invasive threats), general immunological and / or inflammatory processes, or other responses to organic, inorganic or biological agents. Such GO classes include those with systematic names: M14329, M11976, M10574, M13496, M12904, M13657, M12866, M10700, M16728 and M16306. In particular, three genes (CCL7, MARCO, MSR1) are specifically associated with macrophages, one (OAS3) with activated DCs, and one (LAIR2) with Th2 T cells. Two further genes (CD163, CD36) correspond to receptors involved in phagocytosis.

[0227] Alternatively, these genes can be analyzed based on their protein localization and / or enzymatic activity. In the first group of upregulated genes, the corresponding proteins are enzymes whose action can be inhibited by small molecules, and these chemicals often have therapeutic properties by altering immune responses and / or responses to cancer, either related or not to TLR3. For example, IRAK2 is a mediator of TLR3 signaling (Jain A et al., 2014), and OAS3 plays an important role in cellular innate responses. Cathepsin L1 and BTK are both targets of anticancer and / or immunomodulatory compounds (Feng M et al., 2015 , Molina-Cerrillo J et al., 2017, Ping L et al., 2017, Li YY et al., 2017, Sudhan D and Siemann D, 2015). The second group of up-regulated genes (MSR1, MARCO In the third group of upregulated genes (IL10, IL8, CCL3, CCL7, CXCL1, LY96), the corresponding proteins are secreted proteins whose action or interaction with cell surface receptors can be inhibited by a variety of agents (antibodies or small molecules), which also often have therapeutic properties.

[0228] Using these categorization schemes, and then testing appropriate antibodies, inhibitors or other commercially available products against cell lines, tissue samples or other biological material, it is possible to define how BO-11X administration may affect immune responses and / or responses to cancer by influencing a set (or sets) of genes, immune cells and / or responses to cancer that may or may not be related to TLR3-related activity. The above approach may lead to a series of further embodiments of the invention in which BO-11X formulations (including BO-11Xm formulations) are used in methods of treating patients suffering from disease (such as cancer) and / or preventing disease (such as cancer or infectious disease) after determining the combination of the presence (and / or absence) of expression at the RNA and / or protein level for one or more genes in the patient's cells or tissues (such as tumors, blood samples or blood fractions) after or before treatment with such formulations. These methods thus include: (i) a therapeutically effective amount of a BO-11X formulation (or a BO-11Xm formulation); (ii) a therapeutically relevant biomarker(s) that predicts that a subject will have an anti-tumor or anti-infective response following treatment with the BO-11X formulation (or the BO-11Xm formulation); (iii) a therapeutically effective amount of a BO-11X formulation (or a BO-11Xm formulation) capable of rendering a subject responsive to treatment with the compound after treatment with the BO-11X formulation (or a BO-11Xm formulation); and / or (iv) a therapeutically relevant biomarker(s) that predicts that a subject will respond to treatment with the compound following treatment with the BO-11X formulation (or the BO-11Xm formulation); This may enable one to define a gene expression signature associated with

[0229] Thus, any of the genes in Table I can be used in the uses and methods summarized in (i)-(iv) above, using means for detecting / measuring the RNA and / or protein expression of any of these genes, which are commercially available and amenable to common techniques such as RT-PCR or antibody-based methods). In particular, coordinated up- and down-regulation of selected (sets of) genes in Table I can be used to define the biological response to BO-11X (particularly BO-112) when administered therapeutically, and can be correlated with TLR3-mediated activity, interferon induction and / or modulation of immune response, clinical stage, and / or combination with other drugs in patients presenting with a particular disease, particularly a particular cancer-related indication. In addition to products (such as nucleic acid probes or antibodies) amenable to the techniques listed above, such genes can also be used to detect / measure the RNA and / or protein expression of any of these genes. The biological activity of the drug is often clearly defined using a variety of commercial and technical agents available to adequately test potential interactions with the administration of BO-112 or other BO-11X formulations.

[0230] Additionally, additional therapeutic agents are available for targeting proteins whose expression is affected by treatment with the BO-11X formulation (or the BO-11Xm formulation). Drugs targeting any of the above-mentioned genes may be advantageously used in combination with the BO-11X formulation, either by administration in the same composition or in separate compositions.

[0231] References Abiko K et al., 2015. Br J Cancer;112:1501-9. Ammi R et al., 2015. Pharmacol. Ther.;146:1 20-31. Amos SM et al.,2011. Cancer Immunol. Immunother.; 60: 671-83. Ayers M et al. 2017. J Clin Invest.;127(8):2930-2940. Bald T et al., 2014. Cancer Discov.; 4: 674-87. Bhoopathi P et al., 2014. Cancer Res.; 74: 6224-35. Bilensoy E, 2010. Expert Opin. Drug Deliv.; 7: 795-809. Budczies J et al., 2017. Genes Chromosomes Cancer;56(8):651-659. Chen DS and Mellman I, 2013. Immunity; 25;39:1-10 Chen L et al., 2013. Int. J. Nanomed.; 8:137-145. Chiba Y et al., 2013. PLoSOne.; 8: e76159. Cho K. et al., 2016, Immunobiology. 222(2):394-398 ( Epub 2016 Aug 31). Cobaleda-Siles M et al., 2014. Small.; 10: 5054-67. Da Silva DM et al., 2015. Papillomavirus Res. 1;1:12-21 Duewell P et al., 2015., OncoImmunol.; 4(10): e1029698. Ewell J et al., 1992. Cancer Res.; 52: 3005-10. Feng M et al., 2015. Proc Natl Acad Sci US A.; 112(7):2145-50 Fritsch EF et al., 2014. Oncoimmunology. 25;3:e29311 Fujimura T et al., 2006. Eur. J. Immunol.; 36: 3371-80. Gallois A and Bhardwaj N, 2013. Front Immunol. 10;4:436. Galluzzi L et al., 2014. Oncotarget; 5: 12472-508. Garcia-Pascual C and Gomez R, 2013. J. Endometri.; 5(suppl.1):S13 (SP-04). Germershaus O and Nultsch K, 2015. Asi J Pharm Sci. 10: 159-175. Gong J et al. 2017. J Natl Compr Canc Netw.;15(2):142-147. Gonzalez FE et al., 2014. Hum Vaccine Immunother. 10(11):3261-9. Gupta S et al. 2016. Tumor Biol. 37: 12089 – 12102. Hafner A et al., 2013. Advanced Drug Delivery Rev.; 65 (10): 1386-1399. Hammerich L et al., 2015. Mol Oncol. 9(10):1966-81. Hervas-Stubbs S et al., 2012. J Immunol. 189(7):3299-310 Ho V et al.,2015. Oncotarget. 6: 27252 - 27266). Islam M et al., 2014. Journal of Controlled Release; 193: 74-89. Jain A et al., 2014. Front Immunol.; 17;5:553. Kabilova T et al., 2014. BMC Cancer.; 14: 338. Keir M et al., 2008. Annu. Rev. Immunol.; 26: 677-704. Kubler K et al., 2011. Eur. J. Immunol.; 41: 3028-39. Kurosaki T et al., 2009. Biomaterials,30: 2846-2853. Le U et al., 2008. Canc. Biol. Ther.; 7: 440-447. Le U et al., 2009. Radiother. Oncol.; 90: 273-279. Levitzki A, 2012. Front. Oncol.; 2: 4. Li YY et al., 2017. Expert Opin Ther Pat.; 27: 643-656. Lim J and Tan D, 2017. Cancers (Basel;9(8). pii:E109. Ling H, 2016. Adv Exp Med Biol.; 937:229-37. Masucci G et al., 2016. J Immunother Cancer. 4: 76. Matijevie T et al., 2011. Chemotherapy; 57: 460-7. McBain S et al., 2007. J. Mater. Chem.; 17: 2561-2565. Molina-Cerrillo J et al., 2017. Cancer Treat Rev.; 58:41-50. Nagato T and Celis E, 2014. Oncoimmunology; 3: e28440. Ochoa MC et al., 2017. Immunol Cell Biol. 95(4):347-355. Ohashi T et al., 2013. Int. J. Cancer; 133: 1107-18. Osada T et al., 2015. J Immunother. 38(4):155-64 Palchetti S et al., 2013. RSC Adv.; 3: 24597-24604. Perica K et al, 2015. Rambam Maimonides Med J. 6(1): e0004. Perrot I et al., 2010. J. Immunol. 185:2080-2088. Ping L et al., 2017. Oncotarget; 8(24):39218-39229. Pozuelo-Rubio M et al., 2014. Nano-Oncologicals in Adv. Del. Sci. Tech., Springer, pp. 453-470. Saheki A et al., 2011. Int. J. Pharm.; 406: 117-21. Sajadian A et al., 2014. Arch. Virol.; 159: 1951-1960. Sanchez-Paulete AR et al., 2015. Cancer Discov.; pii: CD-15-0510. Schaffert D et al., 2011. Pharm. Res., 28: 731-741. [ PubMed ] Shabani M et al. Biotech.; 2: 123-1 Shin DS et al., 2017. Cancer Discov.;7(2):188-201. Storz U, 2011. MAbs. 3: 310-7 Pharmacol Ther.;155:105–16. Szabo A et al., 2012. Melanoma Res.; 22: 351-3 Tai LH et al. 2013, Clin Cancer Res. 19:5104-1 Tan S et al. 2016. Cell Proteins;7(12):866-877. Taura M et al., 2010. Cancer Sci.; 101: 1610–7. Tormo D et al., 2009.Cancer Cell; 16: 103-1 Tutin-Moeavin I et al., 2015.Org & Biomol Chem. 13: 9005–9 Umemura N. et al., 2012. Cancer Res. 72: 45-55. Vacchelli E et al., 2013. Oncoimmunology; 2: e25396, e23510, e2 Van der JeughtK et al., 2015. Oncotarget; 6: 1359-8 Vanderlocht J et al., 2010. Int J Immunopathol Pharmacol.;23(1):35-50. Vega-Letter A et al., 2016. Stem Cell Res. & Ther. 7:150 Yoshino H and Kashiwakura I, 2013.Blood; 122: 4721. Yu L et al., 2016. Immunol Cell Biol. 94:875-885. Zaretsky J et al., 2016. N Engl J Med. 375:819-829 Zhang Y et al., 2014.Cancer Lett. 355: 76-84. Zhou Y et al., 2013. Innate Immun.; 19: 184-192.

Claims

1. A composition comprising a double-stranded polyribonucleotide-containing polyinosinic-polycytidylic acid (poly(I:C)), or a salt and / or solvate thereof, (a) at least 40% of the double-stranded polyribonucleotides have at least 850 base pairs; (b) at least 50% of the double-stranded polyribonucleotides have between 400 and 5,000 base pairs; (c) between 5% and 60% of the double-stranded polyribonucleotides have fewer than 400 base pairs; (d) between 10% and 70% of the double-stranded polyribonucleotides have between 850 and 5000 base pairs; and (e) A composition, wherein 0%-10% of the double-stranded polyribonucleotides have more than 5000 base pairs.

2. (a) at least 10% of the poly(I:C) molecules have less than 400 base pairs; (b) at least 40% of the poly(I:C) molecules have at least 850 base pairs; (c) at least 70% of the poly(I:C) molecules have between 400 and 5,000 base pairs; and (d) 20% to 45% of the poly(I:C) molecules have 400 to 850 base pairs.

3. (a) between 10% and 30% of the poly(I:C) molecules have less than 400 base pairs; (b) between 20% and 30% of the poly(I:C) molecules have between 400 and 850 base pairs; (c) between 40% and 60% of the poly(I:C) molecules have between 850 and 5000 base pairs; and (d) 0% to 5% of the poly(I:C) molecules have more than 5000 base pairs.

4. (a) between 11% and 28% of the poly(I:C) molecules have less than 400 base pairs; (b) between 23% and 27% of the poly(I:C) molecules have between 400 and 850 base pairs; (c) between 42% and 55% of the poly(I:C) molecules have between 850 and 5,000 base pairs; and (d) 0% to 3% of the poly(I:C) molecules have more than 5000 base pairs.

5. The composition according to any one of claims 1 to 4, further comprising glucose.

6. A single-stranded polyinosinic acid (poly(I)) molecule and a single-stranded polycytidylic acid (poly(C)) molecule are annealed to form a double-stranded poly(I:C) molecule, wherein: (a) 80%-99% of the poly(I) molecules have less than 400 bases, 1%-20% of the poly(I) molecules have 400-850 bases, 0%-5% of the poly(I) molecules have 850-5000 bases, and 1% or less of the poly(I) molecules have more than 5000 bases; and (b) the composition of any one of claims 1 to 4, wherein 20% to 82% of the poly(C) molecules have less than 400 bases, 15% to 40% of the poly(C) molecules have 400 to 850 bases, 3% to 50% of the poly(C) molecules have 850 to 5000 bases, and 1% or less of the poly(C) molecules have more than 5000 bases.

7. A single-stranded polyinosinic acid (poly(I)) molecule and a single-stranded polycytidylic acid (poly(C)) molecule are annealed to form a double-stranded poly(I:C) molecule, wherein: (a) 81%-98% of the poly(I) molecules have less than 400 bases, 6%-17% of the poly(I) molecules have 400-850 bases, 0%-3% of the poly(I) molecules have 850-5000 bases, and less than 1% of the poly(I) molecules have more than 5000 bases; and (b) the composition of any one of claims 1 to 4, wherein 33% to 73% of the poly(C) molecules have less than 400 bases, 20% to 37% of the poly(C) molecules have 400 to 850 bases, 5% to 48% of the poly(C) molecules have 850 to 5000 bases, and less than 1% of the poly(C) molecules have more than 5000 bases.

Citation Information

Patent Citations

  • Method for identifying candidate compounds for cancer treatment

    JP2012531193A

  • Polyinosinic acid - polycytidylic acid (poly(I:C)) formulation for the treatment of upper respiratory tract infections

    JP2016535094A

  • Shortened-chain polynucleotides and process for the preparation thereof

    WO2000047601A1

  • Nucleic acid-cationic polymer compositions and methods of making and using the same

    WO2016178233A1

  • Preparation method of polyinosinic acid-polycytidylic acid lyophilized powder injection

    CN102988303A

Cited By

  • Semiconductor device

    CN121692678A